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ABSTRACT. 
An understanding of the criteria governing lymphatic 
absorption of drugs from the gastrointestinal tract 
may lead to selective uptake of drugs via this 
route. Lymphatic absorption may have potential 
advantages over the portal absorption of drugs; 
first pass elimination may be avoided as the drug 
reaches the systemic circulation before it reaches 
the liver, the absorption of some poorly absorbed 
drugs may be improved and it may provide a means of 
targeting anticancer agents directly to the 
lymphatics. 
In the present study, the lymphatic uptake of a 
series of retinoids was investigated after oral 
administration. The most important factors which 
were found to affect lymphatic absorption were, the 
chemical nature of the compound and the nature of 
the oily vehicle in which the retinoid was 
administered. 
It was found that the greater the lipophilicity of 
the retinoid, (as defined by the logarithm of its 
octanol : water partition coefficient, log. P), the 
greater was its lymphatic absorption. Temarotene, Ro 
15-0778, (log. P = 8.7) exhibited a maximum dose 
adjusted lymphatic absorption rate of 4100 ng/h 
compared with the less lipophilic Ro 04-3780 (log. P 
= 6.8) which showed a maximum rate of only 150 ng/h. 
- 19 -
The oily vehicle in which the retinoid was orally 
administered strongly influenced the rate of 
absorption YiA the lymphatic route. Ro 04-3780 
demonstrated a 150 fold difference between the 
selected oils giving the maximum and the minimum 
lymphatic absorption rate. The best oils in this 
role appeared to be those in which the retinoid 
showed the least solubility. 
Mesenteric lymph flow rate was also shown to vary 
depending upon the oil. Basal lymph flow rate in the 
fasted rat, after dosing with saline, was 
1.6 m1/h/kg. cottonseed oil and soyabean oil 
promoted an increase in this flow rate to greater 
than 3.0 ml/h/kg (p < 0.01) when orally administered 
with Ro 04-3780. Conversely, linoleic acid 
suppressed the mean lymph flow rate to 0.8 ml/h/kg 
(p < 0.01) after oral administration with 
Ro 04-3780. 
Lymph turbidity was evaluated as an indication of 
chylomicron formation and transport in the lymph. 
Since the chylomicron is the particle in which 
dietary fats enter the lymphatic system, it was 
thought that lipophilic drugs, which are soluble in 
dietary lipid, may be carried into the lymphatic 
system ~ ~ this pathway. The mixed long chain fatty 
tri-acyl glycerol oils, cotton seed oil, soyabean oil 
and peanut oil, when orally dosed to rats, produced 
the most turbid lymph (25 - 48 times greater than 
- 20 -
the turbidity produced after an oral dose of 
saline). These type of oil also promoted the highest 
lymphatic uptake rate for the retinoids. Other oils 
including, oleic acid, linoleic acid and MTS (a 
Miglyol S12 based self-emulsifying oil system), 
demonstrated much wider ranging extents of lymphatic 
absorption, but produced lymph with similar but 
lower turbidity (10 - 12 times greater than the 
turbidity produced after an oral dose of saline). 
A self-emulsifying oil system was developed for use 
in the oral administration of a retinoid. This 
system (MTS), produced a stable emulsion with a 
particle size of 500 nm after gentle mixing with an 
aqueous solvent and contained so % Miglyol 812 and 
20 % surfactants. MTS increased both the lymphatic 
and portal absorption rates for Ro 15-0778 by three 
fold compared with Miglyol S12 alone, improving the 
overall bioavailability but without selective 
promotion of lymphatic uptake. 
The effect of feeding, prior to orally dosing with 
an oil (linoleic acid) containing Ro 10-9359, was to 
suppress greatly the portal absorption rate of the 
retinoid from 310 ng/h to less than 25 ng/h. 
A number of factors, which were believed to be 
important in the lymphatic absorption of the 
- 21 -
retinoids, have been investigated here, using the 
rat as an animal model. The data obtained in this 
work suggest that lymphatic absorption is a very 
complex process and the factors which govern this 
absorptive pathway vary depending upon the nature of 
the drug being studied and the nature of the orally 
dosed vehicle. 
- 22 -
INTRODUCTION. 
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i. Historical background to the lymphatie system. 
Historical records show that there has been interest 
in the anatomy and physiology of the lymphatic 
system since antiquity. While the phenomena of 
lymphoedema and elephantiasis were mentioned in some 
of the early Hebrew and Greek literature, the first 
direct references to the lymphatic vessels were made 
by the Greeks in the fourth century B.C. At this 
time Aristotle may have observed lymphatics, since 
he described vessels containing a colourless fluid, 
while Hippocrates referred to "white blood" 
(Barrowman, 1978). More accurate descriptions of 
lymph vessels however, came from the Alexandrian 
school of medicine. In the fourth and third 
centuries B.C., Herophilus and Erasistratus of that 
school described mesenteric lymph vessels and 
glands. Erasistratus is quoted by Galen: "For on 
dividing the epigastrium and along with the 
peritoneum we may see arteries in the mesentery of 
sucking kids, full of milk" (Cruickshank, 1786). 
Little progress was made in the investigation of the 
lymphatic system until the great experimental work 
of Arsellius (1581-1625), Professor of Anatomy and 
Surgery in Milan. In 1622 he demonstrated an 
extensive system of ramifying white vessels, "venae 
albae et lactae", in the mesentery of a dog which 
had been fed shortly before its death. Incising one 
of these with a scalpel, he observed the leakage of 
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white fluid. These vessels were not readily 
demonstrated in a second animal which had been 
starved, but Arsellius correctly assumed that the 
vessels would be best seen in the post-prandial 
state. He confirmed this in an experiment on a third 
animal. Arsellius' thesis "De lactibus sive lacteis 
venis", was published (Arsellius, 1627) by two of 
his friends two years after his death. Arsellius 
believed that mesenteric lymphatics ran to the liver 
conveying absorbed nutrients for the "concoction" of 
blood in that organ. 
Between 1650 and 1653, Olaf Rudbeck, a Swedish 
Professor of Medicine studied lymph vessels of the 
liver, abdominal wall and thoracic viscera, and 
traced the course of vessels lying on the posterior 
surface of the rectum to the cisterna chyli (a large 
collecting vessel in the abdomen). In 1652 he gave a 
famous demonstration of his findings to Queen 
Christina of Sweden. Rudbeck showed that the 
lymphatic vessels constituted a system comparable 
with the blood vascular system and he was able to 
show that lymph in the cisterna chyli does not flow 
to the liver as had been supposed by Arsellius. He 
later showed that lymph flowed from the thoracic 
duct to the venous circulation. 
Along with increasing understanding of the anatomy 
of the lymphatic system came the acceptance of the 
concept of the absorptive function of the 
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lymphatics. Much of the work supporting this idea 
came from the work of Hewson (Hewson, 1774) and 
Cruikshank, (1786). Hewson observed the motility of 
lymphatic vessels, referring to "peristaltic 
contraction of the coats" of the vessels and 
considered that this activity, together with the 
transmitted pulse from neighbouring arteries would 
account for the lymph propulsion, the valves 
observed in the lymphatic vessels contributing a 
directional component to the flow. Cruikshank 
(Cruikshank, 1786) made the interesting observation 
that certain dyes introduced into the intestinal 
lumen were taken up by mesenteric lymphatics. 
The now commonly accepted definition of the 
lymphatic system is a system composed of channels 
having the principal function of maintaining blood 
volume by returning to the general circulation, 
fluid and protein molecules that leak from the 
capillaries into the interstitial space. In 
addition, the lymphatic system includes circulating 
lymphocytes and lymphoid organs, which are important 
in defence against infection and tumour growth. 
The structure of the lymphatic system is very 
similar to that of the vascular system. In the 
lymphatic system, there are innumerable small 
vessels that flow into larger, thicker-walled 
collecting vessels. These vessels in turn flow into 
the major lymphatic ducts. 
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The peripheral vessels, which have been termed 
lymphatic capillaries, or initial lymphatic ducts, 
undertake the primary function of the lymphatic 
system, removal of material from the tissues. The 
larger vessels transport the collected material to 
the lymph nodes, and from there to the large veins 
at the base of the neck. 
The initial lymphatic (lymphatic capillary) forms a 
blind-end tube or saccule in the interstitium. The 
vessels are located near the site of cellular 
metabolism and are situated near to the blood 
capillaries and smaller venules. This one-way 
drainage system is strategically placed and is 
constructed to permit a continuous and rapid removal 
of transient interstitial fluids, plasma proteins 
and cells. 
The initial lymphatics are characterised by several 
properties. They have a wider and more irregular 
lumen than the corresponding blood capillaries. 
Their endothelial lining is attenuated, with the 
exception of the perinuclear region. Their 
intercellular junctions are loosely opposed and 
easily separate to form patent junctions. Anchoring 
filaments, which provide a strong connection between 
the lymphatic wall and surrounding connective 
tissue, reside in a dense section of the thin outer 
layer of the plasma membrane. 
Lymph drained from the interstitium by the initial 
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lymphatics is received by the collecting vessels 
which flow to the lymph nodes. The size and shape of 
endothelial cells of the collecting vessels is 
similar to those of the initial lymphatic duct, 
however, the basement membrane is well developed, 
often continuous, and elastin and collagen fibres 
are frequently observed in close contact with the 
basement membrane. Smooth muscle cells, comprising 
the tunica media, are arranged in a spiral around 
the wall of the collecting vessel. Surrounding these 
smooth muscle cells are bundles of collagen, small 
blood vessels and non-myelinated nerve fibres. 
The structure of the major lymphatic trunk resembles 
the structure of the muscular arteries and large 
veins. There are three distinct layers, the tunica 
intima, the tunica media and the tunica adventitia. 
The tunica intima consists of an endothelium having 
tight intercellular junctions, a continuous basement 
membrane and small bundles of elastic fibres between 
the basement membrane and the tunica media. The 
tunica media is comprised of smooth muscle cells 
arranged in three to six layers around the vessel, 
whilst the tunica adventitia, the outermost layer, 
is comprised of a connective-tissue complex of veil 
cells (flattened, fibroblast-like cells), collagen 
fibres, nerves and a ramifying series of blood 
capillaries. 
Lymph from most tissues filters through at least one 
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lymph node in its passage from the tissue 
interstitium to the blood. The lymph nodes are ovoid 
or rounded structures and in the human, vary in size 
from 1 mm to 25 mm in diameter. Fibrous tissue 
surrounds the node and an internal stroma of 
reticular endothelial tissue forms the basic outline 
of the nodes. The node contains two types of cells, 
the primitive (reticular) cells that produce 
lymphocytes and plasma cells, and the macrophages or 
phagocytes, members of the reticuloendothelial 
system, which line the walls of the lymph node 
sinuses. 
The lymph node filters the lymph, retaining 
particulate antigens and senescent and faulty cells 
by phagocytosis. The node produces antibodies, 
provides a site for exchange between blood and 
lymph, supports the proliferation of lymphocytes and 
related cells and is an important area for the 
recirculation of lymphocytes. 
This description of the lymphatic system is limited 
to its structural elements ego cells, vessels and 
organs and to the function of these elements within 
the system ego lymph protein transport. However, the 
lymphatic system serves the whole living organism by 
maintaining the physiological environment of 
individual cells in the non-lymphoid tissues of the 
body. This cellular environment includes the fluid 
and interstitial matrix surrounding the cells. 
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Therefore, lymphology can be defined as the 
biomedical discipline dealing with regulation of the 
cellular micro-environment. The principal tasks of 
the lymphatic system are (1) maintenance of the most 
favourable composition of the mobile intracellular 
fluid and matrix for the integrity and function of 
the tissue cells; (2) removal and processing of 
chemical products released from cells as well as 
their shed subcellular substances ego membrane 
receptors; (3) elimination of dying or mutant cells; 
and (4) removal of foreign organic particles ego 
bacteria, viruses and inorganic matter that have 
entered the intercellular space (Olszewski, 1985). 
ii. Dietary fat absorption. 
Dietary fats are mixed with gastric juices in the 
stomach and produce small fat globules during 
mechanical mixing of the chyme (blended food 
material produced by the action of gastric 
secretions). The fat droplets are further emulsified 
within the lumen of the small intestine by 
interaction with bile acids and the activity of 
lipase, carboxylic acid hydrolase and phospholipase 
A2 from pancreatic juice. These pancreatic enzymes 
catalyse the splitting of dietary triglyceride into 
long chain fatty acid (LCFA) and mainly 2-mono-acyl 
glycerols (Tso, 1985). The enzymes also hydrolyse 
cholesterol esters, and are responsible for the 
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formation of biliary phospholipids, of which 
lysolecithin (lysophosphatidylcholine) accounts for 
90% of total biliary phospholipid (Borgstrom, 1976). 
Bile salts are known to be amphiphilic compounds ie. 
they have a hydrophilic group at one end and a 
hydrophobic group at the other end. This property 
enables bile salts to form, together with 2-mono-
acyl glycerols, LCFA's, phospholipids and 
cholesterol, the so-called mixed micelles in which 
the polar hydrophilic groups of bile salts are 
directed towards the aqueous environment, whereas 
the non-polar hydrophobic ends are facing towards 
the interior of the micelle (Friedman & Nylund, 
1980). These micelles are typically less than 500 
nanometres in diameter (Carey & Small, 1972). 
It is widely accepted that the lipid digestion 
products (fatty acids, 2-mono-acyl glycerols, 
lysolecithin and free cholesterol) pass into the 
absorptive cell membrane from aqueous dispersions by 
a carrier-mediated, passive absorption process. This 
fact is clearly demonstrated by the absence of an 
effect on lipid absorption of metabolic inhibitors 
(oligomycin, potassium cyanide) and an uncoupler of 
oxidative phosphorylation (2,4-dinitrophenol) 
(Hollander, 1981). 
Once digestion products have penetrated the cell 
membrane, they are transported through the 
cytoplasmic matrix to the site where resynthesis of 
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triglyceride occurs. The major site of metabolism of 
absorbed lipid is the endoplasmic reticulum 
(Schiller, 1970). However, the mechanism by which 
fatty acids and other lipid fractions are 
transported to the endoplasmic reticulum is unknown. 
Ockner (1972) have described the presence of a fatty 
acid binding protein in the intestinal mucosa, and 
have characterized this protein. 
Two pathways of triglyceride resynthesis are 
possible; the importance of each depends upon the 
lipid mixture absorbed. The reconstitution of 
triglycerides through the monoglyceride pathway 
(Figure 1) becomes important when monoglycerides and 
fatty acids are absorbed (Tso, 1985). The enzymes 
involved are acyl coenzyme-A synthetase, 
monoglyceride transacylase and diglyceride 
transacylase. These enzymes are present together as 
an enzyme complex called "triglyceride synthetase" 
(Johnston, 1968). The L-a-glycerophosphate pathway 
(Figure 2) is important when LCFA's are absorbed 
(Tso, 1985). This pathway involves five major 
reactions; the activation of fatty acid to an acyl 
CoA derivative, formation of L-a-glycerophosphate 
from glycerol, conversion of L-a-glycerophosphate to 
phosphatidic acid, conversion of the phosphatidic 
acid to a diglyceride and finally conversion of 
diglyceride to triglyceride (Tso, 1985). 
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Figure 1. The monoglyceride pathway for triglyceride synthesis. 
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iii. oil in water emulsion systems as delivery 
vehicles tor lipid soluble drugs 
oil in water emulsion systems have been investigated 
as formulation vehicles which may deliver lipid 
soluble drugs to the site of absorption from the 
gastrointestinal tract after oral administration 
(Hashida et al., 1977, Myers & Stella, 1989). These 
lipid emulsions range in lipid content and particle 
diameter but resemble the emulsified dietary lipids 
which are formed in the stomach and which exist as 
droplets of less than 5 ~ m m in diameter (Carey 
et al., 1983). The mechanisms, rate and extent of 
drug absorption from these emulsions is strongly 
dependent on the oils and surfactants used in each 
formulation. Absorption may be influenced by the 
ability of the intestinal enzymes to digest the oil 
and by the partitioning of the drug between the oil 
and water (Armstrong & James, 1980). In addition, 
the surfactant may modify absorption by a variety of 
mechanisms (Attwood & Florence, 1983). Excipients 
used for such formulations need to be non-irritant 
and free from other acute or toxicity problems. The 
choice of oils is likely to be restricted to 
vegetable oils and their derivatives. These may be 
used in combination with non-ionic surfactants which 
are generally less toxic than ionic surfactants 
(Attwood & Florence, 1983), examples may include the 
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Tweens which are pharmaceutically acceptable (Varma 
et al., 1985). 
iv. Chylomicron formation. 
Dietary fats are absorbed almost entirely into 
intestinal lymph in the form of chylomicrons and 
very low density lipoproteins (VLDL). The process of 
the assembly of chylomicrons in the enterocytes is 
poorly understood, however, certain aspects of the 
process are now quite well documented. Chylomicrons, 
are synthesised mainly from tri-acyl glycerols 
produced from the L-a-glycerophosphate or 
monoglyceride pathway and irrespective of the fat in 
the diet, consist of about 70-90% long chain 
triglycerides (more than 14 carbon atoms in the 
.aliphatic chain), 4-8% phospholipids, 4% cholesterol 
esters, 3% cholesterol and about 2% protein and 
other triglyceride rich lipoproteins (Gurr & James, 
1971). The chylomicrons are secreted from the Golgi 
complex into the lateral intracellular spaces where 
they then enter the lacteals and the intestinal 
lymphatics through the lamina propria. The movement 
of chylomicrons across the lymphatic endothelium 
occurs both by passive diffusion and active 
transport within pinocytotic vesicles (Friedman & 
Nylund, 1980., Gangl & Ockner, 1975). Since dietary 
fats enter the intestinal lymphatic system by this 
pathway, it is believed that lipophilic drugs, which 
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are highly soluble in the dietary lipid, may be 
carried from the gut lumen into the lymphatic system 
Y1A this chylomicron pathway. 
v. Lymphatic absorption. 
It is now generally accepted that many, mainly 
lipophilic, substances can be transported in the 
lymph chylomicrons after absorption from the gut. 
These include endogenous compounds such as; lipid 
molecules (Morgan, 1966., Ockner et al., 1969., 
Barrowman, 1978); triglycerides (Mansbach et al., 
1985., Mansbach & Arnold, 1986), fatty acids (Bloom 
et al., 1951., Bernard et al., 1990), cholesterol 
(Watt & Simmonds, 1984), steroid hormones such as 
testosterone (Horst et al., 1976) and testosterone 
esters (Noguchi et al., 1985), the fat soluble 
vitamins; A, D, E & K (Forsgren, 1969., Yeung & 
Veen-Baigent, 1972., Hollander, 1980., Blomhoff 
et al., 1984) and many lipophilic drugs (DeMarco & 
Levine, 1969., Levine et al., 1969., Olszewski, 
1985., Stella & Charman, 1990) and pharmacological 
agents are also reported to be transported ~ ~ this 
route, these include; chemotherapeutic agents; 
interferon (Yoshikawa et al., 1984., Yoshikawa 
et al., 1986, Bocci et al., 1989., 5-fluorouracil 
(Hashida et al., 1977) and bleomycin (Yoshikawa 
et al., 1983), antifungal agents and immuno-
suppressants; griseofulvin (Noguchi et al., 1977), 
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cyclosporin A (Ueda et al., 1983)., Takada et al., 
1985., Hirate & Ueda, 1989., Yangawa et al., 1989), 
analgesics and anxiolyticsi diazepam (Lamka et al., 
1990), naproxen (Sugihara et al., 1988) and the 
novel analgesic compound, LY108964 (Ho et al., 
1989), the antiepileptic agent; phenytoin (Gowan & 
stavchansky, 1986), the ~ - b l o c k i n g g agent; propanolol 
(White et al., 1991) and carcinogens (Kamp & 
Neumann, 1975) including the highly lipophilic DOT 
( 1 , 1 - ~ ( p - c h l o r o p h e n y l ) - 2 , 2 , 2 - t r i c h l o r o e t h a n e ) )
(Sieber, 1976., Palin et al., 1982., Noguchi et al., 
1985., Charman et al., 1986b., Charman & Stella, 
1986). These data are summarised in Table 1. 
Work in the early part of this century addressed the 
problems of the absorption of fat soluble 
sUbstances. Orummond et al. (1935) questioned how 
chemical substances, sharing with the fats the one 
common property of showing similar solubilities in 
certain solvents, are absorbed from the intestine to 
an extent which was unsuspected. Two main theories 
were suggested by the then existing knowledge. There 
was good reason for considering the view that 
specific absorption from the gut may occur. 
Alternatively, a more conventional path may be 
followed by trying to picture an intermediate 
conversion of these "fat soluble" substances into 
"water soluble" and "diffusible" forms. In thinking 
of "water soluble" complexes the possible function 
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Table 1. Pharmacological agents absorbed via the lymphatic route 
Author 
Yoshikawa 
et aI., 1984 
Bocci 
et al., 1989 
Hashida 
et aI., 1977 
Yoshikawa 
et al., 1983 
Noguchi 
et al., 1977 
Ueda 
et aI., 1983 
Takada 
et al., 1985 
Substance studied 
Human interferon 
(mixed micelle 
infused into large 
intestine) 
Human interferon 
(intramuscular dose 
in saline) 
5-fluorouracil 
(Gelatin in oil 
microspheres) 
Bleomycin 
(FITC labelled) 
Griseofulvin 
(oil in water 
emulsion) 
Cyclosporin-A 
(oral dose in 
olive oil) 
cyclosporin-A 
(mixed micelle 
into duodenum) 
Animal 
Rat 
Rabbit/Pig 
Rat 
Rat 
Rat 
Rat 
Rat 
Result 
0.050% of dose absorbed via thoracic 
lymph after 6h. 
Lymph/plasma ratio = 4.3. 
Intraduodenal administration of 5-FU 
microspheres in oil gave a concentration 
of 5-FU in lymph nodes of 12 ~ g / g g but only 
0.1 ~ g / m l l in plasma. 
0.33% of dose absorbed via thoracic 
lymph after 3h. 
Approximately equal peak concentrations 
found in plasma and mesenteric lymph 
after infusion into in-situ gut loop. 
2% of total absorption via 
thoracic lymph. 
0.78% of dose absorbed via 
thoracic lymph after 6h. Lymph/plasma 
concentration ratio = 25. 
Table 1. continued 
Author 
Yanagawa 
et al., 1989 
Lamka 
et al., 1990 
sugihara 
et al., 1988 
Ho et al., 
1989 
Gowan et al., 
1986 
White 
et al., 1991 
Kamp et al., 
1975 
Substance studied 
Cyclosporin-A 
(in a lipid 
microsphere) 
Diazepam 
(intra-duodenal 
infusion in 
olive oil) 
Naproxen 
(glyceryl 
octyl-ester) 
LYI08964 
(corn oil 
emulsion) 
Phenytoin 
Propanolol 
(in a novel 
delivery system) 
3-Methyl-
cholanthrene 
Animal 
Rat 
Rat 
Rat 
Mouse 
Rat 
Pig 
Rat 
Result 
Thoracic lymph/plasma concentration 
ratio = 16. 
0.032% of of dose absorbed via 
thoracic lymph. Lymph/plasma 
concentration ratio = 2.20. 
Thoracic lymphatic absorption rate = 
28.3% of dose. 
Thoracic lymph/plasma concentration 
ratio = 50. 
Thoracic lymph/plasma concentration 
ratio approx. = 1. 
Hepatic portal vein concentration of 
propanolol were initially lower than 
those observed in mesenteric lymph. 
9% methylcholanthrene was recovered in 
thoracic lymph. 
Table 1. continued 
Author 
Palin et al., 
1982 
Substance studied 
DOT 
(in Arachis oil) 
Noguchi et al.,OOT 
1985 (in oleic oil) 
Animal 
Rat 
Rat 
Charman et al.,OOT Rat 
1986 (intra-duodenal 
infusion in peanut 
oil over 2h) 
Charman et al.,OOT Rat 
1986 (intra-duodenal 
infusion in oleic 
acid over 2h) 
Result 
Thoracic lymph/plasma concentration 
ratio approx. = 4. 
21.9% - 16.6% of dose appeared in 
mesenteric lymph after 24h. 
Approx. 42% of dose collected from 
mesenteric lymph in 24h. 
Approx. 36% of dose collected from 
mesenteric lymph in 12h. 
of bile was implicated. Observations by Channon & 
Collinson, (1929) questioned whether solubility in 
bile might be the chief factor in determining the 
absorption of certain fatty sUbstances. 
Vitamin A (retinol), is necessary for the 
development and maintenance of human life, but 
cannot be synthesized by the body and must therefore 
be supplied in the diet. It is necessary for the 
support of growth, differentiation of epithelial 
tissues, the synthesis of protein, and the 
preservation of vision (Hollander, 1980). Vitamin A 
alcohol (retinol) and its esters ( ~ - c a r o t e n e , , a pro-
vitamin which is cleaved in the intestine to vitamin 
A) are the major dietary sources (Lucek & Colburn, 
1985). vitamin A is metabolised to vitamin A esters, 
vitamin A aldehyde (retinal) and vitamin A acid 
(retinoic acid) which are stored in the liver. 
(Lucek & Colburn, 1985). 
Drummond et al. (1935) studied two fat soluble 
substances, vitamin A and ~ - c a r o t e n e . . These 
molecules were found to have hydrophobic properties, 
and were therefore thought to exist in a form which 
would be transported through the intestinal wall in 
a way similar to other fats. 
Studies were carried out on a patient suffering from 
a chylothorax, in which a considerable proportion of 
the chyle (a milky fluid produced from food after 
digestion and emulsification by gastric, biliary and 
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pancreatic fluids) was diverted from the thoracic 
lymph duct and collected in the pleural cavity. It 
was necessary to remove this fluid every few days 
for the relief of the patient. During the course of 
these studies, it was determined to what extent, and 
in what form, the p-carotene and vitamin A 
administered orally in the course of treatment 
appeared subsequently in the chyle. Approximately 
125 milligrams of vitamin A and 100 milligrams of 
p-carotene were given orally divided over 60 and 7 
days respectively. In the case of vitamin A, 100 
milligrams (80%) were recovered in the chyle after 
correcting for an estimated daily chyle production 
of 3000 ml, however, of p-carotene less than 20 
milligrams «20%) was recovered. From these data the 
conclusions drawn were that vitamin A is almost 
exclusively absorbed Yig the lymphatic route, 
p-carotene, however, shows poor absorption Yia this 
route. 
Studies have also been performed on oxen, sheep and 
rats (Eden & Sellers, 1949) which had been orally 
dosed with halibut liver oil (containing approx. 
17 mgfml (5000 iu.fml) of vitamin A). vitamin A 
levels were estimated in systemic blood, portal 
blood and in the lymph glands from various regions 
of the body. The samples were collected as soon as 
possible after slaughter of the animals. The results 
confirmed that vitamin A was absorbed almost 
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exclusively via the lymphatic route, mainly from the 
upper part of the intestine. The differences 
observed between the concentration of vitamin A in 
portal and systemic blood were not significant, 
further supporting the conclusion that the extent of 
portal absorption was small. 
Although the methods used to assay the vitamin A 
levels in these early studies were crude, more 
recent studies (Blomhoff et al., 1984) generally 
agree that the intestinal absorption process of the 
fat soluble vitamins closely follows the pathways of 
lipid absorption. It should be noted however, that 
an increased amount of retinol may be absorbed via 
the portal route when the thoracic lymph duct has 
been ligated (Yeung & Veen-Baigent, 1972). 
The close association of the absorption of fat 
soluble compounds with fat absorption has prompted 
many workers to search for other possible associated 
features of these absorptive processes and in 
particular the effects of oily vehicles, including 
food, and oil emulsion systems. 
Noguchi et al. (1977a), have studied the absorption 
from the small intestine of the model oily 
compounds: sudan blue, oil red-O and vitamin A 
acetate from emulsions containing oleic acid and 
triolein. The amount absorbed decreased as the ratio 
of oleic acid:triolein in a mixed micelle increased, 
suggesting selectivity for certain types of oil 
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emulsion systems. 
Hashida (Hashida et al., 1977), evaluated the 
efficiency of water in oil and gelatin microspheres 
in oil emulsions as a delivery system for 5-
fluorouracil (5-FU) into the lymphatics of the rat. 
After oral gavage, both emulsion systems increased 
the area under the concentration time curve (AUC) 
for 5-FU in the regional lymph nodes and cumulative 
amount transported into thoracic lymph compared to 
aqueous solutions of 5-FU. 
Myers (Myers & Stella, 1989), studied the effect of 
various emulsion systems on the absorption and 
bioavailability of the lipophilic compound 
penclomidine. Their results showed that soyabean and 
triolein emulsions gave the greatest cumulative 
lymphatic transport of penclomidine because 
chylomicron formation was increased by the LCFA 
triglycerides. 
There is a general belief that the lipophilicity of 
an administered molecule, as estimated by its 
partition coefficient, e.g. between octan-1-ol and 
water, or between the chylomicron fraction and 
infranatant phases of lymph is a major determinant 
of the eventual degree of lymphatic transport of a 
lipophilic molecule (Sieber et al., 1974., Sieber, 
1976., Ramp & Neumann, 1975., Palin, 1985). This 
hypothesis is based on the fact that most drug 
molecules which are transported in significant 
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quantities in the intestinal lymph are highly 
lipophilic, and reside in the chylomicron fraction 
(as opposed to the infranatant fraction) of 
intestinal lymph (Sieber, 1976., Kamp & Neumann, 
1975., Vost & Maclean, 1984). 
Chylomicrons are the major lipid-transporting 
lipoproteins of intestinal lymph and are composed of 
a triglyceride core which is stabilised in the 
aqueous environment of the lymph by a surface 
coating of protein and phospholipid (Sabesin, 1976., 
Zilversmit, 1978). An apparent relationship between 
the partition coefficient of a drug molecule and its 
lymphatic transport has been demonstrated within an 
homologous series of DDT analogues (sieber, 1976), 
and a series of testosterone esters (Noguchi et al., 
1985a). 
Most lymphatically transported lipophilic drugs are 
present in the chylomicron fraction of the 
intestinal lymph (Charman & Stella, 1986a). There 
are therefore two major factors which can influence 
the amount of drug transported by this intestinal 
absorptive pathway. Firstly, the quantity of lipid 
transported in the lymph in the form of chylomicrons 
and secondly, the amount of drug per chylomicron. 
Both of these factors can be manipulated in order to 
optimise or promote the lymphatic absorption of a 
particular drug (Charman & Stella, 1986a). The 
chylomicron flux can be influenced by factors such 
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as the type of lipid vehicle which is co-
administered with the drug and also by the diet. 
Colburn et al. (1983a) have demonstrated a 1.5 to 2 
fold increase in AUC in groups of healthy human 
volunteers when a synthetic retinoid, isotretinoin 
(Ro 04-3780) was given 1 h after food, with food or 
1 h before food compared with the AUC measured in a 
fasted group. Holazo et al. (1990) also showed that 
food increased the AUC for the highly lipophilic, 
Temarotene (Ro 15-0778) 12 fold, and greatly 
increased the maximum plasma concentration (C_). It 
has been suggested that such increases in AUC and C_ 
are due to transient changes in gastrointestinal 
motility; the slowing of stomach emptying and an 
increase in gastric and intestinal secretions, 
resulting in more complete dissolution and prolonged 
residence time at the site of absorption (Welling 
(1980). Food may also increase the absorption of fat 
soluble vitamins by the formation of bile salt 
emulsion systems after increasing bile flow (Holazo 
et al., 1990). The loading of drug per chylomicron 
will be affected by a combination of partition 
coefficient and lipid solubility considerations, as 
well as the nature of lipid vehicle in which the 
drug is administered (Charman & Stella, 1986a). The 
lipid vehicle may include variable chain length free 
fatty acids, a mono-acyl or mixed tri-acyl glycerol 
containing long, medium or short chain fatty acid 
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esters, oil emulsions, or some combination of these 
oil systems. 
vi. The retinoids, 
Since the first synthetic production of retinoids in 
the early 1970's much work has been carried out 
studying their pharmacology, pharmacokinetics and 
toxicological effects. 
The number of similarities between the clinical 
manifestations of hypervitaminosis A syndrome 
(Silverman et al., 1987), such as hyperkeratosis and 
squamous metaplasia, and skin alterations observed 
in various disease states (keratinisation disorders 
and certain precancerous conditions) have provided a 
basis for the investigation of the role of vitamin A 
in dermatology and oncology (Bollag, 1970., Bollag & 
Hanck, 1977., Mayer et al., 1978., Bollag, 1979), 
Sporn & Newton, 1979., Bollag & Matter, 1981., 
Bollag, 1989., Lippman et al., 1989., Orfanos 
et al., 1987., Warren & Khanderia, 1989., Shealy, 
1989, Natruzzi et al., 1990). 
Clinical investigations of the antikeratinising 
properties of vitamin A in such diseases as acne, 
ichthyosis, lichen ruber planus, Dariers disease and 
pityriasis rubra pilaris have met with only moderate 
success. Furthermore, the doses required for 
therapeutic effect were accompanied by severe 
adverse reactions, such as changes in skin and 
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mucous membranes, and the bone, liver and 
neurological complications (Biesalski, 1989., 
Silverman et al., 1987). In an attempt to separate 
the numerous side effects associated with use of the 
retinoids (including vitamin A) from clinical 
efficacy, more than 1500 retinoids have been 
synthesized as a result of the chemical manipulation 
of the vitamin A molecule. 
The retinoids possess three main structural 
features; a cyclic ring, a tetraene side chain and a 
terminal group which may be polar or non-polar. 
Modifications to these three regions have enabled 
the development of three generations of retinoids 
(Bollag, 1981). These show a range of 
physicochemical and pharmacological properties. The 
first generation of retinoids includes vitamin A 
(retinol) and naturally occurring compounds 
(metabolites of vitamin A) which have been found in 
the body. These show similarity in structure to 
retinol but have modified terminal polar groups. 
This class includes the two acidic compounds, all-
trans-retinoic acid (Ro 01-5488) and 1 3 - ~ ~ retinoic 
acid (Ro 04-3780). 
The second generation of retinoids contain an 
aromatic ring which forms a conjugated system with 
the tetraene side chain and this therefore increases 
the lipophilicity of these compounds. This group 
includes compounds such as Acitretin (Ro 10-1670, 
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Etretin), its ethyl ester Etretinate (Ro 10-9359) 
and Ro 11-5036. 
The third generation of retinoids are essentially 
non-polar and are commonly termed arotinoids. They 
possess both an aromatic ring and a non-polar 
terminal group produced by the cyclisation of the 
tetraene side chain. Examples include Temarotene 
(Ro 15-0778) and its sulphone derivative Etarotene 
(Ro 15-1570). The structures of the some of these 
compounds are displayed in Figure 3. 
A deficiency of vitamin A in man, has been shown to 
enhance the susceptibility to carcinogenesis 
(Bjelke, 1975). Symptoms include a marked 
hyperplasia and enhanced synthesis of DNA by basal 
cells of various epithelia and reduced cellular 
differentiation. The administration of vitamin A and 
other retinoids to animals reverses these changes in 
the epithelium of the respiratory tract, mammary 
gland, bladder and skin (Mandel et al., 1980). The 
exact mechanism of this anticarcinogenic effect 
remains unclear but is clearly of great interest. 
vii. The pharmacokinetics of the retinoi4s, 
Pharmacokinetic studies performed by Khoo et al. 
(1982) demonstrated that after oral administration 
of 100 milligrams isotretinoin (Ro 04-3780) to 12 
healthy human volunteers, the drug appeared in the 
blood after a lag time of 0.5 to 2 hours. Peak blood 
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Figure 3. Chemical structures of some of the retinoids. 
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Arotinoid Ro 11-5036 
concentrations (74 to 511 ng/ml) were found at 
between 1 and 4 hours after administration, falling 
to below 5 nglml at 72 hours; secondary peaks were 
observed between 6 and 24 hours after dosing. The 
mean half life was approximately 20 hours. 
Following a single 80 mg dose of Roaccutane (a 
gelatin capsule containing Ro 04-3780 dissolved in 
oil) to 15 healthy human male volunteers, peak blood 
concentrations of 436 to 950 nglml were found at 
between 1 to 4 hours after dosing. Ro 04-3780 
exhibited mean half lives of 1.3 and 17.4 hours for 
distribution and elimination respectively (Colburn 
et al., 1983b). 
Whilst the studies by these two groups reported 
similar results, some marked differences were 
evident; Khoo et al. (1982) have reported an 
absorption time lag which was not seen by Colburn 
et al. (1983) this difference has been purported by 
Colburn (Colburn et al., 1983b) to be due in part to 
differences in the dosage forms used, the drug being 
absorbed more rapidly from an unencapsulated oral 
suspension than from the soft gelatin capsule 
formulation (Roaccutane). 
Secondary peaks in Ro 04-3780 blood concentrations 
were observed by Khoo et al. (1982) which were said 
to reflect enterohepatic circulation of the drug. 
These peaks were not seen by Colburn et al. (1983b). 
Low bioavailability and high intersubject variation 
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in blood concentrations in humans after oral 
administration was reported in both studies. This 
may have been the result of degradation of the 
retinoid in the gut lumen, extensive first pass 
metabolism or poor absorption (Brazzell & Colburn, 
1983). 
The bioavailability of Ro 04-3780 has also been 
shown to be influenced by food intake, the relative 
bioavailability being between 1.5 and 2.0 times 
greater when the dose is administered between 1 hour 
before and 1 hour after or concomitantly with food, 
than when given after a complete fast (Colburn 
et al., 1983a). 
Following a single oral dose of J or 5 mg/kg 
Ro 04-3780 to patients with advanced cancer of the 
colon, peak plasma concentrations of 200 - 800 ng/ml 
and 190 - 1500 ng/ml, respectively, were found at 
3.2 ± 1.1 hours and 4.5 ± 2.4 hours (Goodman et al., 
1982). The mean distribution phase half lives 
observed were 2.0 ± 0.7 hours and 2.4 ± 1.6 hours, 
these values were not significantly different. The 
almost eight fold range in peak plasma 
concentrations and AUC values have been explained as 
a result of malabsorption due to the advanced 
disease condition (Lucek & Colburn, 1985). 
In a similar study in which advanced cancer patients 
received 0.5 mg/kg/day Ro 04-3780 initially, 
increasing stepwise over 4 weeks to 8 mg/kg/day, a 
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linear correlation of plasma concentration with dose 
was observed with large inter-individual variation 
in peak plasma concentrations (Kerr et al., 1982). 
The pharmacokinetics of Ro 04-3780 during a multiple 
dose regimen were studied in 10 patients with cystic 
acne (Brazzell & Colburn, 1982, Brazzell et al., 
1983). Each patient received an initial oral dose 
(80 mg) of Ro 04-3780 (two 40 mg gelatin capsules), 
followed by 25 days of 40 mg twice daily and then a 
final single 80 mg dose. Peak blood concentrations 
of Ro 04-3780 following the initial dose were found 
between 2 and 4 hours (mean 2.9 hours) post dosing 
and ranged from 98 to 535 ng/ml (mean 262 ng/ml), 
whereas, following the final dose, peak blood 
concentrations were 188 to 473 ng/ml (mean 
310 ng/ml) occurring also at between 2 and 4 hours 
(mean 2.5 hours). No significant difference in the 
pharmacokinetics of Ro 04-3780 between the first and 
last dose was found. The areas under the plasma 
concentration time curves (AUC) and elimination half 
lives (10.4 and 9.2 hours) were similar for the 
first and last 80 mg dose. Thus, neither enzyme 
induction nor drug accumulation were evident. 
Isotretinoin (Ro 04-3780) is used widely in the 
treatment of acne and acneform conditions. However 
there is a wide discrepancy between the doses 
applied by European dermatologists (0.5 to 
1.0 mg/kg/day) and the very high doses (up to 
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3 mg/kg/day) used in the USA (Saurat, 1989b). 
Dose ranging studies have only been performed in 
acne patients. It has been shown that doses as low 
as 0.1 mg/kg decreased sebum excretion and brought 
clinical improvement. Relapse rates were higher in 
patients treated with 0.1 mg/kg/day than in those 
treated with 1 mg/kg/day. Peck (Peck et al., 1979), 
reported the complete remission of acne in 13 of 14 
patients undergoing treatment with a maximum dose of 
2 mg/kg/day. The 1 4 ~ ~ patient was reported to show 
89% improvement after 3 years post treatment. Lucek 
(Lucek & Colburn, 1985) have suggested a therapeutic 
dose of 0.5 mg/kg/day for Ro 04-3780 but also noted 
acute side effects at doses above 1.0 mg/kg/day. 
The aromatic retinoid, Etretinate (Ro 10-9359), is 
less effective than Ro 04-3780 in the treatment of 
acne (Goldstein et al., 1982), but is currently 
marketed for the treatment of psoriasis and 
disorders of keratinisation. 
Oral administration of Ro 10-9359 has been shown to 
produce an excellent response in up to 80% of 
psoriatics (Ehmann & Voorhees, 1982). Ro 10-9359 has 
a narrow therapeutic range, with a recommended 
dosing regimen of 0.75 to 1.0 mg/kg/day in divided 
doses. It is poorly bioavailable (less than 25%) in 
the dog (Cotler et al., 1983) and moderately 
bioavailable (40%) in humans (Paravicini, 1981). 
Plasma concentrations after oral administration have 
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been shown to be highly variable. Wills (Wills 
et al., 1982) studied the dose proportional 
absorption of Ro 10-9359 given to 12 healthy male 
volunteers. Intersubject variation in peak plasma 
concentration was large, 45 - 229 ng/ml, 111 -
292 ng/ml, 115 - 492 ng/ml and 173 - 1120 ng/ml 
following doses of 25, 50, 75 and 100 mg. Dose 
proportional increases in maximum concentration (3.3 
to 3.9 hours) and AUC(O-12 h) (p < 0.05) were 
observed. After oral administration the drug was 
quickly absorbed with a time lag of 1.7 to 2.3 hours 
and the peak plasma level was found at 2 to 3 hours. 
The elimination half life was estimated to be 7.3 
hours (Paravicini et al., 1981). Using the graphical 
method of residuals, three phases of decline of drug 
concentrations following a single i.v. dose were 
apparent (half life of the phases: 5 - 10 minutes, 
30 - 60 minutes, 6 - 12 hours). Evidence of at least 
one other longer phase was indicated but the 
sensitivity limits of the assay method did not 
permit visualization, however the presence of 
significant plasma levels of etretinate 140 days 
after cessation of chronic therapy suggested a long 
elimination phase (half life approx. 100 days) 
(Bollag, 1981, Paravicini et al., 1981). 
Ro 15-0778 is an arotinoid and in contrast to the 
other retinoids has no polar terminal carboxyl 
group. In animal experiments using Ro 15-0778, no 
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hypervitaminosis A was induced and in contrast to 
Ro 04-3780, the inhibition of sebum production in 
rats was superior CBoris et al., 1988). After oral 
administration of 96 mg of Ro 15-0778 in an oil 
filled gelatin capsule to fasted healthy human 
subjects the mean peak plasma concentration was 
achieved after 6.9 hours, with a harmonic mean 
elimination half life of 24.1 hours CHolazo et al., 
1990) • 
viii. Aims of the project. 
The lymphatic route of drug delivery offers several 
potential advantages over portal absorption of drugs 
including the retinoids. First pass elimination may 
be avoided as the drug reaches the systemic 
circulation before the liver, absorption of some 
poorly absorbed compounds may be improved and it may 
also provide a means of targeting anticancer agents 
directly to the lymphatics (Hashida et al., 1977). 
Since it is now generally accepted that vitamin A is 
absorbed from the gut via the lymphatic system, it 
was decided to investigate the molecular and 
formulation factors which influence the absorption 
of the retinoids (vitamin A analogues) YiA the 
lymphatic route following oral administration. These 
investigations may be divided into a number of 
phases to include determination of the lipophilicity 
and solubility of the retinoids, since these 
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properties would appear to be important factors for 
compounds selectively absorbed via the lymphatics 
ego cholesterol, octadecanoic acid, octadecanol and 
DOT, (Sieber et al., 1974., Kamp & Neumann, 1975., 
Ueda et al., 1983). It was also intended to assess 
whether there was a relationship between these 
parameters and the extent of lymphatic absorption of 
a particular compound. The effect of a formulation 
vehicle on the delivery of selected lymphatically 
absorbed retinoids into the venous system was to be 
considered. Previous studies have shown some 
selective absorption into the general circulation of 
drugs from oily emulsions, therefore the effects of 
different oily formulations and self-emulsifying oil 
systems on the lymphatic and venous absorption were 
to be studied. A self-emulsifying system is a 
mixture of oil and surfactant which emulsifies in 
water under conditions of gentle agitation. Such a 
system may have potential uses for the 
administration of lipophilic drugs by the oral 
route. There may be a need for formation of small 
particles, less than 500 nanometres in diameter, by 
analogy with chylomicrons (Barrowman, 1978). Such a 
formulation will present a lipophilic drug in oily 
solution with a large interfacial area across which 
diffusion can take place. 
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MATERIALS AND EQUIPMENT 
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a) Equipment and chemicals. 
- LKB model 2150 hplc pump and model 2151 
ultraviolet detector. LKB, Bromma, Sweden. 
- Spectra Physics model SP4290 computing 
integrator. 
Spectra Physics, Palo Alto, california, USA. 
- Gilson model 231 sample injector and model 401 
sample dilutor. 
Gilson Medical Diagnostics, Villiers le-Bel, France. 
- Rheodyne model 7010 sample loop injector. 
Rheodyne, Cotati, California. USA. 
- chromacol, hplc autosampling vials and caps. 
Anachem, Luton, Bedfordshire. LU2 OEB 
- 5 ~ m m Spherisorb S50DS2 (125 mm x 4.6 mm) and 3 ~ m m
Spherisorb S3CN (150 mm x 4.6 mm) hplc columns. 
Hichrom, Theale, Reading. RG7 4AA 
- MSE centaur 2 and MSE Microcentaur. 
Fisons PLC., Loughborough, Leicestershire. 
- "Gyrovap" centrifugal vacuum evaporator. 
V A Howe & Co., London. SW18 2LS 
- Gas-liquid chromatograph, model 104. 
PYE unieam Ltd., Cambridge, Cambridgeshire. 
- Gold/red fluorescent safelights. 
Thorn EMI, Birmingham. 
- "Microman" 250 #Jol, positive displacement pipette. 
"Pipettman" P200 & P1000, air displacement 
pipette. 
Gilson Medical Diagnostics, Villiers le-Bel, France. 
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- Analytical balance (5 decimal place). 
Ohaus, Florham Park, New Jersey, USA. 
- Coulter "Nano-sizer", emulsion particle sizer. 
Coulter Electronics Ltd., Harpenden, Herts. 
- DMS 100, ultraviolet/visible scanning 
spectrophotometer. 
Varian Techtron pty. Ltd., Australia. 
- Ultrasonic water bath. 
Decon Ultrasonics Ltd., Conway House, Hove, Sussex. 
- Ultrafree, 0.1 ~ m m ultrafiltration units. 
Millipore (UK) Ltd, Watford, Herts. WD1 8YW 
- Magnetic stirrer 
Analytical Supplies, Little Eaton, Derbyshire. 
- Rotary tube mixer. 
Denley, Billinghurst, Sussex. RH14 9EZ 
- MFC Microfluidiser. 
Microfluidics Corporation, Newton, Mass., USA. 
b) Disposables. 
- Polypropylene microcentrifuge tubes (1.5 ml). 
Elkay Laboratory Products (UK) Ltd., Basingstoke, 
Hants RG2 ONA. 
- Hypodermic needles; 25 9 x 5/8", 23 9 x 1 ~ " , ,
Syringes, polythene disposable 1 ml and 2 ml volume. 
Sabre International Products Ltd., Reading, 
Berkshire RG2 OLQ. 
- Sagatal: Sodium Pentobarbitone 60 mg/ml. 
RMB Animal Health Ltd., Dagenham RM10 7XS. 
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- Borosilicate glass tubes (15 ml capacity). 
Corning Glass Co., Halstead, Essex. 
c) Chemicals. 
- Ammonium acetate (Analar), 
Hydrochloric acid (Analar), 
Sodium chloride (Analar). 
BDH chemicals Ltd., Poole, Dorset. 
- Acetonitrile, HPLC grade. 
Diethyl ether, HPLC grade. 
Methanol, HPLC grade. 
May & Baker, Dagenham, Essex. 
- Tetrahydrofuran, HPLC grade. 
Sigma Chemical Co., Poole, Dorset. 
- Octan-1-ol: glass distilled. 
Aldrich Chemical Co. Ltd., Gillingham, Dorset. 
- Retinoids; Ro 01-4955 (Retinol) 
Ro 01-5488 (All-trans retinoic acid) 
Ro 04-3780 (13-cis retinoic acid) 
Ro 10-9359 (Etretinate) 
Ro 11-5036 (Aromatic retinoid) 
Ro 15-0778 (Temarotene) 
Ro 15-1570 (Etarotene) 
Roche Products Ltd., Welwyn Garden City, Herts 
AL7 3AY 
- Softigen 767 (PEG-6 caprylic/capric glycerides) 
Dynamit Nobel, Gateway House, Slough, OK. 
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- Tween 20 (Po1yethy1ene sorbitan mono1aurate) 
Tween 80 (Po1yethy1ene sorbitan monoo1eate) 
Tween 85 (Po1yethy1ene sorbitan trio1eate) 
BDH chemicals Ltd., Poo1e. Dorset. 
Labrafil M1944CS (Apricot kernel oil PEG-6 
complex). 
- Labrosol (Glyceryl caprylate/caprate and PEG-8 
caprylate/caprate) 
A1fa Chemicals Ltd., Brackne11, UK. 
- Span 20 (Sorbitan monolaurate) 
Span 80 (Sorbitan monoo1eate) 
Span 85 (Sorbitan trio1eate) 
Sigma Chemical Co. Ltd., Poo1e, Dorset. 
- Lipoid E80 
BASF, Parsippany, NJ 07054. 
- Soyabean oil, cottonseed oil, Linoleic acid (95%), 
Oleic acid (95%), caprylic acid (99%), Tri1ino1ein 
(99%) • 
Sigma Chemical Co. Ltd., Poo1e, Dorset. 
- Mig1yo1 812 (Mixed medium chain tri-acyl 
glycerol) • 
Dynamit Nobe1, Gateway House, Slough, UK. 
- DL Monoolein 
Fluka Bio-Chemika, G10ssop. SK13 9XE 
- Neobee M5 (Mixed medium chain mono-acyl glycerols) 
Alfa Chemicals, Bracknell, Berkshire. 
- Monocaprylin (Imwitor 308) 
Huls (UK) Ltd., Slough, Berkshire 
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- Arachis oil BP (Peanut oil). 
Evans Ltd.,Greenford, Middlesex. 
-sos water soluble diet 821338 
Special Diet Services Ltd., Witham, Essex. 
d) Surgical equipment and apparatus. 
- Clippers. 
Wahl Clipper corporation, Illinois, USA 
- Polythene cannula: i.d. 0.5 mm lo.d. 1.0 mm 
Portex Ltd., Hythe, Kent. 
- Scalpel blades size 22, cotton buds, surgikos 
disposable surgical gloves. 
Medical School Stores, Queens Medical Centre, 
Nottingham. NG7 2RO 
- Swann-Morton scalpel handle size 4, "Spencer-
Wells" artery forceps, round ended scissors, 
miniature spring scissors (5 mm blades), medium and 
small curved ended forceps, small rodent artery 
clip. 
H. Wilkinson & Co. Ltd., Nottingham NGl 4EJ 
- Electrically heated mat 15 Watts. 
IMS, Congleton, Cheshire. CW12 lLA 
- Stereo dissecting microscope. 
Leitz UK Ltd.,Milton Keynes. MK5 aLB 
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CHAPTER 1 
A STUDY OF THE PHYSICOCHEMICAL PROPERTIES 
OF THE RETINOIDS. 
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1.1. Partition behaviour of the retinoids. 
1.1.1.1. The octanol-water partition coeffioient. 
A partition coefficient (P) is defined as the ratio 
of the equilibrium solution partitioning of a solute 
between an organic and an aqueous phase, most often 
octan-1-01 and water (Pow). 
Pow = Conoentration in the octan-l-01 phase 
concentration in the aqueous phase 
Equation ••.•• 1 
"Solutes which display some preference for the 
octan-1-01 phase (Pow > 1) are designated lipophilic 
or hydrophobic, those with preference for the 
aqueous phase (Pow < 1) are labelled as hydrophilic" 
(Van der Waterbeemd & Testa, 1987). 
The simplest and most frequently used technique for 
the experimental determination of P is to allow a 
compound to distribute between an aqueous and an 
organic phase in a glass vessel. Once equilibrium 
has been reached the concentration of the solute in 
one or both phases is measured. This is known as the 
shake flask method (Lyman, 1982). 
The range of possible values for P covers several 
orders of magnitude, therefore it is most convenient 
to express the partition coefficient in terms of its 
logarithm to base 10 (log. P). 
The precision and accuracy of partition coefficients 
depend heavily upon numerous experimental factors: 
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a) The pH and the ionic strength of the aqueous 
phase may influence the degree of ionisation of the 
solute if this contains basic or acidic 
functionalities (Scherrer & Howard, 1977). 
b) The nature of any buffer may influence ion-pair 
formation. An ionic solute may be stabilised by a 
counter ion present in the buffer which may affect 
its affinity for the aqueous phase. 
c) The purity of the organic phase, which may affect 
the solubility of the solute and may result in 
analytical interference. 
d) The purity and stability of the solute, solute 
concentrations, the ideality of the solution 
(formation of dimers, aggregates, micelles) the 
problems of centrifugation (formation of emulsions) 
and the mutual solubility of the two phases may 
influence the analytical method (Brookes et al., 
1986). It has been reported that log. P is a 
function of the solute concentration for 
concentrations greater than 0.01 mol/l. 
The shake flask method is normally restricted to 
compounds with log. P values of less than 4 units in 
order to reduce these effects (Lyman, 1982., Brookes 
et a1., 1986). 
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1.1.1.2.1. Validation of a slow stir method for 
measurement of log. p ~ ~
A novel method for the determination of log. P 
values for solutes with log. P > 5 has been 
described by Brookes et al. (1986). 
The method describes the difficulties in determining 
log. P values for chemicals with high values of P 
when using the traditional shake flask method. Large 
volumes of equilibrated aqueous phase are usually 
required for analysis and traces of octan-1-ol in 
this sample can lead to large errors. contamination 
of the aqueous phase is a particular problem in 
shake flask experiments because emulsion formation 
in the aqueous layer often occurs during shaking. 
The technique described to surmount some of these 
problems was to equilibrate the water and octan-1-ol 
phases under conditions of slow stirring. The octan-
1-01 containing the compound being tested was 
floated onto the water phase in a small conical 
flask. A glass sampling tube was dipped into the 
aqueous phase to allow sampling but preventing 
contamination of the sampling pipette with the 
octan-1-ol phase. The flask was stirred slowly using 
a magnetic bar and equilibration between the two 
phases was reported to be achieved within 2 to 3 
days. 
In order to validate this method for determining the 
lipophilicities of the retinoids, a number of simple 
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experiments were performed in order to determine the 
solubility of octan-1-ol in the aqueous phase of the 
slow stir flask. Slow stir flasks, containing water 
(90 ml) and octan-1-ol (10 ml) were prepared and 
allowed to stir for 72 hours. Samples of the aqueous 
phase were removed from the flasks and analysed for 
the presence of octan-l-ol using the gas-liquid 
chromatographic (G.L.C.) method described below. 
1.1.1.2.2. G.L.C. method tor the analysis of octan-
1-01 in water. 
The G.L.C. system comprised a PYE 104 gas 
chromatograph fitted with a 1.5 m Porapak Q column. 
Nitrogen carrier gas was passed down the column at a 
flow rate of 85 ml/min. A flame ionisation detector 
was used with an air flow of 10 ml/min and a 
hydrogen flow of 17 ml/min. 
The column temperature was adjusted to 230°C and the 
injector and detector temperatures to 250°C. 
A stock standard of octan-1-ol (37.00 mg/l) was 
prepared by weighing 37.00 mg into a 1000 ml 
volumetric flask and diluting to volume using double 
distilled water. A second standard (18.50 mg/l) was 
prepared by diluting the standard with an equal 
volume of water. 
Samples (5 ~ l ) ) of the aqueous octan-l-ol standard or 
the aqueous phase from the slow stir flask were 
injected onto the G.L.C. system. 
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1.1.1.2.3. Results and discussion. 
Using the GLC method described, octan-l-ol eluted at 
a retention time of 25.8 minutes. 
The peak heights of the octan-l-ol peaks were 
measured on samples taken from the aqueous phase of 
the slow stir flask and were compared with those 
measured for the octan-l-ol standard solutions. The 
octan-l-ol concentration in the aqueous phase of the 
slow stir flask was estimated to be 1.36 (± 0.09) x 
1 0 ~ ~ molll (17.7 p.p.m.). To permit a clearer 
understanding of the proportion of octan-1-ol in 
water, concentrations of octan-l-ol have also been 
expressed in parts per million (p.p.m.). 
Previous reports of the concentrations of octan-1-ol 
in water and water in octan-1-01 have been reported 
on samples t,aken from a shake flask (Leo et al., 
1971). At equilibration the aqueous phase was 
reported to contain 4.5 x 10-3 molll (585 p.p.m.) of 
octan-1-ol. 
An explanation for the difference in concentration 
estimated using the two methods may be the presence 
of a micro-emulsions of octan-1-01 in water formed 
during vigorous shaking in the shake flask method. 
It seems likely that slow stirring will prevent the 
formation of such emulsions and these data may be 
closer to the true solubility of octan-1-ol in 
water. 
These data support the hypothesis that both the slow 
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stir flask method and the shake flask method would 
tend to underestimate values of log. P for solutes 
with log. P values greater than 5. For example, in a 
slow stir flask containing a solute with a 10g.P 
of 6, there will be 17.7 times more solute dissolved 
in the octan-1-01 which is present in the aqueous 
phase than the amount of solute dissolved in the 
water itself. This predicted negative deviation 
between the log. P data, measured using the slow 
stir flask technique, and the theoretical log. P 
would explain some of the discrepancies between 
experimentally determined and computer predicted 
log. P values reported in the original text (Brookes 
et al., 1986). 
1.1.2. Other methods for the measurement of log. P. 
Many other methods have been used to determine log. 
P. These include the use of a continuous solvent 
extraction method (Davis et al., 1976), segmented 
continuous flow (Kinkel & Tomlinson, 1980), 
potentiometric titrations, automated log. P 
measurements using a segmented continuous flow 
technique (Garst & Wilson, 1984) and liquid membrane 
electrodes (staroscik & Blasciewicz, 1985). 
Various workers have also correlated the 
lipophilicity of a number of compounds with their 
respective chromatographic retention parameters and 
some of these methods are considered below. 
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1.1.2.1. Chromatographio methods for measurement of 
log. P. 
Many authors have correlated log. P measured using 
the shake flask method with the logarithm of 
capacity factors (log. k') using an high performance 
liquid chromatographic (hplc) method (Bruggeman 
et al., 1982., Thus & Kraak, 1985., Minick et al., 
1987., Miyake et al., 1986., Sabatka et al., 1987) 
or the retention parameter (Rm) measured from a thin 
layer chromatographic system (Equation 2 and 
Equation 3) (Hulshoff & Perrin, 1976). 
= loq. k' = log. «l/Rr )-l) 
Equation •••• 2 
Rr = distanoe travelled by sample spot 
distanoe travelled by eluent 
Equation •••• 3 
Rm = thin layer chromatographic retention 
parameter. 
k' = capacity factor. 
These various authors have claimed to demonstrate 
good correlations between log. P and Rm, but only for 
congeneric series of compounds such as the n-alky1 
and ch10ro-substituted benzenes (Thus & Kraak, 
1985), phenols, anilines and nitroimidazole 
derivatives (Carlson et al., 1975). None made any 
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predictions of log. P on the basis of experimentally 
determined log.k' values. 
1.1.2.2. Experimentallv determined log. P values 
from group contribution or "-fragment constant data. 
The partition coefficient for most drugs can be 
predicted reasonably well by several functional 
group contribution approaches. Either the Hansch 
"-system (Leo et al., 1971., Leo et al., 1975), or 
the Rekker f-system (Rekker, 1977., Rekker & 
de Kort, 1979). 
Both systems are based on the addition of various 
functional groups or fragmental constants to the 
overall properties of a molecule and log. P values 
may be calculated from the Equation 4a (Rekker) and 
Equation 4b (Hansch). 
Equation ••••• 4a 
t D= fragmental constant for a molecular fragment n 
aD= number of times this fragment appears 
log. P (RG) 
log. P (RG) 
log. P (Km 
= log. P (Rlt) + wG Equation ••••• 4b 
= Compound containing a constituent 
group, G. 
= Parent compound. 
= Constant, which is characteristic 
for a given atom or group. 
The Hansch system has been reported to be more 
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convenient when log. P of the parent compound is 
known and a single group is changed from parent to 
drug (Lyman et al., 1982). The Rekker system is 
simpler if no data on the log. P are available and 
calculations are based on the complete chemical 
structure (Lyman et al., 1982). 
These two methods give differences in their 
predictive values (Van der Waterbeemd & Testa, 
1987). For example, DDT and propanolol have 
experimental log. P values of 5.98 and 3.56, 
respectively using the shake flask method (Van der 
Waterbeemd, 1986) but the Rekker and Hansch methods 
predict values of 7.56 and 3.66, and 6.89 and 2.90 
respectively (Leo et al., 1971., Leo et al., 1975, 
Rekker, 1977., Rekker & de Kort, 1979). 
Van der Waterbeemd & Testa (1987), have studied the 
partitioning behaviour of protonated amines and 
concluded that, "predictive models of averaging 
values such as existing fragmental systems are 
acceptable only as a first approximation, with 
predictive values ranging from excellent to 
illusory." 
1.1.2.2.1. Calculation of log. P values for the 
retinoids using a computer database ot tragmental 
data. 
A computer modelling program was used (Compudrug 
ProLog P. version 2.) which contained a database of 
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the Rekker fragmental constants. After entry of the 
various constituent groups of a molecule into a 
spreadsheet the log. P value for the composite 
molecule was computed. Data could be entered into 
the program in number of forms: 
a) as the constituent atoms in the molecule e.g. 
carbon (C), hydrogen (H), oxygen (0), sulphur (S). 
b) as the main functional groups in the molecule 
e.g. methyl (CHa), carboxylic acid (COOH), alkenyl 
(C=C). 
or c) as the larger constituent fractions within the 
molecule e.g. napthyl, phenyl. 
Log. P values were calculated using this program 
(Rekker system) for a series of six retinoids; 
retinol (Ro 01-4955), tretinoin (Ro 01-5488), 
isotretinoin (Ro 04-3780), acitretin (Ro 10-1670), 
etretinate (Ro 10-9359) and temarotene (Ro 15-0778). 
These values were compared with log. P data obtained 
on the same molecules using the Hansch system (Van 
der Waterbeemd, 1990). 
1.1.2.2.2. Results and Discussion, 
The calculated values for log. P using the methods 
of Rekker and Hansch are displayed in Table 2. 
It can be seen that each method gave slightly 
different results for the same retinoids but the 
general trend for this series of compounds was 
similar. Retinol (Ro 01-4955) showed the lowest 
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Table 2. Calculated values of log P for a seleotion of 
retinoids using Hansch and Rekker fragmental data. 
Retinoid 
Ro 01-4955 
Ro 01-5488 
Ro 04-3780 
Ro 10-1670 
Ro 10-9359 
Ro 15-0778 
Log P 
Rekker method * 
6.908 
6.921 
6.921 
7.718 
8.625 
8.925 
Log P 
Hansch method I 
6.203 
6.614 
6.614 
6.115 
7.020 
8.400 
I .. From Van der Waterbeemd (Van der Waterbeemd, 1990» 
* .. From Compudrug (ProLog P, Version 2). 
values (least lipophilic) of 6.908 and 6.203 for the 
Rekker and Hansch methods respectively and the 
arotinoid (Ro 15-0778) gave the highest values (most 
lipophilic) of 8.950 and 8.481. All the retinoids 
showed log. P values in excess of 6 and could 
therefore be classed as highly lipophilic. 
A number of points should be stressed with respect 
to calculated log. P values; 
i) Hansch and Leo have been cited by Lyman (1982) as 
saying that values of log. P greater than 6 are 
likely to be over-estimates of experimentally 
determined log. P perhaps by one or more log units. 
ii) neither the Rekker or Hansch methods take into 
consideration the ionisation of polar groups in the 
molecule and deal with the situation where the 
molecule is completely unionised. Calculated values 
for log. P obtained for compounds such as Ro 04-3780 
or Ro 10-1670, which contain a ionisable acid group 
and will partially ionise in an aqueous environment, 
will be overestimates of experimentally determined 
log. P. It is however, simple to correct these 
calculated log. P values if the pH of the solvent 
and pKa of the molecule is known. 
iii) calculation of log. P values using the Rekker 
fragmental data and using the three methods for 
entering structural data as described in 1.1.2.2.1. 
gave identical log. P values for all the retinoids 
estimated. 
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The data for log. P calculated here confirmed the 
predicted increase in 1ipophi1icity in the three 
compounds selected for the lymphatic absorption 
studies. 
Ro 04-3780 (Isotretinoin - Roaccutane - 13 ~ ~
retinoic acid) was one of the least lipophilic of 
those studied (log. P = 6.921 or 6.614). 
Ro 10-9359 (Etretinate - Tigason) was found to be 
approximately ten times more lipophilic (log. P 
= 8.625 or 7.020) than Ro 04-3780. This compound is 
the ethyl ester of the aromatic acid derivative of 
retinoic acid. 
Ro 15-0778 (Temarotene) is approximately ten times 
(log. P = 8.925 or 8.480) more lipophilic than 
Ro 10-9359 and one hundred times more so than 
Ro 04-3780. These data are displayed in Table 2. 
1.2. Solubility studies of seleoted retinoids in a 
range of oils. oil mixtures and self-emulsifying oil 
systems. 
The measurements of partition coefficient and oil 
solubility are often used as estimates of the 
lipophi1icity of a particular molecule. As discussed 
in section 1, the partition coefficient is defined 
as the ratio of the equilibrium solution 
partitioning of a drug between an organic and an 
aqueous phase (most often octan-l-01 and water). The 
solubility of a compound in oil is an absolute 
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measurement of the solubility of a solute in 
equilibrium with its pure phase. It is possible for 
a compound to have a large log. P value but not 
necessarily a high solubility in an oil whilst 
another compound may be very soluble in an oil but 
have a relatively low log. P value (Charman & 
Stella, 1986). In addition a high solubility of a 
compound in a solvent such as octan-1-ol will not 
always relate to a high solubility in a poorly 
solvating, largely hydrocarbon vehicle such as a 
long chain fatty acid triglyceride (Charman & 
Stella, 1986b). 
It was decided to study the solubility of the three 
chosen retinoids (Ra 04-3780, Ra 10-9359 and 
Ro 15-0778) in a range of oils, oil mixtures and 
self-emulsifying oil systems which were thought to 
be possible candidates for use in the oral dosing 
studies in the rat. A complete list of oil systems 
is shown in Table 3. 
1.2.1.1. The determination of the solubility of 
seleoted retinoids in a series of oil systems. 
a) Duplicate measured volumes of each oil (1.0 ml) 
were transferred by positive displacement pipette 
into microcentrifuge tubes (1.5 ml). One pair of 
tubes was used for each retinoid to be tested. 
b) Small additions (5 - 10 mg) of the retinoid were 
accurately weighed into each tube, to give a known 
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Table 3. oil systems used in the solubility studies ot 
three selected retinoids. 
1) Free fatty acids. 
caprylic acid c 8 : 0 
Oleic acid C18 : 1 
Linoleic acid C18 : 2 
2) Monoglyceride oils. 
Glyceryl monocaprylate 
Glyceryl monooleate 
3) Mixed medium chain monoglyceride. 
Neobee M5 Glyceryl monocaprylate C8 : 0 and 
Glyceryl monocaprate C10 : O 
4) Mixed medium chain triglyceride. 
Miglyol 812 Glyceryl esters of caprylic 
(approx. 55%) and capric acid (approx. 45%). 
5) Mixed long chain triglycerides (Altman & Dittmer, 
1972). 
Palmitate Oleate Linoleate 
C16 : 0 C18 : 1 C18 : 2 
cottonseed 26% 18% 52% 
Soyabean 12% 24% 51% 
Peanut 12% 53% 26% 
Trilinolein 99% 
concentration in the oil. 
c) The oil samples were placed in an ultrasonic 
water bath for 30 minutes (during which time the 
temperature of the samples rose from 24°C to 55° -
60°C) • 
d) The samples were allowed to equilibrate at a 
temperature of 24°C and each tube was examined for 
visible signs of precipitation. 
e) After centrifugation (3000 x g for 10 minutes), 
small aliquot of the oil was removed from each tube 
for analysis. In oil samples where no visible signs 
of precipitation was observed, steps b) to e) were 
repeated until 'visible precipitation was observed. 
f) Quantitative analysis of the retinoid in each 
sample of oil was carried out using the hplc method 
as described below. 
1.2.1.2. Method for the quantitative analysis of 
retinoids in oil samples. 
Analysis of the retinoid concentration in the oil 
samples was carried out using the hplc method 
described in Chapter 2 and summarised in Table 6. 
For analysis, standard solutions of the three 
retinoids were prepared by accurately weighing the 
pure compounds into a volumetric flask and diluting 
with THF (tetrahydrofuran, hplc grade). standard 
solutions contained 6.88 mg/ml of Ro 04-3780, 
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9.00 mg/m1 of Ro 10-9359 or 12.85 mg/ml of 
Ro 15-0778. 
An a1iquot (approximately 0.15 m1) of each oil 
sample was transferred by positive displacement 
pipette into a Millipore Ultra free filter unit (0.1 
~ m ) ) and centrifuged (10,000 x 9 for 20 minutes) to 
remove undissolved retinoid. A small accurately 
weighed sample (10.0 - 50.0 mg) of the filtered oil 
was dispensed into a 10 ml volumetric flask and 
adjusted to volume using THF. THF was found to 
disperse and solubilise the oil samples completely 
and was also miscible with the hp1c mobile phase. 
A sample (25 ~ l ) ) of the retinoid in THF was injected 
onto the appropriate hplc system using a fixed 
volume loop injection system. Peak areas were 
calculated using a Shimadzu CR3-A computing 
integrator and retinoid concentrations were 
calculated by comparison of the peak areas of the 
oil samples with the standard retinoid solutions. 
Retinoid concentrations measured on oil samples to 
which accurately weighed additions of retinoid had 
been made, but in which the retinoid was completely 
soluble, were used to assess the recovery of 
retinoid from the oils. 
1.2.1.3. Results and Discussion. 
From the analysis of the concentration of retinoid 
measured in a fixed volume of oil (1 ml) containing 
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accurately weighed additions of retinoid, an 
estimate of the mean recovery of added retinoid of 
95.4% (± 4.25) was achieved after dispersion of the 
oil in THF (compared with only 77.8% (± 4.28) when 
oil was dispersed in mobile phase). 
The concentration of the retinoid in each oil system 
was adjusted for the density (obtained from the 
suppliers' data sheets) of the oil and expressed as 
milligrams retinoid per millilitre of oil. These 
data are shown in Table 4. 
The oil solubility data for the three retinoids were 
consistent with the data reported by Roche Products 
Ltd. The solubility of Ro 04-3780 in peanut oil was 
6.1 mg/ml (compared with 3.0 mg/ml (Weber & Felix, 
1983», the solubility of Ro 10-9359 in peanut oil 
was 22.0 mg/ml (compared with 26.0 mg/ml (Weber & 
Felix, 1983» and the solubility of Ro 15-0778 was 
144.9 mg/ml (compared with greater than 100 mg/ml 
(Weber et al., 1983). 
The oil solubility data for the three retinoids show 
a number of common trends. 
a) For any oil type, Ro 15-0778 showed the greatest 
solubility, Ro 10-9359 was the second most soluble 
and Ro 04-3780 the least soluble. This decrease in 
solubility relates closely to the decrease 
lipophilicity as defined by the respective log. P 
values (Table 2) of these compounds. 
b) All retinoids showed poor solubilities in the 
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Table 4. Solubility (mg/ml) at 24°0. of three retinoids in a 
range of oils, oil mixtures and self-emulsifying systems. 
Ro 15-0778 Ro 10-9359 Ro 04-3780 
Monocaprylin 47.8 Monoolein 6.60 Monoolein 
Monoolein 58.0 Monocaprylin 16.0 Trilinolein 
A.T.S. 
A.T.L. 
M.T.L. 
79.3 Oleic acid 
89.2 Soyabean 
103.8 Cotton seed 
Linoleic 109.5 Peanut 
Soyabean 126.8 A. T. s. 
Trilinolein 139.5 A.T.L. 
Peanut 144.9 Linoleic 
20.9 Cottonseed 
21. 2 Soyabean 
21.3 Peanut 
22.0 Neobee 
22.8 Miglyol 812 
23.5 A.T.L. 
25.1 A.T.S. 
Oleic 154.1 Mig:Oleic 26.3 M.T.S. 
Mig: Linoleic 155.8 Mig: Linoleic 27.4 Oleic 
Mig: Oleic 165.3 Trilinolein 33.2 M. T. L. 
2.16 
2.51 
5.10 
5.68 
6.10 
11.1 
12.0 
15.8 
15.9 
23.8 
24.4 
25.3 
Cottonseed 165.5 M.T.S. 33.5 Monocaprylin 26.9 
170.6 M.T.L. 35.2 Linoleic 30.5 Miglyol 812 
M.T.s. 171.7 Mig:caprylic 36.0 Mig:Linoleic 35.7 
Mig: Caprylic 173.2 Neobee 
Caprylic 
Neobee 
Notes: 
196.2 Miglyol 812 
201. 8 Caprylic 
42.1 Mig:Oleic 36.7 
44.5 Mig:Caprylic 49.5 
68.7 Caprylic 73.3 
i) Mig:Linoleic, Mig:Oleic and Mig:Caprylic contain equal 
Volumes of Miglyol 812 and either linoleic acid, oleic acid 
or caprylic acid. 
ii) A.T.S., A.T.L., M.T.S. and M.T.L. are self-emulsifying 
oil systems containing, 16% Tween 85 (T) and either, 80% 
peanut oil (A) or 80% Miglyol 812 (M) and either 4% Span 85 
(S) or 4% Labrasol (L). 
iii) A full list of oils is shown in table 2. 
long chain unsaturated oil, monoolein and medium 
chain saturated fatty acyl glycerol oil, 
monocaprylin. However, in the mixed monoglyceride 
oil Neobee MS, which contains glyceride esters of 
both capric or caprylic acid, the more lipophilic 
retinoids Ro 10-9359 and Ro 1S-0778 showed higher 
solubilities than in the respective medium chain 
fatty acyl monoglycerol oil. 
c) The solubilities of the retinoids in mixed long 
chain fatty acyl triglycerol oils (peanut, 
cottonseed and soyabean) were generally low, and 
consistently lower than solubilities measured in the 
mixed medium chain fatty acyl triglycerol oil 
(Miglyo1812). 
d) The solubilities of retinoids in the mixed medium 
Chain fatty acyl monoglycerol oil (Neobee MS) and 
mixed medium chain fatty acyl triglycerol oil 
(Miglyol 812) were similar. This observation may be 
anticipated, since these oils contain the same types 
of medium chain fatty acid esters. 
e) The solubilities of the retinoids in the medium 
chain fatty acid (caprylic) were very high, however 
solubilities in long chain (unsaturated) fatty acids 
(linoleic and oleic acid) were variable and 
generally found to be intermediate in value between 
caprylic acid and the mixed LCFA triglyceride oils. 
f) There is a trend in the relative solubilities of 
the retinoids in a range of different oil systems as 
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the lipophilicity of the retinoids increase. For 
example: Linoleic acid has a solubility of 
Ro 04-3780 almost six times greater than that found 
in cottonseed oil (Linoleic/Cottonseed = 5.98). The 
ratio for the solubility of Ro 10-9359 in these oils 
was near to unity (Linoleic/Cottonseed = 1.18) and 
was less than one (Linoleic/Cottonseed = 0.66) for 
Ro 15-0778. 
g) Some of the solubility data shown in Table 4 are 
surprising. For example; the solubility of 
Ro 04-3780 in Miglyol:oleic acid is considerably 
higher than in either component alone, whereas for 
the other retinoids it lies, as expected, between 
the two values. This effect may be explained by some 
specific interaction between the retinoid and the 
oil. These may include hydrophobic interactions (Van 
der Waals forces) and hydrogen bonding. 
When comparing the solubility of retinoids in the 
self-emulsifying oil systems (SES) containing 80% 
peanut oil with peanut oil alone, one might have 
predicted the solubility to be 20% lower to reflect 
the reduction in oil content. Ro 15-0778 gave a much 
lower solubility in this SES, which is difficult to 
explain, unless the surfactant systems have some 
desolubilising effect on this compound influenced by 
the ionic nature of the SES or the retinoid. 
The increased solubility of the more polar 
Ro 04-3780 in SES compared with its solubility in 
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oil alone, may also be explained by a solubilisation 
effect. 
1.3. The molar absorptivity ee) and absorbance 
maximum <A_x) of the retinoids. 
The molar absorptivity (e) and absorbance maximum 
(A-) of the retinoids were measured in order to 
determine their minimum detectable absorbance on the 
proposed hplc system and to determine their optimum 
(maximum) analytical absorption wavelength. 
1.3.1. Method for the measurement of e and ~ . .
stock solutions of three retinoids were prepared by 
accurately weighing small samples (10.0 - 100.0 mg) 
of each compound into a 100 ml volumetric flask and 
adjusting to volume using hplc grade methanol. 
An appropriate dilution of these stock solutions was 
prepared in methanol and placed in an ultraviolet 
spectrophotometer and the absorbance was measured 
between 250 and 400 nanometres. The absorbance 
maximum ( A ~ ) ) was located and the molar absorptivity 
was calculated from Beer's law (Equation 5). 
A = e.b.c Equation •••• 5 
A = Absorbance at a specified wavelength. 
e = Molar absorptivity. 
b = Path length of the measuring cuvette (1 cm) 
c = Molar concentration of the solution. 
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In order to avoid any deviation from linearity due 
to instrumental or chemical factors, the 
concentration at which measurements were taken was 
adjusted to give absorbance readings within a linear 
concentration range of 0.3 to 0.8 absorbance units 
(Willard et al., 1988). 
1.3.2. Results and oono1usions. 
The calculated molar absorptivity (e) and A ~ ~ of the 
three retinoids are shown in Table 5. 
From these data it can be seen that all three 
compounds show strong absorbance maxima in the 
ultraviolet region of the spectrum, with molar 
absorptivities of 23,800 l.mol-'.cm-'. (Ro 15-0778), 
43,600 l.mol-'.cm-'. (Ro 04-3780) and 51,000 l.mol-'.cm-' 
(Ro 10-9359), these data are in close agreement with 
those reported by Groenendijk et al. (1980) for a 
series of vitamin A analogues, including the all-
trans isomers of retinol (52,100 l.mol-'.cm-') and by 
Szuts & Harosi (1991) for retinal (42,400 l.mol-'.cm-') 
retinol (38,300 1 . m o ~ ' . c M ' ) ) and all-trans retinoic 
acid (49,700 l.mol-'.cm·'.). Ro 04-3780 and Ro 10-9359 
show a A ~ ~ around 350 - 360 nm, whereas the 
arotinoid, Ro 15-0778 has an A ~ ~ value further into 
the ultraviolet at 279 nanometres correlating with 
the conjugated aromatic structure of this compound. 
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Table 5. Molar absorptivities and absorption maxima of the 
retinoids. 
Retinoid Molar absorptivity Absorption maximum 
- (litre. mol-·. cm-·) 
~ ~
(nanometres) 
Ro 04-3780 4.358 x 104 349 
Ro 10-9359 5.192 x 104 360 
Ro 15-0778 2.388 x 104 279 
1.4. Effects of liqht exposure on the retinoids. 
It is known that the retinoids undergo photo-
isomerisation and decompose in the presence of short 
wavelength radiation (Brazzell & Colburn, 1982). 
In view of this reported photo-degradation, care was 
taken to protect all retinoid samples from light. 
For this purpose a darkroom was set up and fitted 
with "safelights" which did not emit ultraviolet or 
visible light below 500 nanometres. This room was 
designated the "yellow room" and all unprotected 
procedures using retinoids were performed in this 
room. Procedures performed outside this room were 
protected from light, the samples being wrapped in 
aluminium foil. 
In order to assess the effect of light on the 
handling of retinoid samples during in-vivo and in-
vitro procedures it was decided to test the effect 
of various lighting conditions on the stability of a 
model retinoid, Ro 04-3780. 
1.4.1. Method to study the effects of light on the 
retinoids. 
A series of experiments were performed in order to 
investigate the effects of various lighting 
conditions on the stability of 04-3780. 
A stock solution containing 5 ~ g / m l l of Ro 04-3780 
was prepared in methanol, under protective lighting 
conditions, and was divided into four samples. 
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The first sample was wrapped in foil and kept in 
complete darkness for the duration of the procedure. 
This acted as the control sample. 
The second sample was exposed to light in the 
"yellow room". 
The third sample was exposed to the light from 
standard "daylight" fluorescent tubes in the 
laboratory. 
The fourth sample was exposed to daylight. 
At timed intervals after exposure to light, samples 
from each of the test groups were injected onto the 
hplc system described in Chapter 2. 
The chromatographic peak height was measured for 
each sample and compared with the peak height for 
the control sample (sample one). The data showing 
the change in relative peak heights against time of 
exposure to light are displayed in Figure 4. 
1.4.2. Results and conclusions. 
The three different lighting conditions used in this 
procedure were selected to represent typical 
conditions which might apply during the handling of 
retinoids. 
Under protective yellow lighting conditions over a 
180 minute period, changes in the peak height for 
Ro 04-3780 were not significantly (p > 0.05) 
different from the control sample. 
After exposure to standard laboratory fluorescent 
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Figure 4. Effect of light exposure on the hplc peak 
height of a Ro 04-3780 standard solution. 
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lighting conditions for 30 minutes, there was a 
decrease in the peak height for Ro 04-3780 of 6.2% 
compared with the control sample. This change in 
peak height was significantly different (p < 0.05) 
from the control sample. 
After only 60 seconds exposure to daylight (not 
direct sunlight) more than 50% of the peak height in 
the sample was lost (p < 0.001). 
Although the peak height of Ro 04-3780 decreased in 
the presence of light, any conversion to the all-
trans isomer, Ro 01-5488, could not be detected and 
decomposition to any other metabolites which could 
be detected on the hplc system was not observed 
(Brazzell & Colburn, 1982). 
The following conclusions can be drawn from the 
results of exposure to lights of various types:-
a) The retinoids are extremely sensitive to the 
effects of light. 
b) The retinoids must be protected from exposure to 
daylight. All procedures involving retinoids and 
samples containing retinoids, should be performed 
under safelights and samples should be protected 
from light during storage by the use of aluminium 
foil wrapping. 
c) A brief exposure of samples to laboratory 
lighting was deemed as being acceptable. However, 
when samples are to be stored for long periods, such 
as when large batches of extracted retinoid samples 
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were being analysed using the hplc autosampling 
injector, the sample rack was darkened using a 
wrapping of aluminium foil and repeated standard 
solutions were interspersed within the batch to 
allow correction for photo-decomposition during the 
analysis period. 
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CHAPTER 2. 
ANALYTICAL METHODS FOR THE QUANTITATIVE ANALYSIS OF 
RETINOIDS IN LYMPH, PLASMA AND OIL SAMPLES. 
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2.1. Introduction. 
All retinoids are essentially lipophilic in nature 
and they may be therefore analysed using either 
normal phase; (De Leenheer et al., 1990., McNamara & 
Blouin, 1990., Rhys-Williams, 1985) or reversed 
phase; (Vane et al., 1982., curley et al., 1987., 
Kalin et al., 1984., Cotler et al., 1983., Bugge 
et al., 1985., Cavina et al., 1988., Bhat et al., 
1988) high performance liquid chromatography (hplc). 
Normal phase chromatography uses a polar stationary 
phase (often hydrophilic) such as a silica or a 
cyano-bonded silica packing and a less polar mobile 
phase. To select an optimum mobile phase, it is 
common to start with a pure hydrocarbon mobile phase 
such as heptane or hexane. If the sample is strongly 
retained, the polarity of the mobile phase 
increased, normally by the addition of small amounts 
of a polar solvent such as methanol or dioxan. In 
the normal phase mode, water is the strongest eluant 
and care must to be taken to protect the column from 
aqueous solvents. 
Reversed phase chromatography uses a hydrophobic 
column packing, usually with a octadecyl (C1S ) or 
octyl (Cs) functional group and a polar mobile phase, 
often a partially or fully aqueous mobile phase. 
Polar sUbstances are more soluble in the mobile 
phase and elute first. As the hydrophobic character 
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of the solutes increases, retention increases. 
Generally, the lower the polarity of the mobile 
phase, the higher is its eluant strength. water is 
the weakest eluant. Methanol and acetonitrile are 
popular solvents because they have low viscosity and 
are readily available with excellent purity. Eluants 
intermediate in strength between these solvents and 
water are usually obtained by preparing mixtures 
(Willard et al., 1988). 
A reversed phase chromatographic system is now the 
system of choice for the analysis of compounds in 
biological fluids. The use of such a system removes 
the problems associated with the need for 
conditioning of a normal phase column to remove 
polar materials which may become attached to the 
column packing. The reversed phase system also 
offers the advantages of using less organic 
solvents, faster equilibration with the mobile phase 
and their more established use in analyses of this 
kind. 
The hplc methods which were to be developed for the 
analysis of retinoids had to be fulfil the following 
criteria; 
a) Allow the extraction and quantitation of the 
retinoid in a biological sample such as plasma or 
lymph. 
b) Allow the extraction and quantitation of the 
retinoid from the oil systems which were to be used 
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in the in-vivo and in-vitro studies. 
c) Since the plasma and lymph sample volumes and the 
concentrations of the retinoid in the samples were 
expected to be small, the assay must therefore have 
a low limit of detection (10 ng/ml in 20 - 100 ~ l l
samples) 
d) Be suitable for the extraction and analysis of 
large batches of samples. 
e) Be able to resolve the parent compound from any 
of its possible isomers or metabolites and also from 
the internal standard. 
2.1.1. The hplo assay for Ro 04-3780. 
The first system to be developed (Table 6) was for 
the analysis of Ro 04-3780. Ro 11-5036 was chosen as 
an internal standard because it was structurally 
similar to Ro 04-3780 (Figure 3), had a similar 
absorption maximum to Ro 04-3780 and was readily 
available in a pure form. It was therefore expected 
to elute with a similar retention time to Ro 04-3780 
on the proposed hplc system. 
2.1.1.1. preparation of standard solutions, 
It has been established (Section 1.4) that the 
retinoids are sensitive to the effects of light. All 
unprotected procedures involving the use of 
retinoids were therefore performed in the "yellow" 
room. 
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Table 6. HPLC systems used for the quantitative analysis of 
retinoids in oils, rat plasma and lymph samples. 
Retinoid: Column: Mobile phase: 
Ro 04-3780 Spherisorb S50DS-2 Acetonitrile: 
Ro 10-9359 Spherisorb S3CN 
0.1 M Ammonium acetate 
pH 6. 0 (70 : 3 0 ) 
Detection: 350 nm 
Hexane : Methyl benzoate 
: propionic acid 
(991.5 : 6 : 2.5) 
Detection: 360 nm 
Ro 15-0778 Spherisorb S50DS-2 Acetonitrile: 
0.1 M Ammonium acetate 
pH 6. 0 (9 0 : 10) 
Detection: 280 nm 
a) Ro 04-3780 standard solution. 
A stock standard solution of Ro 04-3780 
(approximately 100 ~ g / m l ) ) was prepared by dissolving 
an accurately weighed sample of the compound into a 
volumetric flask and diluting to volume using hplc 
grade acetonitrile. This stock solution was further 
diluted in acetonitrile to give a range of working 
standards from 50 ng/ml to 1000 ng/ml. 
b) Internal standard. 
The aromatic retinoid, Ro 11-5036 was weighed into a 
volumetric flask and diluted in acetonitrile to give 
a working internal standard solution of 1000 ng/ml. 
c) Other retinoids. 
An acetonitrile solution (approx. 1000 ng/ml) of the 
all-trans isomer of Ro 04-3780 (Ro 01-5488) was also 
prepared. This standard solution was used to assess 
any interference from this compound resulting from 
isomerisation of Ro 04-3780 to Ro 01-5488 during 
either in-vivo or in-vitro procedures. 
2.1.1.2. Seleotion of analytioal oolumn. 
A reversed phase column (5 ~ m m 5pherisorb 550D5) was 
chosen for the analysis. This stationary phase 
material consisted of silica which was covalently 
bonded to an aliphatic (octadecyl) hydrocarbon 
molecule. Residual sites on the silica were end-
capped to decrease the retention of polar components 
of a sample. End capping is a secondary reaction of 
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silanol groups with trimethyl silyl chloride to 
block these polar positions. 
2.1.1.3. Se1eotion of mobile phase. 
The mobile phase was based on that used by Jakobsen 
et al. (1987) and curley et al. (1987) and contained 
acetonitrile and 0.01 M ammonium acetate buffer pH 
6.0. The relative proportions of the two components 
were adjusted using a solvent scouting technique. A 
gradient hplc system was employed to deliver 
acetonitrile through pump-A and 0.01 M ammonium 
acetate buffer pH 6.0 through pump-B. with a 
combined flow rate of 1 ml/min the proportions of 
the two solvents were adjusted between 60% and 80% 
acetonitrile to optimize the retention time and peak 
area of the Ro 04-3780 and Ro 11-5036 peaks. 
2.1.1.4. Seleotion of deteotion system. 
The retinoid compounds have been shown to absorb 
strongly in the ultraviolet region, hence UV 
detection was the hplc method of choice. Ro 04-3780, 
Ro 01-5488 and Ro 11-5036 were shown to have a broad 
absorbance peak around 350 nanometres and this 
wavelength was used in the subsequent 
investigations. 
- 89 -
2.1.2. Extraction methods for Ro 04-3780 in 
biological samples. 
2.1.2.1.1. Acid-ether extraction method. 
An accepted method for extracting weakly acidic 
compounds such as Ro 04-3780 (Ro 01-5488) or Ro 11-
5036 from an aqueous environment is to acidify the 
sample in order to convert the compound into the un-
ionised form and to subsequently extract the 
compound into a non-polar, organic solvent. 
The initial extraction method was similar to that 
used by Vane et al. (1982). -
i) Plasma (100 ~ l ) ) was transferred into a 
borosilicate glass tube (15 ml) using a positive 
displacement pipette. Acetonitrile (200 ~ l ) )
containing the internal standard (Ro 11-5036, 
1000 ng) was added to the tube. 
ii) The sample was acidified with 1 molar 
hydrochloric acid (1 ml) and extracted into diethyl 
ether (5 ml) by mixing on a rotary mixer (10 minutes 
at 30 r.p.m.) 
iii) Samples were centrifuged (2,200 x g for 10 
minutes) and a sample of the upper organic phase 
(4 ml) was transferred into a borosilicate glass 
tube (15 ml) and dried under reduced pressure at 30°C 
in a vacuum centrifuge. 
iv) Mobile phase (500 ~ l ) ) was added to each sample 
tube using a positive displacement pipette and the 
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tube was rotated gently to dissolve the extract. The 
extracted plasma samples were transferred into hplc 
autosampling vials. 
2.1.2.1.2. Direct protein precipitation extraction 
method (1). 
A second method for the extraction of retinoids from 
plasma and lymph samples involved a direct protein 
precipitation method using acetonitrile. 
i) Plasma samples (100 ~ l ) ) were transferred into 
polypropylene microcentrifuge tubes (1.5 ml) using a 
positive displacement pipette. The whole of a lymph 
sample (25 - 100 mg) was analysed in the tube into 
which it had been collected. 
Acetonitrile (100 ~ l ) ) was added to each sample. 
ii) Blank rat plasma samples (100 ~ l ) ) to which had 
been added acetonitrile (100 ~ l ) ) containing the 
appropriate concentration of retinoid standard (0, 
50, 100, 200, 400, 800 or 1000 ng/ml) were extracted 
for use as calibration standards. 
iii) To all lymph samples, plasma samples and 
standard tubes, acetonitrile (100 ~ l ) ) containing the 
internal standard (Ro 11-5036, 150 ng/ml) was added. 
iv) The tubes were mixed on a vortex mixer 
(20 seconds) and centrifuged in a microcentrifuge 
(13,000 x g, 10 minutes). The clear supernatant was 
transferred into an hplc autosampling vial. 
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2.1.2.1.3. Direct protein precipitation extraction 
method (2). 
It has been reported that low ratios of organic 
phase to plasma volume in direct protein 
precipitation methods (Kabra et al., 1977., Stafford 
et al., 1980) result in microprecipitation of 
proteins which may cause column blockage (Chu 
et al., 1980). The organic solvent to aqueous sample 
ratio suggested by Kabra and Stafford (Kabra et al., 
1977., Stafford et al., 1980) was one part 
acetonitrile to one part plasma. Chu et al. (1980) 
suggested the use of three parts acetonitrile to two 
parts plasma was necessary to prevent 
microprecipitation. 
Acetonitrile to plasma extraction ratios of 2:1 and 
3:1 were used to measure the recovery of retinoid 
from plasma and lymph samples. with these ratios it 
was hoped to improve recovery and assay sensitivity 
despite the increased dilution effect on the sample. 
Plasma and lymph samples were extracted as described 
above. (section 2.1.2.1.2.) except that a larger 
volume of acetonitrile was added to the samples in 
the form of 200 ~ l ~ b r r 300 ~ l l of internal standard 
(Ro 11-5036, 75 ng/ml or 50 ng/ml). 
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2.1.2.2. Analytical method evaluation for 
Ro 04-3780. 
A series of analytical procedures were performed in 
order to validate the hplc system for the analysis 
of Ro 04-3780. 
Samples of rat plasma or human plasma were pooled 
and extracted using each of the three extraction 
procedures described above. Analysis of these 
samples was performed using the hplc system and the 
hplc traces were examined for the presence of 
interfering peaks at the retention times of 
Ro 04-3780, its isomer (Ro 01-5488) or the internal 
standard. 
Using duplicate blank plasma samples (100 ~ l ) ) to 
which had been added acetonitrile (100 ~ l ) )
containing 25, 50, 100, 200, 500 or 1000 ng/ml of 
Ro 04-3780, extractions were performed using each of 
the three extraction methods described above. 
A parallel set of duplicate control samples were 
also prepared containing the standards and 
extraction solvent but replacing the plasma volume 
with water. In the acid-ether extraction method, the 
aqueous phase was omitted completely. 
Control samples for the acid-ether standards were 
dried and dissolved in mobile phase (500 ~ l ) . . All 
plasma samples and control sample extracts were 
injected onto the hplc system and peak areas for the 
Ro 04-3780 and Ro 11-5036 plasma extracts and 
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controls were compared to assess recovery after 
extraction (Equation 6). 
Reoovery (%) = Peak area (plasma extraot) x 100 
Peak area (aoetonitrile extraot) 
Equation ••••• 6 
As the concentration of an analyte approaches zero, 
the signal disappears into the noise and the 
detection limit is exceeded. The detection limit is 
defined as the concentration of solute which gives a 
signal which is significantly different from the 
blank or background signal. In practice, the signal 
obtained from a solute which differs by 
approximately two standard deviations from the 
magnitude of the background signal is used as an 
indication of limit of detection for the assay. 
The average peak height of the background signal, 
recorded on the hplc trace was measured. Three times 
the average baseline peak height was compared with 
the standard calibration curve from each hplc method 
to give an estimate of the limit of detection 
concentration. 
2.1.3. Results. 
In general, solute bands broaden gradually as they 
migrate through a chromatographic column. Resolution 
of individual solutes into discrete bands occurs 
only if the bands broaden to a lesser extent than 
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their peak maxima separate. Values of the baseline 
bandwidths of adjacent bands are almost constant. 
Since baseline bandwidth is equal to four standard 
deviations (a) for a given band, resolution can be 
expressed using Equation 7. 
R - t2 - tl 
-
Equation ••••• 7 
" 
a 
R = resolution 
tl = retention time for band 1 
t2 = retention time for band 2 
a = standard deviation 
Resolution may be improved by increasing the 
separation time for the bands or decreasing the 
bandwidth of the bands, which is a function of 
column selectivity or efficiency. 
Using a solvent scouting technique (Section 
2.1.1.3), the optimum mobile phase system was found 
to contain 70 parts of acetonitrile to 30 parts 
ammonium acetate buffer (0.01 M, pH 6.0). At a flow 
rate of 1 ml/min this mobile phase gave baseline 
separation (Table 7) of the internal standard (Ro 
11-5036), Ro 04-3780 and Ro 01-5488 (resolution of 
Ro 01-5488 and Ro 04-3780; R = 1.384). 
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Table 7. Evaluation of a series of mobile phase systems for 
resolving Ro 01-5488, Ro 04-3780 and Ro 11-5036. 
Acetonitrile Ammonium acetate Resolution 
Ro 01-5488/Ro 04-3780 
60 40 0.773 
65 35 0.803 
68 32 0.952 
69 31 1. 282 
70 30 1. 384 
72 28 0.751 
74 26 0.672 
80 20 0.583 
Note: Resolution has been calculated using Equation 7 
(Section 2.1.3.). Baseline resolution occurs when R > 1.000 
The elution times of these compounds were; 
Compound 
Internal standard. 
13-cis Retinoic acid. 
All-trans retinoic acid. 
(Retinol. 
Elution time 
(minutes: seconds) 
2:50 
4:20 
4:58 
7:50) 
Using mobile phase compositions of between 60% and 
80% acetonitrile (the remaining volume made up using 
0.01 M ammonium acetate buffer pH 6.0) similar 
retention times were achieved for the three 
retinoids but baseline separation was not achieved. 
A summary of the hplc extraction methods is shown in 
Figure 5. For each extraction method, the recovery 
of Ro 04-3780 was estimated by comparison of the 
peak area obtained for extracted standard samples 
with the area obtained for direct standard 
injections after correcting for dilution and sample 
size (Table 8). A typical standard calibration curve 
for Ro 04-3780 is shown in Figure 6. A fixed volume 
sample loop injection of 100 ~ l l was used for all the 
analyses. 
The acid-ether extraction method gave a moderate 
mean recovery of 78.0 % (± 8.3) over the range 100 
to 1000 ng/ml. The high degree of variation was 
thought to be due to the effect of the large 
dilution factors when small samples of plasma 
(100 ~ l ) ) were extracted into large volumes (5 ml) of 
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Figure 5. Extraction methods for Ro 04-3780 in plasma and lymph. 
s.! Acid-ether extraction method. 
Plasma (1.0 ml) or 
whole lymph sample. 
~ ~ ~ ~
1 M. Hydrochloric acid (1 ml) 
Internal standard (200 ~ l ) )
(Ro 11-5036, 5000 ng/ml) 
Diethyl ether (5 ml) 
Mix (10 minutes, 30 rpm) 
Centrifuge, (2200 g, 10 minutes) 
Aspirate supernatant 
(diethyl ether, 4 ml) 
Evaporate to dryness 
under reduced pressure. 
Reconstitute in mobile 
phase (500 ~ l ) ) • 
5.ii Direct protein precipitation extraction method (1). 
Plasma (100 ~ l ) ) or whole 
lymph sample (25 - 100 ~ l ) )
Blank acetonitrile (100 ~ l ) )
or acetonitrile containing 
standard Ro 04-3780 (100 ~ l ) )
Internal standard (100 ~ l , ,
Ro 11-5036, 150 ng/ml) . 
Vortex mix, (20 seconds) 
centrifuge, (13000 g, 10 minutes) 
Aspirate supernatant. 
Figure 5.iii. Direct protein precipitation extraction method (2). 
Plasma (100 ~ l ) ) or whole 
lymph sample (25 - 100 ~ l ) )
Blank acetonitrile (200 ~ l ) )
or acetonitrile containing 
standard Ro 04-3780 (200 ~ l ) ) . 
Internal standard (100 ~ l , ,
Ro 11-5036, 75 ng/ml). 
Vortex mix, (20 seconds) 
centrifuge, (13000 g, 10 minutes) 
Aspirate supernatant. 
~ a b l e e 8. Recovery experiments for Ro 04-3780 after 
extraction of spiked plasma samples. 
a) Acid-ether extraction method. (Section 2.2.1) 
Added Recovered 
. ng/ml ng/ml % 
50 
100 
200 
500 
1000 
20.8 
66.6 
158.5 
413.2 
838.3 
42% 
66% 
79% 
83% 
84% 
Mean recovery = 70.7% 
b) Direct acetonitrile extraction 1. (Section 2.2.2) 
Added Recovered 
ng/ml ng/ml % 
25 
50 
100 
200 
500 
1000 
16.9 
35.8 
73.8 
197.2 
489.5 
989.2 
Mean recovery = 
68% 
72% 
74% 
99% 
98% 
99% 
84.9% 
Table 8. continued 
c) Direct acetonitrile extraction 2. (Section 2.2.3) 
Added Recovered 
ng/ml ng/ml % 
25 22.8 91% 
50 49.1 98% 
100 102.3 102% 
200 197.8 99% 
500 489.0 98% 
1000 1006.9 100% 
Mean recovery = 99.6% (± 3.42%) 
a) Coefficients of the linear regression line of the form: 
Peak area ratio = (B x concentration (ng/ml» + A, 
obtained from extracted plasma standards were calculated 
using the method of least squares; 
Intercept CA) 
Slope (B) 
Correlation coefficient ( ~ ) )
= -3.3411 x 1 0 ~ ~
= 2.1229 X 10-3 
= 0.991 
Figure 6. Calibration curve for the analysis of Ro 04-3780 by hplc. 
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organic phase. 
The first direct extraction method which used two 
parts of acetonitrile to one part plasma showed 
slightly improved recovery of extraction (85.0 % 
± 15.1) over the range 25 to 1000 ng/ml compared 
with the acid-ether extraction, however, it was 
thought the poor recovery might still present some 
problems with the overall sensitivity of the assay_ 
On further increasing the acetonitrile to plasma 
phase ratio from two parts to one to three parts to 
one, overall mean recovery was further improved to 
98.0% (± 3.7). Recovery at a retinoid concentration 
of 25 ng/ml dramatically improved from 68% to 91%. 
Although the increased volume of organic phase would 
dilute the sample, the overall increase in recovery 
was a more favourable effect and all further assay 
extractions were performed with a dilution of at 
least three parts acetonitrile. If the concentration 
of retinoid was very low the limit of detection 
could be further improved by reducing the 
acetonitrile volume by evaporation using a vacuum 
centrifuge. This was however, rarely necessary. 
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2.2. Development and validation of hple methods for 
the analysis of Ro 10-9359 and Ro 15-0778. 
2.2.1. Hple methods for the analysis of Ro 10-9359. 
Freshly prepared standard solutions (2000 ng/ml) of 
Ro 10-9359 were prepared in acetonitrile or n-hexane 
for the evaluation of a series of hplc systems. A 
number of reversed phase and normal phase systems 
were studied. 
2.2.1.1. Reversed phase hplo methods. 
Initially the system which had been developed for 
the analysis of Ro 04-3780 (section 2.1.1.) was 
investigated in order to establish its applicability 
to the analysis of Ro 10-9359. 
The system comprised a 5 ~ m m Spherisorb S50DS column 
(100 x 4.6 mm) eluted with a mobile phase containing 
70% acetonitrile and 30% 0.01 M ammonium acetate 
buffer (pH 6.0) at a flow rate of 1 ml/min. 
Detection was by UV absorbance at 360 nanometres ( ~ ~
for Ro 10-9359). 
A sample of the Ro 10-9359 standard in acetonitrile 
(2000 ng/ml) was injected onto the hplc using a 
fixed volume loop injector (100 ~ l ) . . The retention 
time, peak height and peak width of the eluted 
Ro 10-9359 peak were measured from the hplc 
integrator trace. 
The mobile phase of the initial hplc system was 
modified to decrease the retention time of the 
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Ro 10-9359 peak and to produce a peak with a 
narrower peak width and therefore more acceptable 
peak shape. The acetonitrile content of the mobile 
phase was increased from 70% to 80% and the 0.01 M 
ammonium acetate buffer (pH 6.0) was decreased from 
30% to 20%. The retention time, peak height and peak 
width of the eluted Ro 10-9359 peak were measured 
from the hplc integrator trace. 
2.2.1.1.1. Internal standard for the reversed hplo 
system. 
In order to assess the suitability of potential 
internal standards in the assay of Ro 10-9359 using 
this system, a series of retinoids (Ro 01-5488, 
Ro 04-3780, Ro 10-1670, Ro 11-5036) solutions were 
prepared at concentrations of approximately 
2000 ng/ml in acetonitrile. These compounds were 
injected onto the hplc system and their retention 
times were recorded. 
2.2.1.2. Investigations ot normal phase hplo methods 
tor Ro 10-9359. 
A series of normai" phase hplc systems were evaluated 
for the analysis of Ro 10-9359. The column of choice 
was a cyano-bonded silica column. This offered the 
advantages of being capable of separations in either 
the normal phase or reversed phase modes, thereby 
making the column more versatile in its application 
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and also less susceptible to the effects of traces 
of polar solvents when used in the normal phase 
mode. The column was also faster in equilibrating 
with organic solvents than traditional normal silica 
columns. A 3 ~ m m Spherisorb S3CN (CN) column (150 x 
4.6 mm) was used for these analyses. 
In order to remove all traces of polar solvents, 
especially water, from the column all solvents were 
dried over anhydrous magnesium sulphate before use. 
A series of normal phase hplc systems comprising a 
cyano-bonded column (3 ~ m m Spherisorb S3CN (150 x 
4.6 mm» and a range of mobile phase systems were 
studied. The column was stored in methanol and 
before it could be used with a non-polar mobile 
phase a range of solvents with decreasing polarity 
had to be passed down the column. The sequence of 
solvents was methanol (30 minutes), propan-2-o1 
(30 minutes), followed by the non-polar mobile phase 
for several hours. This sequence of solvents was 
used in reversed order when the column was taken 
back into methanol for storage. 
A standard solution (2000 ng/ml) of Ro 10-9359 was 
prepared in n-hexane. Samples (100 ~ l ) ) of this 
standard were injected onto each hplc system using a 
fixed volume loop injector. The retention time, peak 
height and peak width of the Ro 10-9359 and the 
retention time of the solvent front were recorded 
and evaluated after elution from the column with a 
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series of mobile phase systems. 
i) Initial studies were undertaken using a mobile 
phase consisting of 100% n-hexane (hplc grade) at a 
flow rate of 1 ml/min. 
ii) The second group of systems were based on the 
methods of Hanni (Hanni et al., 1979) who developed 
mobile phase systems for the determination of 
etretinate (Ro 10-9359). 
The first system comprised n-hexane : THF : acetic 
acid (980 : 15 : 6). This system was modified by De 
Leenheer (De Leenheer et al., 1990) to comprise, n-
hexane : THF acetic acid : acetonitrile (895 : 100 
: 3 : 2). This system was used by De Leenheer for 
the determination of etretinate (Ro 10-9359) and its 
metabolites in human plasma. Further modifications 
of this mobile phase were made by replacing the THF 
with di-isopropyl ether or dichloromethane. 
The second mobile phase of Hanni (Hanni et al., 
1979) comprised hexane : methyl benzoate propionic 
acid (872 : 125 : 3.5). A similar system has also 
been used by McNamara (McNamara & Blouin, 1990) 
consisting of hexane : methyl benzoate : propionic 
acid (935 : 62 : i.5). 
Each of the above mobile phases were delivered at 
1 ml/min and evaluated using injections of standard 
solutions of Ro 10-9359, Ro 10-1670, Ro 11-5036 and 
Ro 04-3780 in n-hexane. 
iii) To study the importance of the small quantities 
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of methyl benzoate and propionic acid on the 
retention times of the retinoids, the relative 
proportions of each component was varied. 
The proportion of propionic acid in the mobile phase 
was fixed at 2.5% and the proportion of methyl 
benzoate was varied, the remaining volume being made 
up with hexane. The systems shown in Table 9 
(proportions by volume) were examined. 
2.2.1.2.1. Effeot of time of oolumn equilibration on 
retention time of Ro 10-9359. 
In the study of various mobile phase systems on the 
retention time of retinoids after elution from a 
normal phase 3 ~ m m Spherisorb S3CN hplc column, it 
was observed that the retention time varied with 
time of equilibration with mobile phase. The change 
in column equilibration time with mobile phase was 
studied using a mobile phase consisting of hexane : 
methyl benzoate: propionic acid (991.5 6 : 2). 
Mobile phase at a flow rate of 0.5 ml/min was 
allowed to recirculate through the hplc column. 
Daily, the flow was adjusted to 1.0 ml/min and the 
.. 
retention times for the retinoids, Ro 10-9359 and 
Ro 04-3780 in a standard mixture were recorded. The 
column was considered to be equilibrated with the 
mobile phase when consecutive recordings of the 
retention times for retinoid peaks eluting from the 
column were found to remain constant. 
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Table 9. Mobile phase systems used to study the importance 
of the small quantities of methyl benzoate and propionic 
acid on the retention times of the Ro 10-9359 on a 
Spherisorb S3CN hplc system. 
Hexane Methyl benzoate Propionic acid 
a) 996.5 1 2.5 
b) 995.5 2 2.5 
c) 994.5 3 2.5 
d) 993.5 4 2.5 
e) 992.5 5 2.5 
f) 991.5 6 2.5 
g) 957.5 40 2.5 
h) 935 62 2.5 
i) 872 125 3.5 
2.2.1.2.2. Selection ot an internal standard tor the 
normal phase hplc method for Ro 10-9359. 
On a reversed phase hplc system the rank order of 
elution times for a series of compounds is reversed 
compared with their elution times on a normal phase 
hplc system. Therefore on the normal phase system a 
polar compound will elute more slowly than a non-
polar compound. 
The retention times of Ro 10-9359, Ro 01-5488, Ro 
10-1670, Ro 11-5036 and Ro 04-3780 were recorded on 
an Spectra Physics computing integrator after 
elution from the 3 ~ m m Spherisorb S3CN column using a 
mobile phase containing hexane : methyl benzoate : 
propionic acid (991.5 : 6 : 2.5) (Table lO(h)). 
2.2.1.2.3. Extraction procedure for Rc 10-9359. 
The extraction of Ro 10-9359 from plasma was 
investigated using methods identical to those used 
for the extraction of Ro 04-3780. The method of 
choice was a direct extraction into acetonitrile as 
detailed in section 2.1.2.3. which offered the 
advantages of rapid sample extraction and excellent 
recovery of retinoid from plasma and lymph. However, 
it was not believed to be good practice to 
contaminate the normal phase column with repeated 
injections of acetonitrile, containing aqueous 
material from the biological samples. An additional 
final step was added to the extraction procedure 
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Table 10. A summary of the normal phase mobile phase hplc 
systems validated for the analysis of Ro 10-9359. 
a) 100% n-hexane. 
k' 
Solvent 
Ro 10-9359 0.37 
Retention time (minutes) 
1. 63 
2.24 
b) n-Hexane : Tetrahydrofuran : Acetic acid : Acetonitrile 
(895:100:3:2) . 
k' 
Solvent 
Ro 10-9359 0.12 
Retention time (minutes) 
1.58 
1. 77 
C) n-Hexane : Dichloromethane : Acetic acid : Acetonitrile 
(895:100:3:2) • 
k' 
Solvent 
Ro 10-9359 0.17 
Retention time (minutes) 
1. 62 
1. 90 
d} n-Hexane : Di-isopropyl ether : Acetic acid : 
Acetonitrile (895 : 100 : 3 : 2). 
k' 
Solvent 
Ro 10-9359 0.18 
Retention time (minutes) 
1. 52 
1. 79 
Table 10. continued. 
e) Hexane • methyl benzoate • propionic acid (872:125:3.5) • . 
k' Retention time (minutes) 
Solvent 1.60 
Ro 10-9359 0.19 1.90 
Ro 04-3780 2.09 4.95 
Ro 11-5036 Split peaks detected. 
f) Hexane . methyl benzoate • propionic acid (935:62:2.5) • • • 
k' Retention time (minutes) 
Solvent 1.60 
Ro 10-9359 0.55 2.48 
Ro 04-3780 1. 49 3.98 
Ro 11-5036 3.01 6.42 
g) Effect of varying proportions of methyl benzoate (0.1% -
4.0%) in hexane containing 2.5% propionic acid on k' and 
retention time of Ro 10-9359. 
Methyl benzoate k' Retention time 
0.1% 0.80 2.93 
0.2% 0.76 2.87 
0.3% 0.77 2.89 
0.4% 0.79 2.92 
0.5% 0.74 2.84 
0.6% 0.73 2.82 
4.0% 0.68 2.74 
Table 10. continued. 
h) Hexane : methyl benzoate: propionic acid (991.5:6:2.5) 
after extended column equilibration time. 
k' Retention time (minutes) 
Solvent 1.40 
Ro 10-9359 2.9 5.40 
Ro 01-5488 3.3 6.00 
Ro 04-3780 5.6 9.21 
Ro 11-5036 11.8 17.9 
Note.AII systems used a Spherisorb S3CN column and a mobile 
phase elution rate of 1 ml/min. 
which is detailed below. 
Plasma samples (100 ~ l ) ) were transferred into 
polypropylene microcentrifuge tubes (1.5 ml) using a 
positive displacement pipette. The whole of a lymph 
sample (25 - 100 mg) was analysed in the tube into 
which it had been collected. 
Acetonitrile (300 ~ l ) ) was added to each sample. 
Standard extracts were prepared by transferring 
blank rat (or human) plasma (100 ~ l ) ) into 
microcentrifuge tubes (1.5 ml) using a positive 
displacement pipette followed by the addition of 
acetonitrile (100 ~ l ) ) containing the appropriate 
concentration of standard material (0, 50, 100, 200, 
400, 800 or 1000 ng/ml). 
To all lymph samples, plasma samples and standard 
tubes, acetonitrile (100 ~ l ) ) containing the internal 
standard (Ro 04-3780, 2000 ng/ml) was added. 
The tubes were mixed on a vortex mixer (20 seconds) 
and centrifuged in a microcentrifuge (13,000 x g, 
10 minutes). The supernatant was transferred into a 
further set of polypropylene microcentrifuge tubes 
(1.5 ml). 
The samples were evaporated to dryness under reduced 
pressure at 50°C in a vacuum centrifuge. 
The samples were dissolved in mobile phase (500 ~ l ) )
and transferred into hplc autosampling vials. 
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2.2.1.2.3.1. Validation of the extraction procedure 
for Ro 10-9359. 
A series of experiments were performed to validate 
the direct protein precipitation extraction 
procedure. 
Blank rat and human plasma samples were analysed 
using the method described in section 2.2.1.2.3. and 
using the hplc system (Table 6). The hplc integrator 
traces were examined for the presence of interfering 
peaks at the elution times for Ro 04-3780 or 
Ro 10-9359. 
Acetonitrile (100 ~ l ) ) containing Ro 10-9359 at a 
range of concentrations from 25 ng/ml to 1000 ng/ml 
was transferred to a series of rat (or human) plasma 
samples (100 ~ l ) ) using a positive displacement 
pipette. A parallel set of standards samples was 
prepared in which acetonitrile (lOO ~ l ) ) replaced the 
plasma volume. Each set of samples was diluted using 
acetonitrile (300 ~ l ) ) and acetonitrile (lOO ~ l ) )
containing the internal standard (Ro 04-3780, 
2000 ng/ml). The samples were mixed using a vortex 
mixer (20 seconds) and centrifuged (13,000 x g, 
10 minutes). Aliquots of the supernatant from each 
sample were evaporated to dryness using a vacuum 
centrifuge and the samples were dissolved in mobile 
phase (500 ~ l ) . . samples were injected onto the hplc 
system (Table 6) using a fixed volume loop injection 
(100 ~ l ) . . The peak areas obtained for the plasma 
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extracts were compared with the parallel set of 
extracted control samples from which plasma had been 
omitted. Recovery of the added Ro 10-9359 was 
calculated using the Equation 6. 
2.2.2.1. Results and Disoussion. 
The capacity factor (k') is a quantity used in 
column chromatography. It relates the equilibrium 
distribution of the sample within the column to the 
thermodynamic properties of the column and to the 
temperature. For a given set of operating 
parameters, k' is a ratio of the time spent by the 
analyte in the stationary phase relative to the time 
spent in the mobile phase. It is defined as the 
ratio of the amount of solute in the stationary 
phase to the amount in the mobile phase 
(Equation 8). 
k' = C. x V. Equation ••••• 8 
CID X V ID 
CID = Molar concentration in mobile phase. 
VID = Volume of mobile phase. 
C. = Molar concentration in stationary 
V. = Volume of stationary phase. 
Capacity factor may be calculated from hplc 
retention time data (Equation 9). 
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phase. 
k' = ~ ~ t. Equation ••••• 9 
t. 
tr = Retention time for the sample peak. 
t. = Retention time for un-retained solute. 
It can be shown that a k' value of 2 is the optimum 
value for maximum resolution in unit time and k' 
values greater than 10 can waste valuable analytical 
time (Willard et al., 1988). 
The capacity factors have been calculated and used 
along with retention time data for comparison of the 
hplc systems studied here. 
The hplc system which was developed for the analysis 
of Ro 04-3780 showed a retention time of 17.7 
(± 0.01) minutes for Ro 10-9359 (k' = 10.1). This 
time was considered unacceptable since it would have 
resulted in a total analytical time for some larger 
batches (100 - 130 samples) in excess of 36 hours. 
On increasing the percentage of acetonitrile in the 
mobile phase from 70% to 80% the retention time was 
decreased to 11.0 (± 0.01) minutes (k' = 7.0). This 
was considered to be a much more acceptable run 
time. However, the peak obtained for Ro 10-9359 on 
this system was of a poor shape, showing peak 
broadening, some evidence of peak splitting and peak 
asymmetry. 
The retention times for the retinoids, Rc 01-5488, 
Ro 04-3780, Ro 10-1670 and Ro 11-5036 were found to 
-
be 3.50, 3.13, 1.8 and 2.07 minutes and the capacity 
factors 1.5, 1.2, 0.3 and 0.5 respectively. 
Since the peaks for Ro 10-1670 and Ro 01-5488 did 
not show baseline resolution and also Ro 10-1670 was 
a metabolite of Ro 10-9359 neither of these 
compounds were considered suitable as internal 
standards in the determination of Ro 10-9359. 
The peaks obtained for Ro 04-3780 and Ro 11-5036 did 
not show baseline resolution from each other and 
also eluted very close to the solvent front with 
capacity factors well below unity. These compounds 
were also considered to be unsuitable for use as 
internal standards. 
The poor resolution of the retinoid peaks and the 
poor peak shape for Ro 10-9359 together with the 
inability to find a suitable retinoid which would 
act as an internal standard for the assay of 
Ro 10-9359 had the result of rendering the reversed 
phase hplc system unsuitable for the analysis of 
Ro 10-9359. 
A number of normal phase systems were therefore 
investigated as a potential alternatives for the 
analysis of Ro 10:9359. 
The following observations were made based on the 
peak retention times and k' values of Ro 10-9359 
(Table 10) using the various normal phase solvent 
systems described in section 2.2.1.2. and using a 
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3 ~ m m Spherisorb S3CN column (150 x 4.6 mm) in the 
normal phase mode; 
a) 100% n-hexane. 
This mobile phase gave only a slight separation of 
the Ro 10-9359 peak from the solvent front (k' 
= 0.4). Baseline separation was not aChieved. 
b)i) n-Hexane : Tetrahydrofuran : Acetic acid: 
Acetonitrile (895 : 100 : 3 : 2) or 
ii) n-Hexane: Dichloromethane : Acetic acid : 
Acetonitrile (895 : 100 : 3 : 2) or 
iii) n-Hexane : Di-isopropyl ether : Acetic acid : 
Acetonitrile (895 : 100 : 3 : 2). Each of these 
three mobile phases failed to resolve the Ro 10-9359 
peak from the solvent front to any extent (k' < 0.2) 
and were therefore unsuitable for the analysis of 
Ro 10-9359. 
c) Hexane : methyl benzoate : propionic acid (872 : 
125 : 3.5) and Hexane : methyl benzoate : propionic 
acid (935 : 62 : 2.5). Each of these two systems 
were unable to sufficiently resolve the Ro 10-9359 
peak from the solvent front, however, the second 
system, which contained a lower proportion of methyl 
benzoate, gave a slightly higher value of k' for 
this compound (0.6 compared with 0.2). 
f) varying proportions of methyl benzoate (0.1% -
4.0%) in hexane containing 2.5% propionic acid. None 
of these systems gave k' values above unity, the 
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lowest percentages of methyl benzoate gave the 
highest value (k' = 0.8). 
g) Hexane : methyl benzoate : propionio aoid (991.5 
: 6 : 2.5) with extended oolumn equilibration time. 
After recirculating the mobile phase through the 
column at a flow rate of 0.5 ml/min for 72 hours the 
retention time for Ro 10-9359 increased slowly to 
give a k' value of 2.9 with a retention time of 5.40 
minutes. This value was considered acceptable and 
gave good resolution from the solvent front. 
This mobile phase system was selected as a suitable 
system for the analysis of Ro 10-9359 and is 
summarised in Table 6. 
A number of retinoid standards were injected onto 
normal phase hplc system (mobile phase system g) in 
order to assess their suitability as an internal 
standard; 
Ro 10-1670 could not be used since it is a 
metabolite of Ro 10-9359 and there are reports of 
metabolic interconversion of these two compounds 
in-vivo (Jensen, 1991). 
Ro 11-5036 gave a k' value of 11.8 from a retention 
time of 17.9 minutes which would have increased 
analysis time to an unacceptable figure. Ro 01-5488 
gave a retention time of 6.0 minutes (k' = 3.3), 
however, this peak was not adequately resolved from 
Ro 10-9359. Ro 04-3780 exhibited a retention time of 
9.21 minutes (k' = 5.6) and was therefore ideally 
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positioned with respect to Ro 10-9359 for use as an 
internal standard. 
The direct protein precipitation extraction method, 
described in section 2.2.1.2.3. and summarised in 
Figure 7, proved successful in extracting both 
Ro 10-9359 and the internal standard, Ro 04-3780. 
The method gave a good recovery of the two ~ e t i n o i d s s
with minimal interference with other extracted 
compounds. 
After extraction of blank rat or human plasma 
samples; 
a) No interfering substances were eluted with 
elution times near to those of either Ro 10-9359 or 
Ro 04-3780. 
b) The overall recovery of Ro 10-9359 in the 
concentration range 25 - 1000 ng/ml in spiked plasma 
was 93.8% + 4.93 (Table 11). Ro 04-3780 was 
recovered with 93.2% ± 4.66 efficiency at an 
internal standard concentration of 2000 ng/ml. 
c) The limit of detection was estimated to be 
approximately 10 ng/ml after extraction of a 100 ~ l l
sample of plasma, 'based on the concentration 
equivalent to three times the level of baseline 
noise. Variability in background noise from the 
detector caused some variation in the limit of 
detection for Ro 10-9359 but never exceeded 
25 ng/ml. 
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Figure 7. Method for the extraction of Ro 10-9359 
from plasma and lymph. 
Plasma (100 ~ l ) ) or whole 
lymph sample (25 - 100 ~ l ) . .
~ ~ ~ ~
Acetonitrile (100 ~ l ) ) or 
standard in acetonitrile (100 ~ l ) ) . 
. , ~ ~
Internal standard in acetonitrile 
(300 ~ l ) ) (Ro 04-3780, 2000 ng/ml) . 
., ~ ~
Vortex mix, (20 seconds) . 
, ~ ~
Centrifuge, (13000 g, 10 minutes) . 
.,,. 
Aspirate and evaporate to 
dryness under reduced pressure . 
.. b 
~ ~ ~ ~
Reconstitute in mobile 
phase (500 ~ l ) ) • 
Table 11. Recovery and linearity studies on Ro 10-9359 after 
extraction of spiked plasma samples. 
a) Recovery of Ro 10-9359. 
Added Recovered Recovered 
ng/ml ng/ml % 
25 22.5 90% 
50 45.0 90% 
100 93.9 94% 
200 195.1 98% 
400 371. 7 93% 
800 776.9 97% 
1000 953.1 95% 
Mean recovery = 93.8% (± 4.93%) 
(Recovery of the internal standard (Ro 04-3780, 2000 ng/ml) 
from extracted spiked plasma samples was 93.2% (± 4.66». 
b) Coefficients of the linear regression line of the form: 
Peak area ratio = (B x Concentration (nq/ml» + A, 
obtained from extracted plasma standards were calculated 
Using the method of least squares; 
Intercept (A) 
Slope (B) 
Correlation coefficient (r2) 
= -6.9724 x 10-3 
= 2 • 24 6 6 x 10-3 
= 1. 000 
d) A standard curve plotted over the range 25 -
1000 ng/ml of Ro 10-9359 (Figure 8) showed a 
correlation coefficient of 0.999 with an intercept 
equivalent to 3.1 ng/ml. 
2.2.2.2. Conclusion. 
A sensitive and specific normal phase hplc system 
has been developed and validated for the analysis of 
Ro 10-9359 in rat plasma and lymph samples. 
The method allows the extraction of small 
concentrations of retinoid from small volumes of 
samples with a limit of detection of approximately 
10 ng/ml from a 100 ~ l l sample. 
The extraction method allows the rapid analysis of 
numbers of samples on the hplc system with an 
analysis time of 12 minutes per sample. 
2.2.3. Bp1c method for Ro 15-0778. 
Initially the hplc method which had been developed 
for the analysis of Ro 04-3780 was studied (section 
2.1.1.). However, these indicated that a mobile 
phase containing 70% acetonitrile: 30% 0.01 M 
ammonium acetate buffer (pH 6.0) gave a retention 
time of 23.7 minutes (± 0.01) for Ro 15-0778. It was 
therefore necessary to increase the proportion of 
acetonitrile in the mobile phase in order to elute 
the retinoid with a shorter retention time. 
The absorption maximum for Ro 15-0778 was found to 
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Figure 8. Calibration curve for the analysis of Ro 10-9359 by hplc. 
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be 279 nanometres (section 1.3.) and in consequence 
an internal standard with an absorbance maximum near 
to this value would also be required. 
2.2.3.1. Mobile phase selection. 
A standard containing Ro 15-0778 (2000 ng/ml) was 
prepared in acetonitrile. This solution was injected 
onto the 5 ~ m m Spherisorb S50DS column (100 x 4.6 mm) 
using a fixed volume loop injection of 100 ~ l . . The 
mobile phase circulating through the column was 
adjusted to contain either 70%, 75%, 80%, 85% or 90% 
acetonitrile, the remaining volume was 0.01 M 
ammonium acetate buffer (pH 6.0). The retention 
times for the solvent front and the Ro 15-0778 peak 
were recorded and capacity factors (k') calculated. 
2.2.3.2. Internal standard selection. 
Ro 15-0778 is an arotinoid and as such differs in 
structure from the majority of the retinoids. The 
arotinoids do not possess the tetraene side group 
and terminal polar group traditionally found in the 
retinoids since these groups have incorporated into 
an aromatic terminal group (Figure 3). These 
conjugated aromatic molecules in consequence have a 
~ ~ further into the ultraviolet than other 
retinoids. Temarotene (Ro 15-0778) has been shown to 
absorb at a maximum of 279 nanometres (section 1.3.) 
and it was therefore desirable to analyse the 
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compound at this wavelength in the hplc analytical 
method. An internal standard with similar absorption 
wavelength and physical properties to Ro 15-0778 was 
therefore sought for use as an internal standard. 
The absorbance maximum of the sulphone derivative 
(Ro 15-1570, Figure 3) of Ro 15-0778 was studied 
together with its retention properties on the 
proposed hplc system. 
i) A standard solution of Ro 15-1570 (2000 ng/ml) 
was prepared in acetonitrile and diluted to allow a 
UV absorption spectrum to be measured over the range 
200 - 400 nanometres. 
ii) Samples (100 ~ l ) ) of the Ro 15-1570 standard were 
injected onto the hplc system using a fixed volume 
loop injection. The retention time and capacity 
factor were recorded and evaluated. 
2.2.3.3. Extraotion prooedure for Ro 15-0778. 
A direct protein precipitation extraction procedure 
was used for the extraction of Ro 15-0778 and Ro 15-
1570 from plasma and lymph. Essentially the method 
was identical to that described for Ro 04-3780. 
Plasma samples (100 ~ l ) ) were transferred into 
polypropylene microcentrifuge tubes (1.5 ml) using a 
positive displacement pipette. The whole of a lymph 
sample (25 - 100 mg) was analysed in the tube into 
which it had been collected. 
Acetonitrile (300 ~ l ) ) was added to each sample. 
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standard extracts were prepared by transferring 
blank rat (or human) plasma 100 ~ l l into 
microcentrifuge tubes (1.5 ml) followed by 
acetonitrile (100 ~ l ) ) containing the appropriate 
concentration of standard material (0, 50, 100, 200, 
400, 800 or 1000 ng/ml). Blank acetonitrile (200 ~ l ) )
was added to each tube. 
To all lymph samples, plasma samples and standard 
tubes, acetonitrile (100 ~ l ) ) containing the internal 
standard (Ro 15-1570, 2000 ng/ml) was added. 
The tubes were mixed (20 seconds) using a vortex 
mixer and centrifuged in a microcentrifuge 
(13,000 x g, 10 minutes). The supernatant was 
transferred into an hplc autosampling vial. 
2.2.3.3.1. Validation of the extraction procedure 
for Ro 15-0778. 
A series of experiments was performed to validate 
the direct protein precipitation extraction 
procedure. 
a} Blank rat and human plasma samples were analysed 
using the method described in section 2.2.2.3.3. and 
using the hplc system summarised in Table 6. The 
hplc traces were examined for the presence of 
interfering peaks at the elution times for 
Ro 15-0778 or Ro 15-1570. 
Acetonitrile (100 ~ l ) ) containing Ro 15-0778 at a 
range of concentrations from 25 ng/ml to 1000 ng/ml 
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was transferred to a series of rat (or human) plasma 
samples (100 ~ l ) ) using a positive displacement 
pipette. A parallel set of standards samples was 
prepared in which acetonitrile (100 ~ l ) ) replaced the 
plasma volume. Each set of samples was diluted using 
acetonitrile (300 ~ l ) ) and acetonitrile (100 ~ l ) )
containing the internal standard (Ro 15-1570, 
2000 ng/ml). 
The samples were mixed using a vortex mixer (20 
seconds) and centrifuged (13,000 x g, 10 minutes). 
Aliquots of the supernatant from each sample was 
injected onto the hplc system (Table 6) using a 
fixed volume loop injection (100 ~ l ) . . The peak areas 
obtained for the plasma extracts were compared with 
the parallel set of extracted control samples from 
which plasma was omitted. Recovery of the added 
Ro 15-0778 was calculated (Equation 10). 
Recovery (%) = Peak area (plasma extract) x 100 
Peak area (acetonitrile extract) 
Equation •.••• 10 
2.2.3.4. Results and Discussion. 
A mobile phase system containing 80% acetonitrile 
and 20% 0.01 M ammonium acetate buffer (pH 6.0) was 
selected from the systems tested (Table 12) as the 
system of choice for the analysis of Ro 15-0778 
using the reversed phase hplc, which is summarised 
in Table 6. This system gave retention times of 
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Table 12. Effect of acetonitrile content on the retention 
properties of Ro 15-0778 and Ro 15-1570. 
a) 70% acetonitrile: 30% 0.01 M Ammonium acetate (pH 6.0) 
k' Retention time (minutes) 
Solvent 1.0 
Ro 15-0778 22.3 23.7 
Ro 15-1570 8.2 9.3 
b) 75% acetonitrile: 25% 0.01 M Ammonium acetate (pH 6.0) 
k' Retention time (minutes) 
Solvent 1.2 
Ro 15-0778 12.2 15.7 
Ro 15-1570 4.5 6.5 
c) 80% acetonitrile: 20% 0.01 M Ammonium acetate (pH 6.0) 
k' Retention time (minutes) 
Solvent 1.4 
Ro 15-0778 5.5 9.4 
Ro 15-1570 2.2 4.6 
d) 85% acetonitrile: 15% 0.01 M Ammonium acetate (pH 6.0) 
k' Retention time (minutes) 
Solvent 1.4 
Ro 15-0778 4.6 7.9 
Ro 15-1570 1.3 3.2 
Note. All systems were run at a flow rate of 1 ml/minute on 
a spherisorb S50DS reversed phase column. 
9.4 minutes for Ro 15-0778 (k' = 5.5) and 4.6 
minutes (k' = 2.2) for Ro 15-1570. 
A solution of Ro 15-1570 in acetonitrile was found 
to have a A max of 295 nanometres, the compound 
showed a broad absorbance peak, similar to those 
found for other retinoids. Absorption for a solution 
of Ro 15-1570 at 279 nanometres was approximately 
97% of the absorption at ~ ~ (295 nanometres) and 
this loss in sensitivity was considered to be 
acceptable. 
Ro 15-1570 has structural similarities to 
Ro 15-0778, and showed a retention time of 4.6 
minutes on the proposed hplc system for Ro 15-0778, 
and was efficiently extracted (recovery 99% ± 3.48 
at 1000 ng/ml) using the proposed direct protein 
precipitation extraction method. 
These features suggested that the compound was 
therefore suitable for use as an internal standard 
in the analysis of Ro 15-0778. 
The direct protein precipitation extraction method 
described in section 2.2.3.3. and summarised in 
Figure 9, proved successful in extracting both 
Ro 15-0778 and the internal standard, Ro 15-1570. 
The method was sensitive, gave a good recovery of 
the two retinoids with minimal interference from 
other extracted compounds. 
No interfering substances were extracted which 
eluted near the elution times of either Ro 15-0778 
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Figure 9. Method for the extraction of Ro 15-0778 from 
plasma and lymph. 
Plasma (100 ~ l ) ) or whole 
lymph sample (25 - 100 ~ l ) )
~ ~ ~ ~
Acetonitrile (100 ~ l ) ) or 
standard in acetonitrile (100 ~ l ) ) . 
~ ~ ,.. 
Internal standard in acetonitrile 
(300 ~ l ) ) (Ro 15-1570, 2000 ng/ml) . 
~ ~ ,.. 
l Vortex mix, (20 seconds) . 
~ ~ ~ ~
Centrifuge, (13000 g, 10 minutes) . 1 
~ ~ ,.. 
Reconstitute in mobile phase 
(500 Ill) • 
or Ro 15-1570. 
Overall recovery of Ro 15-0778 in the concentration 
range 2.5 - 1000 ng/ml in spiked plasma was 92.6% (+ 
6.93) (Table 13). A standard calibration curve for 
Ro 15-0778 is shown in Figure 10. 
The limit of detection for the assay of Ro 15-0778 
was estimated to be approximately 2 ng/ml from a 
100 ~ l l sample, based on the concentration equivalent 
to three times the level of baseline noise on the 
hplc integrator trace. 
A standard curve plotted over the range 2.5 -
1000 ng/ml of Ro 15-0778 showed a correlation 
coefficient of 0.983 with an intercept equivalent to 
0.0015 ng/ml. 
The extraction method allowed a rapid throughput of 
large sample batches with a mean analysis time of 
less than 12 minutes per sample. 
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Table 13. Recovery and linearity studies on Ro 15-0778 afte 
extraction of spiked plasma samples. 
a) Recovery of Ro 15-0778. 
Added Recovered Recovered 
ng/ml ng/ml % 
2.5 1.9 76% 
5 4.5 90% 
10 9.5 95% 
25 22.8 91% 
50 49.0 98% 
100 98.9 99% 
250 229 92% 
500 478 96% 
1000 962 96% 
Mean recovery = 92.6% (± 6.93%) 
b) Coefficients of the linear regression line of the form: 
Peak area ratio = (B x Concentration (ng/ml» + A, 
obtained from extracted plasma standards were calculated 
Using the method of least squares; 
Intercept (A) 
Slope (B) 
Correlation coefficient (r2) 
= 1 • 4365 x 10-3 
= 1. 088 X 10-1 
= 0.991 
Figure 10. Calibration curve for the analysis of Ro 15-0778 by hplc. 
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CHAPTER 3 
INVESTIGATION OF SELF-EMULSIFYING OIL SYSTEMS 
FOR THE ORAL DELIVERY OF RETINOIDS. 
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3. Introduction. 
Dietary fat consists of triglyceride (tri-acyl 
glycerols), mainly as esters of glycerol and long 
chain fatty acids such as palmitic acid, stearic 
acid, oleic acid and linoleic acid. In addition, 
cholesterol, cholesterol esters and phospholipids 
(lecithin) are normally present in the diet. 
These lipid materials are emulsified in the stomach 
and the lipid emulsion enters the small intestine as 
tiny droplets of less than 5 ~ m m in diameter (Carey 
et al., 1983). As a result of enzyme action both in 
the stomach and the small intestine and of the 
effects of bile salts, there is a marked change in 
the chemical and physical form of the ingested 
lipid. The lipid exists in the form of mixed 
micelles together with larger uni-lamellar vesicles 
(liposomes). It has been suggested that the mixed 
micelles are dissociated in the mucous layer which 
is present at the surface of the absorptive cells as 
a result of a pH gradient in this layer (Lucas 
et al., 1975). After dissociation of the mixed 
micelles the free fatty acids are subsequently 
incorporated i n t o ~ t h e e membrane of the absorptive 
cells by passive diffusion. When the fatty acids 
have entered the cytoplasm of the enterocyte, an 
active transport process is necessary to carry them 
from the membrane into the cytoplasm of the cell 
(Ockner & Manning, 1974). 
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The incorporation of drug molecules into bile salt 
stabilized emulsions has been shown to promote 
absorption via the lymphatic route. For example 
Yoshikawa (Yoshikawa et al., 1985) found that mixed 
micelles of linoleic acid and the surfactant HCO 60 
(poly-ethoxylated hydrogenated castor oil) enhanced 
enteral absorption of human interferon whereas 
neither linoleic acid alone or the surfactant alone 
was effective. 
It was decided to investigate the formation of 
simple self-emulsifying oil systems (SES) which 
might be used to solubilise the retinoids and 
present them to an animal in a form which might 
enhance the absorptive process. 
It was believed that this type of emulsifying system 
may present the retinoids in a form which would 
increase both chylomicron formation and lymph flow 
and hence improve lymphatic absorption. 
3.1. preparation of self-emulsifying oil emulsion 
systems. 
In preparing SES it was desirable to achieve a 
system which would readily self-emulsify when mixed 
with the small volume of gastric fluid present in 
the rat stomach and remain stable in this form. 
In order that emulsified systems resemble bile salt 
emulsions (Barrowman, 1984) in terms of particle 
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size it was necessary that the particle dimensions 
of the system be small, typically less than 500 
nanometres. It is likely that fine droplets will 
empty rapidly from the stomach and thereby promote 
wide distribution of the drug throughout the 
intestinal tract. This effect will minimize the 
irritation frequently observed with extended contact 
between bulk drug substances and the gut wall 
(Charman et al., 1992). 
A series of self-emulsifying oil-water systems was 
prepared, based on the oils selected for use in the 
oral dosing studies in the rat (Section 4.2.3.1). 
The oils included; Miglyol 812, peanut oil, 
cotton seed oil and linoleic acid. The oils were 
mixed with a range of surfactants, selected from the 
list in Table 14. 
The suitability of a SES for oral administration was 
assessed after the determination of the particle 
size and the stability of the diluted SESe 
Emulsions were to be visually examined for signs of 
instability and classified using the following 
terms: 
i) stable. System" remains emulsified and of constant 
particle size over several days. 
ii) Biphasic (creaming). System rapidly separates 
into two distinct layers. 
iii) oily floaters. oily droplets seen floating on 
the surface of the emulsion system. 
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Table 14. Surfactant and co-surfactant systems used in self 
emulsifying oil systems. 
Surfactant 
Labrafil M1944CS 
Labrosol 
Softigen 767 
Span 20 
Span 80 
Span 85 
TWeen 20 
TWeen 80 
TWeen 85 
composition 
unsaturated polyglycolised glycerol, 
(Apricot kernel oil PEG-6 complex). 
Glyceryl caprylate/caprate and PEG-8 
caprylate/caprate. 
PEG-6 caprylic/capric glycerides. 
Sorbitan monolaurate 
Sorbitan monooleate 
Sorbitan trioleate 
polyethylene sorbitan monolaurate 
polyethylene sorbitan monooleate 
polyethylene sorbitan trioleate 
iv) Unstable. System breaks down irreversibly into 
individual components within 24 h. 
v) Overrange. "Nano-Sizer" reading, out of range due 
to excessive turbidity. Sample requires further 
dilution to allow particle size measurement. 
3.1.1. Preparation of artificial gastric contents. 
A solution was prepared in which to dilute the SES 
systems. This solution contained both sodium 
chloride and hydrochloric acid in order to simulate 
the ionic content and pH of gastric juice. 
Sodium chloride (2 g) was dissolved in distilled 
water (approximately 500 ml). To this solution was 
added hydrochloric acid (40 ml, 2 M) and the volume 
was adjusted to 1 litre with distilled water. The 
final pH of this solution was approximately 1.2 pH 
units. 
3.1.2. Use of the coulter "Nano-sizer". 
The particle size of the diluted emulsion systems 
was measured using the Coulter "Nano-Sizer". This 
instrument detects dynamic changes in laser light 
scattering intensity, which occurs when particles 
oscillate due to Brownian motion (Pouton, 1985). A 
mean particle size is computed for those particles 
between 40 and 3000 nm. The polydispersity index 
indicates the size range, as a score between 0 and 
9, (narrow to wide size range). 
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The Coulter "Nano-Sizer" was allowed to equilibrate 
for at least 30 minutes before use. 
The components for oil system of the SES were 
weighed into a tared 25 ml beaker. Artificial 
gastric contents were measured into the beaker and 
the emulsion was stirred gently on a magnetic 
stirrer. 
The cuvette of the "Nano-Sizer" was filled with the 
diluted emulsified system and placed in the chamber 
of the instrument. The instrument controls were set 
to measure on automatic size ranging over a period 
of 2 minutes and each sample was assayed in 
triplicate to obtain a mean particle size 
measurement. A figure for the polydispersity index 
of the emulsion was also recorded. 
The operation of the Coulter "Nano-Sizer" was 
validated on a daily basis by measuring the particle 
size in suspensions of polystyrene latex beads 
covering the range, 100 - 2000 nm 
3.2.1. Ettect ot SEa constituents on stability and 
particle size. 
In order to establish the optimum proportions of 
components in a SES, a series of experiments was 
performed. For each SES the stability of the 
emulsion and its particle size were determined. 
The main variables to be examined were: 
The effect of different surfactants and co-
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surfactants, changes in the surfactant : co-
surfactant ratio, changes in the oil:surfactant/co-
surfactant ratio, effect of diluent volume and 
effect of oil type. 
Miglyol 812 was the oil used in the initial studies. 
This oil, when mixed with Tween 85 has been shown to 
produce systems which emulsify rapidly and produce 
emulsions which have small mean particle sizes (278 
- 562 nm) (Pouton, 1985). 
The most promising variables selected at each stage 
were used in subsequent investigations. 
i) Surfactant and co-surfactant. 
Surfactants and co-surfactants were selected from 
those known to be pharmaceutically acceptable. 
A series of Miglyol 812 SES's were prepared based on 
the following basic formula; 
0.08 ml Miglyol 812 
0.02 ml Surfactant:co-surfactant (4:1) 
and were emulsified in 25.00 ml of artificial 
gastric contents. 
Surfactants were selected from Tween 85, Tween 80, 
Tween 20 and the co-surfactant selected from Span 
85, Span 80, S p a n ~ 2 0 , , Labrafil or Softigen. 
ii) Surfactant : co-surfactant ratio. 
Tween 85 and Span 85 were mixed in varying 
proportions for these SES's to obtain the optimum 
ratio for these components which produced a diluted 
emulsions with a small particle size. 
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A series of Miglyol 812 SES's was prepared based on 
the following basic formula; 
0.08 ml Miglyol 812 
0.02 ml variable ratios of Tween 85:Span 85 
and were emulsified with 25.00 ml of artificial 
gastric contents. 
iii) Surfactant/co-surfactant to Miglyol 812 ratio. 
The ratio of Miglyol 812 was varied with respect to 
a fixed 4:1 ratio of the surfactant, Tween 85 and 
co-surfactant Span 85. 
The composition of the SES was based on the 
following basic formula; 
(0.1 - x) ml Miglyol 812 
x ml Surfactant/co-surfactant, 
and were emulsified in 25.00 ml of artificial 
gastric contents. 
The volume of surfactant/co-surfactant (x) was 
varied between 0.01 ml and 0.04 ml. 
iv) Diluent volume. 
It was essential to measure the effect of dilution 
of a SES on the particle size in the emulsion since 
this variable may influence the volume of SES which 
could be used i n ~ ~ i v o o to produce a successful 
absorption enhancing effect. The dilution of any SES 
produced a highly turbid emulsion and this required 
SUfficient dilution to allow the Coulter "Nano-
Sizer" to measure the particle size without being 
rejected by the instrument as "overrange". Therefore 
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only a limited series of dilutions were possible. 
The following basic system; 
0.08 ml Miglyol 812 
0.02 ml Tween 85 : Span 85 (4:1) 
was emulsified with artificial gastric contents 
ranging from 10.0 ml to 28.75 ml and the emulsions 
formed were analysed for particle size using the 
"Nano-Sizer" and examined for stability. 
v) SES containing peanut oil. 
Some of the most successful SES's developed for 
Miglyol 812, based on their small particle sizes and 
emUlsion stability, were repeated using peanut oil, 
using the following basic formula; 
0.08 ml peanut oil 
0.02 ml Surfactant:co-surfactant (4:1) 
and was emulsified with 25.00 ml of artificial 
gastric contents. 
Tween 85 was used as the surfactant and the co-
surfactant was selected from Span 85, Labrafil and 
Labrasol. 
vi) SES containing cotton seed oil and linoleic acid. 
It was decided to test various mixtures of 
cottonseed oil arid linoleic acid in a series of 
self-emulsifying oil systems. SES were investigated 
using mixtures in ratios of 3:1, 1:1 and 1:3, and 
using varying amounts of co-surfactant with Tween 85 
as the surfactant. 
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The following basic system was used; 
(0.1 - x) ml cottonseed:linoleic acid mixture 
x ml Tween 85/co-surfactant (4:1) 
and this was emulsified in 25.0 ml artificial 
gastric contents. 
3.3. Results. 
After measuring the particle size and visually 
assessing the stability of a number of the diluted 
SES's containing Miglyol 812 a number of 
Observations were made. 
The most successful Miglyol 812 SES system was 
prepared with combinations of surfactant and co-
surfactant contained Tween 85 together with either 
Span 85 or Labrafil (Table 15). The systems 
containing these components readily emulsified at a 
dilution of 1 part SES to 250 parts aqueous phase 
and produced emulsions which remained stable over 
several days and with mean particle sizes of 509 and 
584 nanometres respectively. The polydispersity 
index of these emulsion systems was however, 
generally high (7 - 9». These particle sizes were 
similar to the diameter of chylomicrons (Barrowman, 
1984). Miglyol 812 SES's prepared using mixtures of 
Tween 85 and either softigen or Span 20 were 
unstable and visible oily droplets could be seen 
floating in the diluted SESe Miglyol 812 SES's 
prepared using Tweens 80 or 20 in combination with 
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Table 15. Composition, particle size and stability of self 
emulsifying oil systems containing Miglyol 812: Effect of 
various surfactant/co-surfactants. 
Systems were based on the following composition: 
0.08 ml Miglyol 812 
0.02 ml Surfactant:Co-surfactant (4 : 1 by weight) 
and were diluted with 25 ml artificial gastric contents 
Surfactant Co-surfactant Size Comments (PD) 
(nm ± sd) 
TWeen 85 Span 85 509 ± 20 Stable (7) 
TWeen 85 Labrafil 584 ± 21 Stable (8) 
TWeen 85 softigen 499 ± 6 oily floaters 
Tween 85 Span 20 823 ± 72 oily floaters 
Tween 80 Span 80 Biphasic, unstable 
TWeen 20 Span 20 Biphasic, unstable 
Notes: 
i) Particle size is the mean (± sd) of three readings on an 
emulsion system take'n at 2 minute intervals. 
ii) (PD) is the polydispersity index. (Stable systems only) 
either Span 80 or 20 did not emulsify and were seen 
to be biphasic after dilution in the artificial 
gastric contents. 
A mixture of Tween 85 and Span 85 was selected for 
further studies. 
Variations in the ratio of Tween 85 and Span 85 in a 
series of Miglyol 812 SES's, showed the most stable 
system to be that which contained a ratio of 4:1 of 
TWeen 85:Span 85. At ratios of Tween 85:Span 85 less 
than 4:1, the emulsions appeared to be stable but 
their mean particle size progressively increased to 
values of over 1000 nanometres. At higher Tween 
85:Span 85 ratios and with Tween 85 alone, the 
emulsion formed was unstable and rapidly became 
biphasic. A 4:1 ratio of Tween 85 to Span 85 was 
used in all subsequent investigations. These data 
are shown in Table 16. 
In order to optimise the incorporation of a 
lipophilic drug in the emulsion system, the 
proportion of oil in the SES should be high. The 
ratio of oil to surfactant : co-surfactant was 
varied to determine the optimum oil content in the 
SES. Increasing the proportion of oil:surfactant/co-
surfactant from 8:2 to 9:1 produced a stable 
emulsion but the particle size increased twofold. 
Decreasing the oil : surfactant/co-surfactant ratio 
slightly increased the particle size of the emulsion 
but also resulted in an unstable system with the 
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Table 16. composition, particle size and stability of self 
emulsifying oil systems containing Miglyol 812: Effect of 
surfactant:co-surfactant ratio. 
Systems were based on the following composition: 
0.08ml Miglyol 812 
0.02ml Variable mixtures by weight of Tween 85:Span 85 
and were diluted with 25 ml artificial gastric contents 
Tween 85:Span 85 Size comments (PO) 
ratio (nm ± sd) 
Tween only 550 ± 18 Biphasic, unstable 
6 1 545 ± 28 Biphasic, unstable 
4 1 509 ± 20 Stable (7) 
2 1 592 ± 29 Stable (8) 
1 . 1 1940 ± 118 Stable (0) . 
Notes: 
i) Particle size is the mean (± sd) of three readings on an 
emulsion system taken at 2 minute intervals. 
ii) (PO) is the polydispersity index. (Stable systems only) 
presence of floating oily droplets. A ratio of 8 
parts oil to 2 parts surfactant/co-surfactant was 
selected as the optimum for future studies. These 
data are shown in Table 17. 
Dilution of an optimised Miglyol 812 SES containing 
8 parts oil to 2 parts of a 4:1 mixture of Tween 
85:Span 85 with artificial gastric contents in 
varying proportions showed the following results. 
At dilutions of 1:200 or less the emulsion formed 
was extremely turbid and the particle size of the 
emulsion could not be measured using the "Nano-
Sizer". However, the diluted emulsions appeared 
stable at a dilution of 1:100. At higher dilutions 
from 1:240 to 1:287.5 the emulsion appeared stable 
but the results showed an increase in particle size 
with increasing dilution. These data are shown in 
Table 18. 
It is difficult to extrapolate from these results to 
the anticipated low d i l u ~ i o n n volume in the rat when 
a 0.5 ml oral dose of SES is given. It may be 
postulated, however, that a bolus dose of oil might 
emulsify progressively in the stomach as gastric 
fluid is secreted and mixing proceeds. 
Following an investigation of the variables which 
affect the production of SES's containing the mixed 
medium chain triglyceride oil, Miglyol 812. It was 
decided to repeat some of these studies using the 
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Table 17. composition, particle size and stability of self 
emulsifying oil systems containing Miglyol 812: Effect of 
oil : surfactant/co-surfactant ratio. 
Systems were based on the following composition: 
(0.1 - x) ml Miglyol 812 
x ml Tween 85:Span 85 (4 : 1 by weight) 
and were diluted with 25 ml artificial gastric contents 
Oil Tween 85/ Size comments (PD) 
Span 85 (nm ± sd) 
0.09 ml 0.01 ml 942 ± 143 Stable (7) 
0.085 ml 0.015 ml 989 ± 96 Stable (7) 
0.08 ml 0.02 ml 509 + 20 Stable (7) 
0.07 ml 0.03 ml 667 ± 32 Oily floater 
0.06 ml 0.04 ml 694 + 50 Oily floaters 
Notes: 
i) Particle size is the mean (± sd) of three readings on an 
emulsion system taken at 2 minute intervals. 
ii) (PD) is the polydispersity index. (Stable systems only) 
fable 18. composition, particle size and stability of self 
emulsifyinq oil systems containinq Miqlyol 812: Effect of 
diluent volume. 
Systems were based on the following composition: 
0.08 ml Miglyol 812 
0.02 ml Surfactant:Co-surfactant (4 : 1 by weight) 
variable volumes of artificial qastric contents 
Diluent volume size comments (PO) 
(ml) (nm ± sd) 
10.0 Overrange 
11.0 Overrange 
12.0 Overrange 
14.0 Overrange 
16.0 Overrange 
18.0 Overrange 
20.0 Overrange 
22.0 Overrange 
24.0 548 ± 20 Stable (8) 
25.0 575 ± 21 Stable (8) 
26.25 580 ± 14 Stable (8) 
27.5 565 ± 31 Stable (8) 
28.75 626 + 20 Stable (8) 
Notes: 
i) Particle size is the mean (+ sd) of three readings on an 
emulsion system taken at 2 minute intervals. 
ii) (PO) is the polydispersity index. (Stable systems only) 
mixed long chain fatty acid triglyceride oil, peanut 
oil, together with the more successful combinations 
of surfactant and co-surfactant. 
The SES systems containing peanut oil with Tween 85 
and Span 85, Labrasol or Labrafil in the ratio of 
4:1 produced emulsions with particle sizes of 1903, 
2656 and 2403 nanometres respectively. These systems 
were generally stable except for those which 
contained Labrasol. The polydispersity index of 
these emulsion systems was, however, much smaller 
than equivalent Miglyol 812 systems (0 - 2). These 
data are shown in Table 19. The systems containing 
peanut oil were not further investigated because the 
particle sizes in these emulsions were at least four 
times greater than the size in corresponding Miglyol 
812 emulsions. 
SES systems containing cottonseed oil alone or 
linoleic acid alone were biphasic when prepared with 
Tween 85 and Span 85 at a ratio of 4:1. 
Mixtures of cottonseed oil and linoleic acid in 
ratios from 3:1 to 1:3 were generally unstable when 
prepared with Tween 85 and either Span 85 or 
Labrosol at a ratio of 4:1. 
The proportion of surfactant/co-surfactant to oil 
phase was increased from 20% to 45%. Under these 
conditions the Tween 85:Labrosol (4:1) produced some 
stable systems. The particle sizes of these systems 
was, however, in excess of 1300 nanometres 
- 131 -
Table 19. composition, particle size and stability of self 
emulsifyinq oil systems containinq Peanut oil: Effect of 
various surfactant/co-surfactants. 
Systems were based on the following composition: 
0.08 ml Peanut oil 
0.02 ml Surfactant:Co-surfactant (4 : 1 by weight) 
and were diluted with 25 ml artificial gastric contents 
. Surfactant Co-surfactant Size Comments (PD) 
(nm ± sd) 
Tween 85 Span 85 1903 ± 69 Stable (2) 
Tween 85 Labrafil 2403 ± 191 Stable (0) 
Tween 85 Labrasol 2656 ± 56 Unstable 
Notes: 
i) Particle size is the mean (± sd) of three readings on an 
emulsion system taken at 2 minute intervals. 
ii) (PO) is the polydispersity index. (Stable systems only) 
(polydispersity index was generally low (0 - 2)}. 
These systems were considered unacceptable because 
of the combination of low oil content and increased 
particle size, compared with the Miglyol 812 
emulsion systems. These data are shown in Table 20. 
3.4. Conolusions. 
An investigation into the effects of varying oil, 
co-surfactant and surfactant systems on the particle 
size and stability of self-emulsifying oil systems 
was carried out. The results showed that the mixed 
medium chain fatty acid triglyceride, Miglyol 812, 
was the oil which could be most easily incorporated 
into a self-emulsifying oil system. An oil content 
of 80% and a surfactant : co-surfactant ratio of 
four parts Tween 85 to one part Span 85, produced 
emulsions which were stable and of the desired size 
(500 nanometres or less (Section 3.1.)}, despite 
showing high polydispersity indices. Stable 
emulsions were produced using Labrafil to replace 
Span 85, these emulsions were of a slightly larger 
particle size (580 nm). 
self-emulsifyini"oil systems produced using the 
mixed long chain fatty acid triglyceride oil, peanut 
oil, were stable but with a mean particle diameter 
at least four times greater (1900 - 2660 nm) than 
with the equivalent Miglyol 812 systems. 
These SES data compare favourably with data reported 
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Table 20. composition, particle size and stability of self 
emulsifying oil systems containing varying proportions of 
cottonseed oil and linoleic acid: Effect of surfactant/co-
surfactant types. 
Systems were based on the following composition: 
(0.1 - x)ml Cottonseed:Linoleic acid (Variable ratios) 
x ml Tween 85:Co-surfactant (4 1 by weight) 
and were diluted with 25 ml artificial gastric contents 
cottonseed/ 
Linoleic 
Cottonseed 
Linoleic 
1 3 
1 1 
3 1 
1 3 
1 1 
3 1 
1 3 
1 1 
3 1 
1 3 
1 1 
3 1 
Notes: 
Surfactant 
volume (x ml) 
0.02 
0.02 
0.02 
0.02 
0.02 
0.02 
0.02 
0.02 
0.03 
0.03 
0.03 
0.045 
0.045 
0.045 
Co-surfactant Size Comment 
(nm (PO) 
± sd) 
Span 85 Biphasic 
Span 85 Biphasic 
Span 85 
Span 85 
Span 85 
Labrosol 
Labrosol 
Labrosol 
Labrosol 
Labrosol 
Labrosol 
Labrosol 
Labrosol 
Labrosol 
2590 Unstable 
± 563 
2370 stable(O) 
± 333 
1863 Unstable 
± 266 
1940 Unstable 
± 730 
2760 Unstable 
± 809 
1277 Unstable 
± 93 
362 Unstable 
± 59 
1893 Stable(O) 
± 261 
1433 Stable(O) 
± 491 
1377 Stable(O) 
± 38 
1313 Stable(O) 
± 65 
822 Stable(O) 
± 21 
i) Particle size is the mean (± sd) of three readings on an 
emulsion system taken at 2 minute intervals. 
ii) (PO) is the polydispersity index. (stable systems only) 
by Charman (Charman et al., 1992), who investigated 
a self-emulsifying drug delivery system for the 
formulation of a lipophilic drug molecule, WIN 54954 
(log. P = 5.3). They reported the smallest mean 
emulsion droplet diameter (MEDD) of 0.7 - 0.8 ~ m m on 
a system which consisted of 40 % Neobee M5 Ca mixed 
medium chain monoglyceride oil similar in fatty acid 
composition to the mixed medium chain tri-acyl 
glycerol oil, Miglyol 812), 30 % Tagat TO (etho-
xylated glyceryl trioleate, nonionic surfactant) and 
30 % WIN 54954. 
In our studies, a mixed oil system containing the 
mixed long chain triglyceride oil, cottonseed oil, 
and the long chain fatty acid oil, linoleic acid, 
produced stable emulsion systems only if the amount 
of surfactant/ co-surfactant in the SES was at least 
45% by weight, the limited quantity of oil in the 
SES may have limited the quantity of retinoid 
incorporated in a system of this type. The emulsions 
produced were also of a larger mean diameter 
( > 1000 nm). 
It is difficult to explain the differences in 
particle size arid stability of the SES's produced in 
these studies since no clear patterns were observed. 
The aim of these studies was to investigate the 
effect of various oral delivery systems on the 
absorption of the retinoids, therefore, the in-vivo 
studies on the absorption of the retinoids 
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(Chapter 4.2) are the most important indicator of 
the success of any oral SES's in retinoid 
absorption. 
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CHAPTER 4 
IN-YIYO STUDIES ON THE ABSORPTION AND DISTRIBUTION 
OF THE RETINOIDS. 
4.1. INTRAVENOUS PHARMACOKINETICS IN THE RAT. 
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4.1.1. Pharmacokinetic studies in the rat. 
Intravenous dosing of the retinoids was essential to 
provide information on the pharmacokinetics of these 
compounds in the rat. Parameters which were 
considered essential for a complete understanding of 
the oral absorption of the retinoids included the 
total body clearance (Cl), volume of distribution 
( ~ ) ) and half-life (tM). 
Vd was to be used in the estimation of the total body 
content of a retinoid in the body at a given time, 
using the plasma concentration data, after oral 
dosing (Section 4.2.). The magnitude of Vd was 
anticipated to be high, since it has been shown in 
Chapter 1 that the retinoids are highly lipophilic 
in nature, and are therefore expected to distribute 
extensively in the fatty tissues within the body of 
the rat. The elimination half-life (tM) would be 
used to correct the estimates of total body retinoid 
content to allow for any elimination of drug which 
had occurred since absorption. The elimination half-
life values for the retinoids were expected to be 
long, due to the extensive distribution and 
relatively low .clearance. These three parameters, 
together with the area under the plasma 
concentration time curve (AUC) , were to be used in 
the evaluation of absolute bioavailability of the 
retinoids after oral administration. 
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4.1.2. In-vivo techniques used to study the 
pharmacokinetics of the retinoids. 
Two in-vivo techniques were used in these studies of 
the pharmacokinetics of the retinoids in the male 
wistar rat. Cannulation of the jugular vein was 
required to permit the intravenous administration of 
oily emulsions of the retinoids used in the 
pharmacokinetic and bioavailability studies. 
The carotid artery was cannulated in order to allow 
the collection of timed blood samples for analysis 
of retinoid concentrations after intravenous dosing. 
The rat was chosen as a model animal species since 
the techniques for cannulating blood vessels and the 
mesenteric lymph duct (Section 4.2.2.4.1.) were 
already established using this animal and a breeding 
colony was available for use in the Animal Unit of 
the Queen's Medical Centre, Nottingham. 
4.1.2.1. Cannulation of the carotid artery of the 
~ ~
Animals were anaesthetised by an intra-peritoneal 
(i.p.) injection of sodium pentobarbitone (0.3 ml 
Sagatal 60 mg/ml in saline (72 mg/kg». Anaesthesia 
was maintained throughout the procedure by the 
administration of further doses of Sagatal i.p. 
(0.1 ml) as necessary. 
The animal was placed, ventral side uppermost, on a 
heated mat. A small section of skin at the front of 
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the neck was removed to expose the muscle which 
covered the trachea. The muscle was separated by 
blunt dissection, using curved-end forceps, to 
expose the carotid arteries, which lie perpendicular 
to the trachea on each side of the neck. 
The left artery was dissected clear of surrounding 
tissues and a micro-spatula was slid under the 
vessel. cotton sutures were placed at either end of 
the artery and the anterior end was tied. The 
posterior end of the vessel was clamped using an 
artery clip. The vessel was cut transversely using 
spring scissors and a saline filled, polythene 
cannula, (approximately 20 cm in length) having a 
sharply tapering bevel (75°) and clamped at the 
distal end with "Spencer Wells" forceps, was 
inserted into the vessel and tied in position using 
a double suture. The artery clip was removed and 
blood was seen to flow along the cannula. Timed 
blood samples (0.2 ml) were collected from this 
vessel into heparinised micro-centrifuge tubes. 
Plasma was separated by centrifugation (13,000 x g, 
5 minutes) and transferred into micro-centrifuge 
tubes. Plasma samples were labelled and stored at 
-20°C. 
4.1.2.2. Cannulation of the iugular vein. 
Cannulation of the jugular vein was performed using 
a method similar to that used for cannulating the 
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carotid artery (Section 4.1.2.1.). The vessel was 
exposed and detached from the surrounding tissues 
using great care to prevent the vessel collapsing. 
The vessel was kept patent by the infusion of 
isotonic saline and was used for the administration 
of intravenous fluids. 
4.1.2.3. preparation of oily emulsions for 
intravenous administration. 
Three soyabean oil-in-water emulsions were prepared. 
Each emulsion contained one of the three retinoids, 
Ro 04-3780, Ro 10-9359 or Ro 15-0778, for 
intravenous administration to fasting rats. 
The retinoid was dissolved in soyabean oil at a 
concentration of approximately 15 mg/ml. Previous 
solubility studies on the retinoids had showed that 
this concentration exceeded the solubility of 
Ro 04-3780 in soyabean oil (Table 4). The following 
procedure was used to ensure maximum solubility of 
the retinoid in the oil. The retinoid (150 mg) was 
weighed into a borosilicate glass test tube (15 ml), 
which had been previously wrapped in aluminium foil 
to protect t h e . ~ e t i n o i d d from exposure to light. The 
retinoid was dissolved in the minimum volume of 
diethyl ether (0.2 - 0.5 ml) and soyabean oil 
(10 ml) was transferred to the tube using a glass 
pipette (10 ml). The contents of the tube were mixed 
by gentle rotation on a rotary mixer (30 rpm, 
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10 minutes). The diethyl ether was removed from the 
solution using a stream of helium. The retinoid 
solution was centrifuged (2200 x g, 20 minutes) to 
remove any precipitate which formed during this 
procedure. 
An aliquot of the retinoid solution in soyabean oil 
(5 ml) was added to a solution of egg lecithin (1.2% 
Lipoid E80) in double distilled water (45 ml) and 
these solutions were homogenised in a micro-
fluidiser (approximately 5 minutes). The resulting 
emulsion was transferred into a multi-dosing vial 
(50 ml), fitted with a rubber septum. The prepared 
emulsions were stored at room temperature (20°C) and 
appeared to remain stable for several weeks. The 
emulsions were normally, used in the iv. studies 
within a period of 7 days after preparation. The 
exact concentrations of each retinoid in the 
prepared emulsions were determined by dispensing an 
accurately weighed sample of each emulsion into a 
volumetric flask and diluting to volume using hplc 
grade THF. Samples of this mixture were analysed to 
determine the retinoid concentration following the 
extraction procedure for retinoids in oil (Section 
1.2.1.2.) and using the appropriate hplc system 
(Section 2.1.1.). 
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4.1.3. Intravenous dosing of rats with an emulsion 
containing retinoid. 
Two groups of six male Wistar rats (200 - 250 g) 
were used in each pharmacokinetic study and were 
fasted overnight on wire grids to prevent 
coprophagia. Each animal was anaesthetised as 
previously described (Section 4.1.2.1.). The animal 
was placed on its back and the carotid artery and 
jugular vein were cannulated as previously described 
(4.1.2.1. and 4.1.2.2.). 
A bolus intravenous dose of the soyabean oil 
emulsion (group ai 0.2 ml and group bi 0.6 ml) was 
administered to each animal via the jugular vein and 
the dose was washed into the animal using isotonic 
saline (approximately 0.3 ml). Intravenous 
administration of the emulsion (including the saline 
wash) was completed in less than 30 seconds. 
Blood samples (0.2 ml) were collected from the 
carotid artery of each animal at timed intervals 
after intravenous dosing. In studies using 
Ro 04-3780, samples were collected at 5, 10, 20, 30, 
45, 60, 90, 120, 150, 180 and 210 minutes and in 
• 
studies using ~ o o 10-9359 and Ro 15-0778, samples 
were also collected at 240, 270 and 300 minutes. 
After centrifugation (13,000 x g, 10 minutes), 
plasma was separated and stored at -20°C. 
Samples of plasma were analysed to determine the 
retinoid concentration of retinoid using the 
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appropriate hplc system (Chapter 2). Pharmacokinetic 
parameters were calculated from the plasma 
concentration data. 
4.1.4. Calculation of pbarmacokinetic parameters on 
the retinoids. 
The concentration of retinoid in each of the 
soyabean oil emulsions were determined by hplc. The 
administered doses of each retinoid were found to 
contain; 
Group a , Group b , 
low dose (O.2ml) higb dose (O.6ml) 
Ro 04-3780 0.264 mg/kg 0.792 mg/kg 
Ro 10-9359 0.655 mg/kg 1.964 mg/kg 
Ro 15-0778 0.732 mg/kg 2.200 mg/kg 
The area under the logarithmic plasma concentration 
time curve (AUC) was calculated using the trapezoid 
approximation method. An estimate of AUC from the 
last data time point to infinite time (AUC 0 .• ) was 
obtained by dividing the final concentration data 
point by the terminal elimination rate constant ( ~ ) . .
The terminal elimination rate constant was 
determined by measuring the gradient of the terminal 
linear section of the logarithmic concentration time 
curve. The terminal phase elimination rate constant 
was used in Equation 11 to determine the terminal 
half-life ( t ~ ) ) of the respective retinoid. 
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Elimination half life, t ~ ~ = 0.693 Equation .•••• 11 
{J 
{J = terminal phase elimination rate constant. 
The mean residence time (MRT) was calculated from 
the ratio of the area under the first moment curve 
(AUMC) and the area under the plasma concentration 
time curve (AUC) using Equation 12. 
Mean residence time, MRT = AUMC 
AUC 
Equation ••••• 12 
AUMC = 
AUC = 
Area under the first moment curve, 
extrapolated to infinity. 
Area under the plasma concentration 
time curve, extrapolated to infinity. 
Clearance (Cl) was calculated from the intravenous 
dose and AUC using Equation 13. 
Clearance, Cl = Dose 
AUC 0 ... 
Equation ••••• 13 
AUC = Area under the plasma concentration time 
curve, extrapolated to infinity. 
The volume of distribution (Vd) was calculated from 
clearance (Cl) ·.nd the terminal elimination rate 
constant using Equation 14. 
Volume of 
distribution, Vd = Cl 
{J 
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Equation •.••• 14 
The volume of distribution at steady state (Vu) was 
calculated as the product of the MRT and the 
clearance using Equation 15. 
Volume of distribution = MRT x Cl Equation .•••• 15 
at steady state, Vu. 
These pharmacokinetic data are displayed in Table 
21, Table 22, and Table 23. 
4.1.5. Results and discussion. 
Pharmacokinetic data were obtained from fasted male 
wistar rats after intravenous dosing of retinoids in 
soyabean oil emulsions. The data obtained from these 
studies and especially data on the clearance (Cl), 
the volume of distribution (Vd) and the elimination 
half life ( t ~ ) , , were necessary for the calculation 
of plasma uptake rate after oral dosing studies 
(Section 4.2.). 
All retinoids have been shown to be highly 
lipophilic in nature and were expected to distribute 
widely into the fatty tissues of the body. The 
volumes of distribution were expected to be large 
H 
and the elimination half-life was consequently 
expected to be relatively long. 
From the pharmacokinetic data for Ro 04-3780 
(Table 21 and Figure 11), a non-proportional 
increase in AUC was observed with increasing dose, 
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Table 21. Pharmacokinetic data for Ro 04-3780 (Isotretinoin 
in the rat after intravenous administration of a soya oil 
emulsion. 
Dose (mg/kg) 0.264 0.792 
A.U.C. (ug/ml.min) 55 + 31 317 + 34 * 
Elimination 48 + 5 61 + 7 * 
half-life, t" (min). 
MRT (min) 73 + 16 79 ± 3 
Clearance (ml/min/kg) 6.0 ± 3.4 2.5 ± 0.2 * 
Volume of Distribution (ml) 421 ± 227 222 + 19 
Volume of Distribution at 438 ± 199 197 ± 48 
steady state (V .. , ml) . 
(* p < 0.05) 
Table 22. Pharmacokinetic data for Ro 15-0778 (Temarotene) 
in the rat after intravenous administration of a soya oil 
emulsion. 
Dose (mg/kg) 0.732 2.200 
A.U.C. (ug/ml.min) 195 ± 37 852 + 100 * 
Elimination 111 ± 38 114 ± 45 
half-life, t% (min). 
MRT (min) 111 + 68 62 ± 14 
Clearance (ml/min/kg) 3.9 ± 0.6 2.6 ± 0.4 * 
Volume of Distribution (ml) 983 ± 746 1221 ± 638 
Volume of distribution at 432 ± 269 325 ± 349 
steady state (V •• , ml) 
(* p < 0.05) 
Table 23. Pharmacokinetic data for Ro 10-9359 (Etretinate) 
in the rat after intravenous administration of a soya oil 
emulsion. 
Dose (mg/kg) 
A.U.C. (ug/ml.min) 
Elimination 
half-life, t ~ ~ (min). 
MRT 
Clearance (ml/min/kg) 
Volume of Distribution (ml) 
Volume of distribution at 
steady state (Vss, ml). 
0.655 
114.6 
3.94 
10 + 
5.72 
32.4 
57 ± 
** 
** 
7 
** 
** 
15 ** 
1.964 
579.6 ± 130.3 
4.95 ± 1.47 
38 + 20 
3.53 + 0.64 
25.99 ± 10.7 
134 ± 133 
(** Insufficient data for statistical analysis) 
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Figure 11.Plasma concentration-time profile for Ro 04-3780 
in the rat after intravenous dosing in a soyabean emulsion. 
L - ~ ~ • 0.264 mg/kg El 0.792 mg/kg 
1 0 ~ 1 - - - - - - - - - - - - ~ - - - - - - - - - - - - ~ - - - - - - - - - - ~ - - - - - - - - - - - - ~ - - - - - - - - - - - - , ,
o 60 120 180 240 300 
time (mins) 
resulting from a decrease in both the total body 
clearance and the volume of distribution. The 
elimination half-life also increased with dose. 
The mean half-life for Ro 04-3780 was found to be 55 
± 5.6 minutes, slightly shorter than data reported 
in the literature ( t ~ ~ = 76 minutes) (Liu et al., 
1990), however the reported data were obtained from 
studies in Sprague-Dawley rats of much larger body 
weight (383 ± 33 g). 
The mean residence time, MRT, an estimate of the 
time taken for 63.2% of the dose to be eliminated 
from the body (Gibaldi, 1990), was 76 minutes and 
was consistent with the observed elimination half-
life ( t ~ ) ) of 55 minutes. 
At the lower dose of 0.264 mg/kg, a volume of 
distribution (Vd) of 220 ml, a volume of distribution 
at steady state (Vu) of 200 ml and total body 
clearance of 2.5 ml/min were obtained, which were 
consistent with data reported in rats (Vu = 230 ml 
and Cl = 2.1 ml/min, (Liu et al., 1990» and dogs (Vd 
= 2020 ml and Cl = 5.2 ml/min, (Cotler et al., 
1983» • 
From the pharmacokinetic data for the more 
lipophilic retinoid, Ro 15-0778 (Table 22 and 
Figure 12), a non-proportional increase in AUC was 
observed with increasing dose, due to a increased t ~ ~
at the high dose, this resulted from a decrease in 
total body clearance. There were considerable inter-
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Figure 12.Plasma concentration-time profile for Ro 15-0778 
in the rat after intravenous dosing in a soyabean emulsion. 
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subject variability in the mean data for Vd (1100 
± 690 ml) and Vu (380 ± 340 ml). The volume of 
distribution (Vd) at the low dose (980 ml) and at the 
high dose (1220 ml) and the volume of distribution 
at steady state (Vu) calculated at the low dose 
(430 ml) and at the high dose (325 ml), were not 
significantly different (p > 0.05). 
The MRT at the lower dose (MRT = 111 ± 68 min) was 
consistent with the elimination half-life observed 
at the lower dose ( t ~ ~ = 111 ± 38 min), however, the 
MRT at the higher dose was much lower (MRT = 62 
± 14 min) than either the MRT at the lower dose or 
the elimination half-life at either dose. These 
differences, however, were not significant 
(p > 0.05) because of the considerable inter-subject 
variation in the data. 
There appear to be no reported pharmacokinetic data 
relating to this compound in the literature. 
However, the data were consistent with those 
expected for a highly lipophilic retinoid. 
After intravenous dosing of Ro 10-9359 at the higher 
dose (1.964 mg/kg) (Figure 13), plasma 
concentrations fell rapidly from 33000 ng/ml at 5 
minutes post dose to less than 100 ng/ml after 150 
minutes and below the limit of detection at 180 
minutes. At the low dose (0.655 mg/kg), a similar 
rapid fall in plasma concentrations from 
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in the rat after intravenous dosing in a soyabean emulsion. 
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approximately 5000 ng/ml at 5 minutes post dose to 
less than 40 ng/ml after 45 minutes post dose and 
below the limit of detection at 60 minutes 
(Figure 13). The pharmacokinetic data showed a mean 
elimination half-life of 3.5 minutes and a mean MRT 
of 24 min. The volume of distribution was estimated 
to be 32 ml at the lower dose and 26 ml at the 
higher dose. At steady state, the volume of 
distribution was slightly higher, being 57 ml at the 
low dose and 134 ml at the higher dose. 
These data (Table 23) were not consistent with those 
expected after studying values reported in humans 
(Paravicini et al., 1981) nor with the lipophilic 
nature of the compound nor with the pharmacokinetic 
data obtained for other retinoids in this study 
(Table 21 and Table 22). The data suggest that a 
prolonged distribution phase was present and the 
terminal elimination phase had not been observed. 
This prolonged distribution phase presented problems 
in accurately measuring the resulting low retinoid 
concentrations in plasma samples after 180 minutes 
post dose. 
Paravicini (Paravicini et al., 1981) has suggested 
that there are at least four elimination phases for 
Ro 10-9359 after intravenous dosing studies in human 
volunteers. These phases had reported half-lives of, 
5 - 10 minutes, 30 - 60 minutes and 6 - 12 hours 
after a single intravenous dose. Although there was 
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evidence in these studies of at least one longer 
phase, it was not possible to quantitate it fully. 
This very long elimination half-life has been 
estimated to be about 100 days. These data were 
obtained from a trial study in psoriatic patients 
undergoing chronic therapy with 10 - 25 mg/day 
etretinate for more than a year (Paravicini et al., 
1981). 
In order to determine the plasma concentrations of 
this retinoid over a prolonged time period in the 
rat, it would have been necessary to increase 
greatly the plasma concentrations of the drug. It 
was possible to achieve this by administering a much 
larger dose of retinoid to the animal (a dose of 
20 mg/kg may have been required). However, it was 
thought inappropriate to exceed the volume of 
intravenous soya bean emulsion beyond the 0.6 ml dose 
size {approximately 5.5 % of the total blood volume 
in a 250 g rat (Griffith & Campbell, 1934). It was 
also impractical to administer a higher dose of 
retinoid in other physiologically acceptable 
vehicles because of the limited solubility of 
Ro 10-9359 in these solvents. The proposed high dose 
would have also greatly increased the potential 
toxicity of the drug to the animal and would have 
far exceeded the upper therapeutic limit for a human 
(2 mg/kg). Alternative procedures would have been to 
use much greater blood sample volumes at each data 
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point, extracting the whole animal blood volume (10 
- 12 ml) for each data point, however, this 
procedure was considered an unacceptable use of 
animals. Alternatively, the dose could have been 
administered over an extended time period by 
intravenous infusion or a more sensitive analytical 
procedure could have been investigated. 
In subsequent estimations of the venous uptake rate 
for Ro 10-9359 from plasma concentrations after oral 
dosing, a volume of distribution value of 1175 ml 
(Liu et al., 1990) was used. 
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CHAPTER 4. 
IN-VIVO STUDIES ON THE ABSORPTION AND DISTRIBUTION 
OF THE RETINOIDS. 
4.2. ORAL DOSING STUDIES IN THE RAT. 
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4.2.1. Introduction. 
It is now well established that many lipophilic 
compounds are absorbed via the lymphatic route 
following oral administration (Table 1). 
The mechanisms whereby lipophilic molecules are 
absorbed from the gastrointestinal tract and 
transported to the general circulation are complex 
and poorly understood (Patton, 1981). However, 
certain factors, thought to be important in 
lymphatic absorption, have been identified. 
Absorption is considered to involve liberation of a 
drug from the vehicle in which it is dosed, into the 
aqueous luminal fluid, followed by passage through 
the gastrointestinal wall. It has been reported that 
the rate of release of drug from a solution is an 
inverse function of its solubility in a solvent 
(Armstrong & James, 1980). These data therefore 
imply that a vehicle in which a drug has a lower 
solubility will promote greater partitioning of the 
drug from the vehicle into the luminal fluid, 
thereby enhancing absorption. This advantage of 
poorly solvating vehicles for the absorption of 
drugs is limited, however, by the total amount of 
drug which the vehicle can dissolve since this 
limiting factor will control drug availability at 
the site of absorption. 
Armstrong et al. (1979) have determined the in-vitro 
rates of release and distribution coefficients of a 
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range of benzoic and phenylacetic acid derivatives 
between either isopropyl myristate and water or 
octanol and water, and compared these with the in-
vivo bioavailability of these compounds in the rat. 
Absorption in-vivo followed an inverse rank order of 
drug-lipid solubility, but was related to the in 
vitro solvent-water transfer rate constant, rather 
than the distribution coefficient. The inference 
from these studies was that bioavailability was 
dependent on the concentration of drug in solution 
in the gastrointestinal fluid which in turn was 
dependent on the rate of supply from the oily phase. 
4.2.1.1. Factors which are thought to affect the 
lymphatic absorption of drugs. 
There is evidence to suggest that fatty acids of all 
chain lengths can alter the permeability of the 
intestinal mucosa to drugs. The short chain fatty 
acids, propionic, butyric and caproic have been 
found to inhibit the absorption of anionic drugs but 
enhance the absorption of neutral and cationic drugs 
at pH 6.5 in the rat, these effects having been 
related to water-flux and changes in the 
microclimate pH (Inui et al., 1974). 
Diet has been shown to increase the overall bio-
availability of retinoids in humans (Gibson et al., 
1984., Holazo et al., 1990., Colburn et al., 1983a). 
This effect has been explained (Colburn et al., 
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1983a) by an increase in splanchnic-hepatic blood 
flow and an increase in the rate of dissolution of 
the drug, possibly by an increase in the flow of 
bile. Colburn et al. (1983a) have also suggested 
that food will increase the total absorption of 
drugs by delaying gastric emptying. 
structurally similar drugs may vary in their 
lymphatic absorption when presented in the same 
vehicle. For example, Fidge et al. (1968) have 
showed that after presenting radio-labelled vitamin-
A compounds to rats, in bile salt-lipid emulsions 
resembling normal intestinal contents, 70% - 80% of 
the radioactivity associated with the vitamin-A or 
vitamin-A aldehyde was found in lymph with only 15% 
- 20% being found in the bile, suggesting 
predominantly lymphatic absorption. In contrast, 
only 5% - 7% of labelled vitamin-A acid was found in 
the lymph, much of the remainder (92% - 95%) being 
located in the bile, suggesting portal absorption. 
This difference may relate to differences in 
lipophilicity, however, the predicted difference in 
log P is only slight (0.031 units from Rekker 
fragmental data (Table 2». It should be noted that 
log P data are calculated on the unionised forms of 
the retinoids and values will be significantly lower 
for a molecule with an dissociated acidic proton 
(Lyman, 1982). 
In order to assess the importance of the oil 
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solubility of a retinoid, retinoid lipophilicity and 
the effect of co-administering a retinoid with oil, 
on the lymphatic uptake of the retinoid, a series of 
in-vivo experiments were performed. 
4.2.2. In-yiyo techniques used to study the 
lymphatic absorption of the retinoids. 
A number of in-vivo techniques using male wistar 
rats were used in the study of the lymphatic 
absorption of the retinoids. 
Following some initial investigations, rats were 
selected with a body weight between 200 g and 250 g. 
Animals of greater body weight had been found to 
contain increasing quantities of body fat which made 
cannulation of the mesenteric lymph duct technically 
more difficult. Animals of body weight less than 
200 g had mesenteric lymph vessels which were 
difficult to cannulate because of their small size 
and which gave very low lymph flow rates. 
Several in-vivo techniques were used in the oral 
dosing studies, retinoids were delivered into the 
stomach of the rat in a series of oily vehicles, in 
order to study .. the effect of various formulations on 
the absorption of the retinoids. The carotid artery 
was cannulated in order to collect blood samples for 
analysis of retinoid concentrations after oral 
dosing and the mesenteric lymph duct of the rat was 
cannulated in order to collect intestinal lymph 
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samples for analysis of retinoid concentrations 
after oral dosing. 
Lymph flow rates were assessed from individual lymph 
sample volumes and the times to collect the samples. 
Lymph turbidity was determined by measuring the 
spectrophotometric absorbance of the lymph samples. 
4.2.2.1. Oral dosing technique in the rat. 
Oily solutions of the retinoids (0.5 ml) or liquid 
food material (2.0 ml) were administered into the 
stomach of the rat from a disposable syringe (1.0 or 
2.5 ml) through a metal oral dosing needle (16 g 
x 3"). 
The animal was restrained by the skin on the back, 
the dosing needle was inserted into the stomach and 
the contents of the syringe were dosed into the 
stomach. Care was taken to prevent accidental dosing 
into the trachea or lungs. This procedure was 
performed without anaesthesia and was completed in 
less than 30 seconds. 
4.2.2.2. Cannulation of the cartotid artery. 
Cannulation of,. the carotid artery was performed as 
previously described in section 4.1.2.1. 
4.2.2.3. cannulation of the mesenteric lymph duct. 
A search of the literature has revealed that 
thoracic lymph duct cannulations appear to have been 
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performed more frequently than mesenteric lymph duct 
cannulations in studies of lymphatic absorption 
(Forsgren, 1969., Kamp & Neumann, 1975., Saldeen & 
Linder, 1960., Sieber et al., 1974., Tucker, 1983., 
Yanagawa et al., 1989., Gowan & Stavchansky, 1986., 
Hashida et al., 1977., Hirate & Ueda, 1989). 
The thoracic lymph duct in the rat, is large thick 
walled vessel, approximately 1 - 2 mm in diameter, 
which runs posterior to the aorta (Bollman et al., 
1948). Cannulation of this vessel is relatively easy 
and large volumes of lymph can be collected from the 
vessel. The high lymph flow through the thoracic 
duct is thought to be due to extensive drainage of 
fluid from tissues around the body including the 
small intestine (Olszewski, 1985). In contrast, 
mesenteric lymph flows directly from the intestine 
and is more likely to give a good estimate of direct 
lymphatic absorption (de Nijs, 1987). This factor 
would tend to dilute any mesenterically absorbed 
compounds and thus cause problems in the analysis of 
minute quantities of lymphatically absorbed drugs 
due to the effect of dilution. 
The importance
d
• of cannulating the mesenteric duct in 
studies of lymphatic absorption was demonstrated by 
Noguchi et al. (1985) who studied the lymphatic 
absorption of the highly lipophilic compound DDT 
( 1 , 1 - ~ ( p - c h l o r o p h e n y l ) - 2 / 2 / 2 - t r i c h l o r o e t h a n e ) ) in 
the rat. After intravenous dosing of DOT in oleic 
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acid, high levels of the compound were detected in 
the thoracic lymph (3.6% of the administered dose / 
24 hours). Small quantities of DDT were also 
detected in mesenteric lymph (0.6% of the 
administered dose / 24 hours) but these were 
explained as being due to extrahepatic recirculation 
of DDT which has been excreted into the duodenum 
through the bile (Noguchi et aI, 1985., Levine et 
li., 1969). 
DDT has also been detected in thoracic lymph after 
occlusion of the mesenteric lymph duct. These data 
suggest that DDT is re-circulated from plasma into 
thoracic lymph after intravenous dosing. 
These data indicate that the collection of thoracic 
lymph may tend to overestimate the extent of direct 
intestinal lymphatic absorption. It was therefore 
decided to collect lymph from the mesenteric lymph 
duct in order to study the lymphatic absorption of 
the retinoids from the gastrointestinal tract. 
4.2.2.3.1 Method for cannulation of the mesenteric 
lymph duct. 
Cannulation of"" the mesenteric lymph duct was carried 
out based on the method of Bollman (Bollman et al., 
1948) and modified by Warshaw (Warshaw, 1972). 
Male rats were fasted overnight on wire grids to 
prevent coprophagia. Animals were anaesthetised as 
previously described (Section 4.1.2.1.). 
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The anaesthetised animal was placed, ventral side 
uppermost, on a heated mat and was shaved on the 
right side from the rib margin to the pelvic area. A 
diagonal incision was made through the body wall, 
using a scalpel, extending from the xiphisternum to 
the right pelvic margin. scissors were used to cut 
through the peritoneum and the intestines were 
displaced to the left to observe the right kidney. 
The mesenteric lymph duct can be seen as a vessel of 
slightly less than 1 mm in diameter, running 
parallel to the mesenteric artery and perpendicular 
to the vena cava.The vessel can be observed to 
contain a milky white fluid after orally dosing the 
animal with a fatty meal. 
A saline filled cannula was prepared using a length 
of polythene tubing (internal diameter; 0.5 mm, 
external diameter; 1.0 mm), cut with a 45 0 bevel, and 
this was fed under the right kidney and vena cava. 
The area around the mesenteric lymph duct was 
examined using a binocular dissecting microscope and 
was cleared using cotton buds. The main mesenteric 
lymph duct was cut transversely using a small pair 
of spring scissors. The cannula was inserted into 
the leaking vessel and glued into position using a 
small drop of cyanoacrylate cement. Lymph was seen 
to flow into the cannula. The cannula was 
exteriorised, cut short (approximately 3 cm outside 
the body of the animal) and immobilised using 'blu-
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tack'. A further length of saline filled cannula 
(approximately 50 cm in length) and containing a 
small air space (5 ~ l ) , , was attached to the 
lymphatic cannula using a broken off hypodermic 
syringe needle. The second length of cannula was 
allowed to hang vertically over the edge of the 
bench to provide a slight negative pressure on the 
mesenteric lymph duct and thereby assist the flow of 
lymph. The small air space in the cannula was used 
to monitor the flow of lymph (a 40 cm length of 
cannula gives an internal volume of approximately 
100 ~ l ) . . The second cannula was replaced 
periodically and lymph was drained from this into 
pre-weighed micro-centrifuge tubes (1.5 ml) and 
stored at -20°C. The time of collection of each lymph 
sample and its volume (mass) was recorded. 
4.2.3. Oral dosing studies. 
It has been suggested that most lymphatically 
transported lipophilic drugs are present in the 
chylomicron fraction of the intestinal lymph and two 
factors may influence the quantity of drug carried 
via this intestinal transportation pathway. Firstly, 
the quantity of lipid transported in the lymph in 
the form of chylomicron and secondly, the amount of 
drug per chylomicron (Charman & Stella, 198Gb). Both 
of these factors may be manipulated in order to 
optimize or promote the lymphatic absorption of a 
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particular drug. 
Chylomicron flow may be influenced by factors such 
as diet and the type of lipid vehicle which is co-
administered with the drug. 
In the present studies it was decided therefore, to 
select a series of oils and oil systems with which 
to investigate the relationships between the 
lymphatic absorption of the retinoids and the nature 
of the oral formulation dosed. 
4.2.3.1. Selection of oil systems for oral dosing 
studies. 
A series of oils was selected from the list in Table 
3. The oils were chosen to test several factors 
which were believed to be important in the promotion 
of lymphatic absorption. 
The effect of the fatty acyl-ester content of mixed 
long chain fatty acyl glycerol oils was to be 
assessed. The mixed long chain fatty acyl 
trig1ycero1 oils (peanut oil, soyabean oil and 
cottonseed oil) were chosen in order to compare the 
effect of different proportions of three component 
long chain fatty acids; palmitic acid (C16:0), oleic 
acid (C18:1) and linoleic acid (C18:2) on the 
lymphatic absorption of the retinoids. These three 
triglyceride oils contain between 87% and 96% of 
these fatty acyl esters, although in differing 
proportions (Mead et al., 1986). 
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It may be seen from the data in Table 3 that peanut 
oil and soyabean oil contain similar compositions of 
palmitate esters but approximately inversed 
proportions of oleate and linoleate esters. 
Soyabean oil and cottonseed oil contain similar 
amounts of oleate and linoleate esters but 
cottonseed oil contains a greater proportion of the 
palmitate ester. 
Mixed long chain fatty acyl glycerol oils were also 
selected to enable comparison of these with the 
effects of the free long chain fatty acid oils 
(oleic acid and linoleic acid). 
Mixed long chain fatty acyl glycerol oils and mixed 
medium chain fatty acyl glycerol oil (Miglyol 812) 
were chosen in order to test the effect of fatty 
acid chain length in triacyl glycerol oils on the 
lymphatic absorption of the retinoids. 
Initially, Ro 04-3780 was orally administered in 
each of six oils; cottonseed, soyabean, peanut, 
oleic acid, linoleic acid and Miglyol 812. Oral 
dosing studies were also carried out on Ro 10-9359 
and Ro 15-0778 using three of these oils, cottonseed 
oil, linoleic ,acid and Miglyol 812. 
In addition, the lymph flow rate and chylomicron 
concentration (lymph turbidity) were measured after 
oral dosing with each of the oil systems in order to 
examine any relationship between these factors and 
lymphatic absorption. 
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Several other factors which were thought may be 
important in influencing the rate and extent of 
lymphatic absorption, including the effect of food 
and the effect of oral oil emulsion systems on 
lymphatic absorption, were also studied (Sections 
4.2.3.3. and 4.2.3.4.). 
4.2.3.2. Method for studying absorption of retinoids 
after oral administration in oil systems. 
Reports in the literature have suggested that some 
lipophilic compounds are extensively absorbed via 
the lymphatic route, including the parent compound 
of the retinoids, vitamin-A (Blomhoff et al., 1984., 
Palin et al., 1982., Drummond et al., 1935) and the 
highly lipophilic compound, DDT (Sieber et al., 
1974., Palin et al., 1982., Noguchi et al., 1985., 
Charman et al., 1986a., Charman et al., 1986b). 
In a study of the blood and lymph transport of DDT, 
O'Driscoll (O'Driscoll et al., 1991) reported low 
blood levels of DDT in mesenteric lymph cannulated 
rats (AUC = 18.2 J,tg.h.ml-
'
), following intraduodenal 
administration. When blood alone was sampled, much 
higher levels of DDT were observed (AUC = 28.1 
+ 5.8 J,tg.h.ml- l ). The higher mean blood values 
reported, when blood alone was sampled, were 
explained by a redistribution of DDT from lymph to 
blood. 
In the present study of the lymphatic absorption of 
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the highly lipophilic retinoids, it was considered 
necessary to collect lymph and blood from separate 
groups of animals since cannulation of the 
mesenteric lymphatic duct and the subsequent 
sampling of mesenteric lymph may remove a major 
route of absorption for retinoids into the systemic 
circulation. 
Male Wistar rats were fasted overnight (16 hours) on 
wire grids, to prevent coprophagia, water was 
available ad-libitum. 
Animals were orally dosed with 0.5 ml of an oily 
solution containing the retinoid at a concentration 
of 3 mg/ml (6 mg/kg in a 250 g rat), using the 
method described in section 4.2.2.1. The animals 
were returned to their cage for 30 minutes to allow 
absorption of the oil to begin. 
The mesenteric lymph duct or the carotid artery was 
cannulated using the methods described above 
(Section 4.2.2.3.1 or Section 4.2.2.2.). Samples of 
lymph or plasma were collected at timed intervals. 
At least twelve animals were used for each oily 
dosing formulation studied. The animals were divided 
into groups of_equal size, the first group of six 
animals had a carotid artery cannulation performed 
on them (Section 4.2.2.2.) and were used only for 
the collection of timed blood samples. The second 
group of six animals had a mesenteric lymph duct 
cannulation performed on them (Section 4.2.2.3.1) 
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and were used only for collection of timed lymph 
samples. 
A maximum of 10 - 12 samples of lymph or plasma were 
collected from each animal. Blood samples (approx. 
200 ~ l ) ) were collected at 15 - 30 minute intervals 
and lymph samples were collected when a sufficient 
volume had been collected in the cannula to permit 
analysis (25 - 100 ~ l ) . . The number of lymph sample 
collections which could be made was often limited by 
the appearance of "clots" within the cannula which 
eventually prevented the flow of lymph. 
The retinoid concentration in each sample of lymph 
or plasma was determined using the appropriate 
analytical procedure (Section 2.1.1.). The 
concentration of retinoid determined in each sample 
was corrected for sample volume and expressed as 
nanograms retinoid per millilitre of sample per 
milligram dose per kilogram body weight (Dose 
adjusted concentration, (ng/ml}). 
This series of procedures was repeated for each oil 
system and retinoid combination. 
4.2.3.3. The effeot of oral dosing in a self-
emulsifying oil system. 
In an attempt to improve the overall absorption of 
retinoids it was decided to study the effect of a 
self-emulsifying oil system (Chapter 3) on the 
absorption of Ro 15-0778. The self-emulsifying oil 
- 164 -
system chosen for this study was MTS, a system 
containing 80% Miglyol 812, 16% Tween 85 and 4% Span 
85. This self-emulsifying oil system produced an 
emulsion which was stable for several days and 
showed a small particle size (509 + 20 nm). 
Ro 15-0778 was selected as the retinoid for use in 
these studies because it showed similar solubility 
in MTS to that measured in Miglyol 812. It was also 
expected to demonstrate a high extent of absorption 
because of its extremely lipophilic nature, thus 
allowing precise analytical data to be obtained. 
Ro 15-0778 (6 mg/kg) was dissolved in MTS and orally 
administered to animals as a bolus dose (0.5 ml) as 
described in section 4.2.4.1. and the absorption of 
Ro 15-0778 was studied using the procedures 
described in section 4.2.3.2. 
4.2.3.4. The effect of food on the lymphatic 
absorption of the retinoids. 
A series of experiments was carried out using a 
selected oil (linoleic acid) to test the effect of 
food on the lymphatic absorption of a retinoid 
(Ro 10-9359). '._ 
Two groups of rats (6 animals per group) were fasted 
overnight (16 hours). The animals were orally dosed 
with a liquid rat diet (2 ml of SOS water soluble 
diet) and returned to their cage for 30 minutes. The 
animals were then orally dosed with linoleic acid 
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(0.5 ml) containing the retinoid Ro 10-9359 
(6 mg/kg). water was available ad-libitum at all 
times. After a further 30 minutes the first group of 
animals had a mesenteric lymph duct cannulation 
performed on them (Section 4.2.2.3.1) whilst the 
second group had a carotid artery cannulation 
procedure (section 4.2.2.2.) performed on them. 
Samples of lymph or blood were collected and the 
absorption of Ro 10-9359 was studied using the 
procedure described in section 4.2.3.2. These data 
were compared with data obtained on a control group 
of animals which had been fasted overnight but had 
not received any food prior to oral dosing with 
Ro 10-9359 (6 mg/kg) in linoleic acid. 
4.2.3.5. studies of lymph turbidity. 
Charman & Stella (1986b) have reported that 
chylomicron flux is important for the transport of 
lipophilic drugs and have studied the lymph optical 
density at 560 nm as a relative index of chylomicron 
lipid content (Charman et al., 1986b). In this study 
it was decided to study the turbidity of lymph (as 
an index of chylomicron transport) as a function of 
orally dosed lipid vehicle. 
A group (18 animals) of fasted male Wistar rats was 
fasted overnight (16 hours) and pairs of animals 
were orally dosed with either isotonic saline 
(0.5 ml), one of a series of oils (0.5 ml) or the 
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SDS water soluble diet (2 ml). Mesenteric lymph duct 
cannulations were performed on each animal (Section 
4.2.2.3.1) and lymph samples were collected for 
turbidity estimation. 
Aliquots (20 - 50 mg) in duplicate from each lymph 
sample were diluted in isotonic saline (2 ml) in 
order to give an absorbance (A = 400 nm) value 
within the range 0.20 - 1.00 when measured on a 
spectrophotometer. The wavelength of 400 nm was 
chosen for these absorbance measurements since at 
lower wavelengths non-specific absorbance was 
observed, possibly due to other chromophores in the 
lymph samples (proteins, vitamins etc.), whilst at 
higher wavelengths the absorbance decreased rapidly 
and may have presented difficulties in obtaining 
sufficient volumes of lymph for analysis. 
The product of the absorbance for each diluted lymph 
sample and its dilution factor was used to determine 
the absorbance of undiluted lymph. 
4.2.4. Results. 
a) Ro 04-3780. 
The mean mesenteric lymph flow rate was calculated 
from the volume of lymph collected in each sample 
(mg) and the time of collection (min), after dosing 
rats with Ro 04-3780 in each of the six oily 
vehicles. These data are shown in Table 24. The 
greatest lymph flow rate was measured after dosing 
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Table 24. Lymphatic absorption data for Ro 04-3780 after 
oral administration in a series of oil systems to fastinq 
rats. 
a) Lymphatic absorption. 
oil 
cottonseed 
Soyabean 
Peanut 
Miglyol 812 
Oleic acid 
Linoleic acid 
Lymph 
flow 
rate. 
mg/h/kg 
3.14 ± 0.82 * 
3.31 ± 1.76 * 
1.73 ± 0.37 
2.05 ± 0.70 
1.94 ± 0.87 
0.80 ± 0.23 * 
Dose adjusted 
lymphatic 
concentration. 
ng/ml 
48.0 
37.5 
41.5 
26.6 
13.5 
1.4 
Total 
lymphatic 
uptake. 
ng/h 
151 
124 
72 
55 
26 
1.1 
b) Plasma absorption. 
Oil Total Estimated Lymph: plasma 
body plasma uptake ratio 
retinoid. uptake. (x 100) 
ng ng/h 
Cottonseed 11520 7530 2.00 
Soyabean 14950 9840 1.26 
Peanut 8630 5680 1.27 
Miglyol 812 16050 10650 0.52 
Oleic acid 4370 2890 0.90 
Linoleic acid 230 154 0.72 
* Indicates result significantly different (P < 0.01) from 
basal flow rate after animals were orally dosed with saline 
(0.5 ml). 
Notes: 
i) Total lymphatic uptake; product of measured lymph flow 
rate and mean 90 minutes dose adjusted lymph concentration. 
ii) Total body retinoid; product of volume of distribution 
and mean 90 minute dose adjusted plasma concentration. 
iii) Plasma uptake; difference between total uptake and 
lymphatic uptake rates. 
Ro 04-3780 in soyabean oil (3.31 mg/min). The 
remaining oils gave lymph flow rates of 3.14 mg/min 
(cottonseed oil), 2.05 mg/min (Miglyol 812), 1.93 
mg/min (oleic acid), 1.73 mg/min (peanut oil) and 
0.80 mg/min (linoleic acid). The least significance 
(p < 0.01) on these results was approximately 
0.8 ml/h. 
The dose adjusted concentration data for Ro 04-3780 
in lymph and plasma have been plotted as a function 
of time after oral dosing with each of six oils. The 
results show that the mixed long chain tri-acyl 
glycerol oils, cottonseed oil (Figure 14), soyabean 
oil (Figure 15) and peanut oil (Figure 16), gave the 
greatest dose adjusted lymphatic concentrations of 
Ro 04-3780 (48.0 ng/ml, 37.5 ng/ml and 41.5 ng/ml 
respectively). The mixed medium chain tri-acyl 
glycerol oil, Miglyol 812 (Figure 17) and the long 
chain fatty acid oil, oleic acid (Figure 18) gave 
slightly lower dose adjusted lymphatic 
concentrations (26.6 ng/ml and 13.5 ng/ml). Linoleic 
acid (Figure 19) gave the lowest dose adjusted 
lymphatic concentration (1.4 ng/ml). 
The lymphatic uptake rates for Ro 04-3780, were 
calculated from the lymphatic concentration data and 
the lymph flow rate (Table 24). The results show 
that the mixed long chain tri-acyl glycerol oils, 
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Figure 14 . Dose adjuste d plasma and lymph concentrations of 
Ro 04 - 3780 in the rat after oral dosing in cottonseed oil (6 mg/kg) . 
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Figure 15. Dose adjusted plasma and lymph concentrations of 
Ro 04-3780 in the rat after oral dosing in soyabean oil (6 mg/kg) 
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Figure 16. Dose adjusted plasma and lymph concentrations of 
Ro 04-3780 in the rat after oral dosing in peanut oil (6 mg/kg) 
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Figure 17. Dose adjusted lymph and plasma concentrations of 
Ro 04-3780 in the rat after oral dosing in Miglyol 812 (6 mg/kg) 
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Figure 18. Dose adjusted plas ma and lymph concentrations of 
Ro 04 - 3780 in the r a t aft e r oral do s ing in ole i c acid (6 mg/kg) 
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Figure 19. Dose adjusted plasma and lymph concentrations of 
Ro 04 - 3780 in the rat after oral dosing in linoleic acid (75 mg/kg) . 
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cottonseed oil, soyabean oil and peanut oil, gave 
the greatest lymphatic uptake rate for Ro 04-3780 
(151 ng/h, 124 ng/h and 72 ng/h respectively. The 
mixed medium chain tri-acyl glycerol oil, Mig1yol 
812 and the long chain fatty acid, oleic acid gave 
slightly lower lymphatic uptake rates (55 ng/h and 
26 ng/h) and linoleic acid, gave the lowest 
lymphatic uptake rate (1.1 ng/h). 
The dose adjusted plasma concentration data, 
together with the volume of distribution (Vd) for 
Ro 04-3780 (Table 21), allowed an estimate of the 
total body Ro 04-3780 content to be calculated. 
These data (Table 24) show a maximum total body 
retinoid content for Ro 04-3780 of 1.60 % of the 
administered dose (16,000 ng from a 1 mg dose) after 
90 mins post dosing in Miglyo1 812, (Table 24). The 
other oils gave a total body retinoid content of 
15,000 ng (1.50% of the dose) after dosing in 
soyabean oil, 11,500 ng (1.15%) after dosing in 
cottonseed oil, 8,500 ng (0.85%) after dosing in 
peanut oil, 4,500 ng (0.45%) after dosing in oleic 
acid and 200 ng (0.02%) after dosing in linoleic 
acid. 
An estimate of the plasma uptake rate of Ro 04-3780 
was made by subtracting the calculated lymphatic 
uptake rate from the total body retinoid uptake 
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rate. Miglyol 812 and soya bean oil gave the greatest 
plasma uptake rate (10,500 ng/h and 10,000 ng/h 
respectively). The plasma uptake rate was 7,500 ng/h 
after dosing Ro 04-3780 in cottonseed oil, 5,500 
ng/h after dosing in peanut oil, 3,000 ng/h after 
dosing in oleic acid, and 150 ng/h after dosing in 
linoleic acid. 
The lymph : plasma uptake ratios of Ro 04-3780 after 
dosing in the six oils ranged from 0.5% (Miglyol 
812) to 2.0% (cottonseed oil). 
~ ) ) Ro 10-9359. 
The mean mesenteric lymph flow rate was calculated, 
after dosing fasted rats with Ro 10-9359 in each of 
three oily vehicles. These data are shown in 
Table 25. The greatest lymph flow rate was measured 
after dosing Ro 10-9359 in cottonseed oil (2.57 
mg/min). Miglyol 812 gave a flow rate of 1.47 mg/min 
and linoleic acid gave a flow rate of 1.48 mg/min. 
The lymph flow rate after dosing Ro 10-9359 in 
linoleic acid after pre-feeding the rats with liquid 
food was 1.38 mg/min. 
The dose adjusted concentration data for Ro 10-9359 
in lymph and plasma have been plotted as a function 
of time after oral dosing with each of three oils. 
The results show that the mixed long chain tri-acyl 
glycerol oil, cottonseed oil (Figure 20), gave the 
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Table 25. Lymphatic absorption data for Ro 10-9359 after 
oral administration in a series of oil systems to fastinq 
and fed rats. 
a) Lymphatic absorption. 
Oil Lymph Dose adjusted Total 
flow lymphatic lymphatic 
rate. concentration. uptake. 
mg/h/kg ng/ml ng/h 
Cotton seed 2.57 ± 0.85 * 1550 3980 
Miglyol 812 1. 47 ± 0.26 350 514 
Food/Linoleic 1. 38 ± 0.54 570 790 
Fast/Linoleic 1. 48 ± 0.70 690 1030 
b) Plasma absorption. 
Oil Total Estimated Lymph: plasma 
body plasma uptake ratio 
retinoid. uptake. (x 100) 
ng ng/h 
Cottonseed 23150 11454 34.7 
Miglyol 812 38660 25260 2.03 
Food/Linoleic 1120 < 25 > 3000 
Fast/Linoleic 2000 310 332 
* Indicates result significantly different (P < 0.01) from 
basal flow rate after animals were orally dosed with saline 
(0.5 ml). 
Note: 
Total body retinoid was calculated as the product of volume 
of distribution and mean 90 minute dose adjusted plasma 
concentration. Volume of distribution (1175 ml) was taken 
from Liu (Liu et al., 1990). 
Figure 20. Dose adjusted plasma and lymph concentrations of 
Ro 10-9359 in the rat after oral dosing in cottonseed oil (6 mg/kg) . 
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greatest dose adjusted lymphatic concentrations of 
Ro 10-9359 (1550 ng/ml). Linoleic acid (Figure 21), 
gave a dose adjusted lymphatic concentration of 690 
ng/ml and Miglyol 812 (Figure 22) gave the lowest 
dose adjusted lymphatic c o n c e n t r a ~ i o n n of 350 ng/ml. 
The lymph and plasma data, obtained effect of 
feeding rats prior to dosing with Ro 10-9359 in 
linoleic acid, were compared with the data obtained 
from fasted rats dosed with Ro 10-9359 in linoleic 
acid and are plotted as a function of time in 
Figure 23. Fed rats, dosed with linoleic acid, gave 
a dose adjusted lymphatic concentration of 570 ng/ml 
compared with 690 ng/ml in fasted rats (Table 25). 
The lymphatic uptake rate data for Ro 10-9359 were 
calculated from the lymphatic concentration data 
using the lymph flow rate (Table 25). The results 
show that the mixed long chain tri-acyl glycerol 
oil, cottonseed oil, gave the greatest lymphatic 
uptake rate for Ro 10-9359 of 3980 ng/h. The long 
chain fatty acid, linoleic acid, gave a lymphatic 
uptake rate of 1030 ng/h and the mixed medium chain 
tri-acyl glycerol oil, Miglyol 812, gave the lowest 
lymphatic uptake rate (514 ng/h). Fed rats, dosed 
with linoleic acid, gave a lymphatic uptake rate of 
790 ng/h (Table 25). 
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Figure 21. Dose adjusted lymph and plasma concentrations of 
Ro 10-9359 in the rat after oral dosing in linoleic acid (6 mg/kg) . 
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Figure 22 . Dose adjusted plasma and lymph concentrations of 
Ro 10- 9359 in the rat afte r ral dosing in Miglyol 812 (6mg/kg) 
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Figure 23. Effect of pre- feeding on the lymph and plasma concentrations 
of Rc 10-9359 in the rat after oral dosing in linoleic acid (6 mg/kg) . 
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The dose adjusted plasma concentration data, 
together with the volume of distribution (Vd) for 
Ro 10-9359 (Liu et al., 1990), were used to estimate 
the total body Ro 10-9359 content. These data (Table 
25) show a maximum total body retinoid content of 
Ro 10-9359, of 3.87% of the administered dose 
(38,660 ng from a 1 mg dose) after 90 mins post 
dosing in Miglyol 812, (Table 25). Cottonseed oil 
gave a total body retinoid content of 23,150 ng 
(2.32% of the'dose) and linoleic acid gave a total 
body retinoid content of 2,000 ng (0.20%). The total 
body retinoid content of Rc 10-9359 in fed rats, 
after dosing in linoleic acid, was 1,120 ng (0.11%). 
Miglyol 812 gave the greatest plasma uptake rate 
(25,000 ng/h). The plasma uptake rates from 
cottonseed oil and linoleic acid were 11,500 ng/h 
and 300 ng/h. The plasma uptake rate in fed rats, 
after dosing in linoleic acid, was less than 
25 ng/h. 
The lymph plasma uptake ratios for the oils ranged 
from 0.02:1 (Miglyol 812) to 3.3:1 (linoleic acid), 
however, in fed rats, the lymph: plasma uptake 
ratio was greater than 30:1. 
c) Ro 15-0778. 
The three oils which had been chosen for use in 
studies of the lymphatic absorption of Ro 10-9359 
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were also studied using Ro 15-0778. 
The mean lymph flow rate was calculated, after 
dosing fasted rats with Ro 15-0778 in each of the 
three oily vehicles and in a self-emulsifying oil 
system (MTS). These data are shown in Table 26. 
The greatest lymph flow rate was measured after 
dosing Ro 15-0778 in cottonseed oil (1.99 mg/min). 
Linoleic acid gave a flow rate of 1.14 mg/min and 
Miglyol 812 gave a flow rate of 0.97 mg/min. The 
lymph flow rate after dosing Ro 15-0778 in the self-
emulsifying oil system (MTS) was 1.38 mg/min. 
The dose adjusted concentration data for Ro 15-0778 
in lymph and plasma have been plotted as a function 
of time after oral dosing with each of the three 
oils. The results show the greatest dose adjusted 
lymphatic concentration after dosing Ro 15-0778 in 
the long chain fatty acid, linoleic acid 
(Figure 24), (3590 ng/ml). The mixed long chain tri-
acyl glycerol oil, cottonseed oil (Figure 25), gave 
a dose adjusted lymphatic concentrations of 
2040 ng/ml and Miglyol 812 (Figure 26) gave the 
lowest lymphatic concentration (1270 ng/ml) (Table 
26) • 
After dosing Ro 15-0778 in MTS, which contains 80% 
Miglyol 812, a dose adjusted lymphatic concentration 
of Ro 15-0778 of 3670 ng/ml was obtained (Table 26). 
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Figure 24. Dose adjusted plas ma and lymph concentrations o f 
Ro 15- 0778 in the rat a fter oral do s ing in linoleic a c id (6 mg/kg). 
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Figure 25. Dose adjusted plasma and lymph concen t rations of 
Ro 15- 0778 in the rat after oral dosing in cottonseed oil (6 mg/kg) . 
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Figure 26. Dose adjust ed lymph and pla sma c oncentrations of 
Ro 15- 0778 in the rat after oral dosing in Miglyo l 812 (6 mg/kg) 
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Table 26. Lymphatic absorption data for Ro 15-0778 after 
oral administration in a series of oil systems to fastinq 
rats. 
a) Lymphatic absorption. 
Oil Lymph Dose adjusted Total 
flow lymphatic lymphatic 
rate. concentration. uptake. 
mg/h/kg ng/ml ng/h 
Cottonseed 1.99 + 0.64 2040 4060 
Miglyol 812 0.97 ± 0.33 1270 1230 
MTS 0.95 ± 0.26 3670 3480 
Linoleic acid 1.14 ± 0.39 3594 4110 
b) Plasma absorption. 
oil Total Estimated Lymph: plasma 
body plasma uptake ratio. 
retinoid. uptake. (x 100) 
ng ng/h 
Cotton seed 14220 4830 84.0 
Miglyol 812 14280 8290 14.9 
MTS 59750 36170 9.6 
Linoleic acid 26400 13493 30.5 
Note: 
MTS is an self emulsifying oil system containing Miglyol 81 
(80 parts), Tween 85 (16 parts) and Span 85 (4 parts). 
This result being higher than that obtained with 
Miglyol 812 alone (1279 ng/ml). These dose adjusted 
lymphatic concentration data are plotted as a 
function of time in Figure 27. 
The lymphatic uptake rates were calculated from the 
lymphatic concentration data using the lymph flow 
rate (Table 26). The results show that the long 
chain fatty acid, linoleic acid, gave the greatest 
lymphatic uptake rate for Ro 15-0778 (4110 ng/h). 
The mixed long chain tri-acyl glycerol oil, 
cottonseed oil, gave a slightly lower lymphatic 
uptake rate (4,060 ng/h) and the mixed medium chain 
tri-acyl glycerol oil, Miglyol 812, gave the lowest 
lymphatic uptake rates (1,230 ng/h). Rats which were 
dosed with Ro 15-0778 in MTS, gave a lymphatic 
uptake rate of 3,480 ng/h (Table 26). 
The total body content of Ro 15-0778 after oral 
dosing in each of the three oils (Table 26) reached 
a maximum of 2.64% of the administered dose (24,600 
ng from a 1 mg dose) after 90 mins after dosing in 
linoleic a c i d ~ ~ The other oils show a total body 
retinoid content of 14,280 ng (1.43% of the dose) 
after dosing in Miglyol 812 and 14,220 ng (1.42%) 
after dosing in cottonseed oil. However, after 
dosing Ro 15-0778 in MTS, the total body retinoid 
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Figure 27 . A comparison of lymph concentrations of Ro 15- 0778 
in the rat after oral dosing in MTS or Miglyol 812 (6 mg/kg) . 
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content reached a still higher value of 59,770 ng 
(5.98%). 
Of the three oils, linoleic acid gave the greatest 
plasma uptake rate (13,500 ng/h). The plasma uptake 
rates from Miglyol 812 and cottonseed oil were 8,300 
ng/h and 4,800 ng/h. The plasma uptake rate in rats 
which had been dosed with Ro 15-0778 in MTS (36,200 
ng/h) was much greater than those found after dosing 
in oils. 
The lymph : plasma uptake ratios for the oils ranged 
from 15% (Miglyol 812) to 84% (cottonseed oil). In 
rats dosed with MTS, the lymph : plasma uptake ratio 
was greater than 10%. 
4.2.5. Disoussion. 
A method for the cannulation of the mesenteric 
lymphatic duct in the male wistar rat has been 
developed. Lymph was allowed to flow into a 
polythene cannula under a slight negative pressure 
and the method permitted the collection of small 
amounts of lymph (20 - 100 mg) over a number of 
hours. 
Lymph collections were seen to become turbid and 
creamy in appearance several minutes after dosing 
the animals with an oily meal. This was believed to 
be caused by an increase in chylomicron formation in 
the enterocytes of the gut and the subsequent 
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transport of these chylomicrons, via the lymphatic 
network, into the venous circulation. 
Lymph flow rate was determined after each sample of 
lymph was collected. The lymph flow rate was also 
seen to vary after dosing the animals with an oily 
meal. 
4.2.5.1. Lymph turbidity after oral dosing. 
After performing numerous mesenteric lymph duct 
cannulations on animals dosed with oily vehicles 
containing retinoid, it was observed that certain 
oils produced a very creamy lymph whilst other oils 
gave rise to a very pale lymph. Charman et al. 
(1986b) have confirmed a strong correlation (r2 
= 0.9561) between lymph turbidity and lymph 
chylomicron lipid concentration. since lymph 
chylomicrons are almost certainly the carrier 
vehicle for lipophilic compounds (Sieber, 1976., 
Vost & Maclean, 1984), it was decided to investigate 
the turbidity of lymph after various dosing regimens 
and examine these data in relation to lymphatic 
uptake rates from the same oily vehicles. Turbidity 
estimations were made by measuring the visible 
absorption of lymph samples diluted in saline as 
described in section 4.2.4.4. 
The lymph turbidity data obtained from animals dosed 
with oils and food were compared with those obtained 
from animals which were dosed with an equivalent 
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volume of saline (Table 27). 
In general, the turbidity of lymph seemed to follow 
the same pattern which had been observed 
subjectively during mesenteric duct cannulation 
procedures. Three distinct groups of oily dosing 
vehicles could be categorised in terms of their 
ability to produce turbid lymph. The first group 
included the three long chain fatty acid triacyl 
glycerol oils: soyabean oil, cottonseed oil and 
peanut oil; these gave the greatest turbidity 
(absorbance greater than 25 x lymph from animals 
dosed with saline). 
The second group contained long chain fatty acids, 
oleic acid and linoleic acid, the self-emulsifying 
oil system containing Miglyol 812, Tween 85 and Span 
85 and the special liquid rat diet. These materials 
gave intermediate turbidity (absorbance greater than 
10 x lymph from animals dosed with saline). 
The third group contained the mixed medium chain 
fatty acid triacyl glycerol oil, Miglyol 812, which 
gave only a very slight increase in turbidity 
(absorbance less than 5 x lymph from animals dosed 
with saline) •. , 
These data are consistent with lymph turbidity data 
(0 - 50 absorbance units/h at 360 nanometres after 
infusion of a 0.2% Tween/saline solution containing 
DOT, into the duodenum) obtained from fasted 
Sprague-Dawley rats (Charman et al., 1986b). Cheema 
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Table 27. Lymph turbidity data after orally dosing fasted 
rats with oils (0.5 ml), SES (0.5 ml), liquid food (2.0 ml) 
or saline (0.5 ml). 
Oral Lymph absorbance Turbidity relative 
dose. (400 nanometres) to saline dose. 
Saline # 1.07 ± 0.346 (8) 
Soyabean 51. 3 ± 9.59 (6) 48.2 
Cottonseed 38.0 + 
** (4) 35.7 
Peanut 26.6 ± ** (3) 25.0 
Oleic acid 12.9 ± 1. 92 (10) 12.1 
MTS 12.5 ± 2.83 (8) 11. 0 
Liquid food 10.5 ± 6.49 (12) 9.9 
Linoleic acid 10.4 ± ** (3) 9.8 
Miglyol 812 4.7 ± 0.91 (6) 4.4 
Note: 
i) Figures are the lymphatic absorbance (absorbance 
units/ml) for lymph after correcting for dilution ± standar 
deviation. Value in brackets indicates number of values 
measured. 
ii) ** Insufficient data for analysis. 
iii) MTS is an self emulsifying oil system containing 
Miglyol 812 (80 parts), Tween 85 (16 parts) and Span 85 (4 
parts) • 
iv) # Lymph flow rate after dosing saline (0.5 ml) was 1.61 
± 0.69 ml/h/kg. ," 
et al. (1987) have also reported the highest 
lymphatic concentration of chylomicrons after the 
intra-duodenal administration of the mixed long 
chain tri-acyl glycerol oil, arachis oil (peanut 
oil), in the rat. However, similar lymphatic 
chylomicron concentrations were also reported after 
administration of the free long chain fatty acid, 
linoleic acid. 
The mixed long chain triacyl glycerol oils promoted 
the highest lymph turbidity and also the greatest 
lymphatic absorption rates suggesting a possible 
link between these two factors. The correlation 
coefficients between lymph turbidity and lymphatic 
transport of a retinoid were highly significant 
(Ro 04-3780; r2 = 0.495, P < 0.001 (n = 292) (Figure 
28): Ro 10-9359; r2 = 0.998, P < 0.001 (n - 136) 
(Figure 29): Ro 15-0778; r 2 = 0.147, P < 0.001 (n 
= 97) (Figure 30». 
4.2.5.2. Lymph flow rates after oral dosing. 
Lymph flow rates measured in mesenteric lymph duct 
cannulae varied between 0.8 ml/h and 3.3 ml/h {the 
least significant difference using p < 0.01 (1% LSD 
= 0.8 ml/h). These lymph flow rates were consistent 
with data (5.7 ml/h/kg) reported in the literature, 
(Tso et al., 1985) after the infusion of an oleic 
acid/1-monoolein emulsion into the duodenum of the 
rat. 
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Figure 28. A comparison between the lymph turbidity and lymphatic 
uptake of Ro 04-3780 in the rat after dosing in a series of oils. 
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Figure 29. A comparison between the lymph turbidity and lymphatic 
uptake of Ro 10-9359 in the rat after dosing in a series of oils. 
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Figure 30. A comparison between the lymph turbidity and lymphatic 
uptake of Ro 15-0778 in the rat after oral dosing in a series of oils. 
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Lymph flow rate may be influenced by the type of oil 
used to formulate a particular retinoid for oral 
dosing and also by the retinoid itself. 
When the data obtained from lymph turbidity studies 
(Table 27) were examined, it was observed that the 
mean intrinsic lymph flow rate, measured in fasted 
animals which had been orally dosed with isotonic 
saline (0.5 ml), was 1.61 ± 0.69 ml/h. These data 
demonstrate that not only do certain oils enhance 
lymph flow rate but that other oils would appear to 
suppress it. There was considerable inter-subject 
variation in the lymph flow rate data and therefore 
only flow rates measured after dosing Ro 04-3780 in 
cottonseed oil (3.1 ml/h) or soyabean oil (3.3 ml/h) 
and Ro 10-9359 in cottonseed oil (2.6 ml/h) were 
significantly elevated (p < 0.01) whilst the flow 
rate after dosing Ro 04-3780 in linoleic acid (0.8 
ml/h) was significantly suppressed (p < 0.01). 
The lymph flow rate data also show a variable effect 
of lymph flow depending upon the oil/retinoid 
combination studied. After orally dosing retinoids 
in cottonseed oil, lymphatic flow rate decreased 
from 3.1 ml/h,. with Ro 04-3780 to 2.6 ml/h with 
Ro 10-9359 and 2.0 ml/h with Ro 15-0778. similarly, 
after orally dosing in Miglyol 812, lymph flow rates 
decreased from 2.1 ml/h with Ro 04-3780 to 1.5 ml/h 
with Ro 10-9359 and 1.0 ml/h with Ro 15-0778. These 
decreases in lymphatic flow rate with increasing 
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retinoid lipophilicity, although only marginally 
significant (5% and 1% LSD's approximately 0.79 and 
0.56 ml/h), appeared to correlate with an overall 
increase in the lymphatic absorption of these 
retinoids and show an effect of the retinoid itself 
on the lymph flow rate. However, after the flow rate 
data obtained after dosing each of the three 
retinoids in linoleic acid were examined, the lowest 
flow rate was observed with Ro 04-3780 (0.8 ml/h) 
and the highest with Ro 10-9359 (1.5 ml/h), 
Ro 15-0778 gave a flow rate of 1.1 ml/h. These data 
suggest that lymph flow rate is not exclusively 
dependent upon retinoid type (lipophilicity) nor on 
the type of oil in which it is administered but upon 
some interaction between these factors. The 
mechanism by which the retinoid has an effect on 
lymph flow rate is not clear, but this may be a 
result of either a pharmacological action of the 
retinoid on the enterocytes to alter the lymph 
formation or a more direct effect on lymphatic 
vessels. 
When the lymph flow rate and lymphatic uptake data 
were analysed.for each retinoid, the correlation 
coefficients were found to be highly significant 
(Ro 04-3780; r2 = 0.709, P < 0.01 (n = 292) 
(Figure 31): Ro 10-9359; r2 = 0.966 P < 0.001 (n 
= 136) (Figure 32):Ro 15-0778 r2 = 0.145, P < 0.001 
(n = 97) (Figure 33». 
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Figure 32. A comparison between the lymph flow rate and lymphatic 
uptake rate of Ro 10-9359 in the rat after dosing in a series of oils. 
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These data, together with the lymph turbidity data 
(Section 4.2.5.1) indicate that both the lymph flow 
rate and the lymph chylomicron transport rate are 
important determinants in the lymphatic absorption 
of the retinoids and confirm the findings of Charman 
& Stella (1986b). 
4.2.5.3. Effeot of oil type on lymphatio uptake of 
retinoids after oral dosing. 
Several workers have studied -the effects of various 
vehicle systems on the bioavailability of drugs. 
Palin et al. (1980) have studied the effects of 
three oily vehicles on the absorption of the highly 
lipophilic (log P = 6.2) model compound DDT in the 
rat. They showed that the area under the plasma 
concentration time curve (AUC) was greater after 
orally dosing DDT in peanut oil compared with dosing 
in Miglyol 812 or liquid paraffin. These workers 
also reported (Palin et al., 1982) that the 
absorption of DDT was almost totally via the 
lymphatic route and that lymph flow was not 
important in determining lymphatic uptake rate since 
both peanut oil and liquid paraffin stimulated lymph 
flow to the same extent. 
Holmberg et al. (1990) studied the absorption of 
vitamin-D in humans after administration in gelatin 
capsules containing either peanut oil or Miglyol 
812. In fasting subjects, the mean peak plasma 
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concentration was approximately three times greater 
when vitamin-D was administered in a mixed long 
chain fatty acid triacyl glycerol oil (peanut oil) 
than in a medium chain triacyl glycerol oil (Miglyol 
812). These data supported the findings of Palin 
et al. (1980). 
Similar data were obtained using the even more 
lipophilic compound, Probucol (estimated log P 
= 11), (Palin & Wilson, 1984., Palin et al., 1984), 
which confirmed peanut oil to be the oil which 
promoted the greatest increase in lymphatic 
absorption compared with Miglyol 812 or liquid 
paraffin. 
Charman et al. (1986a) have studied the effects of 
peanut oil and the long chain fatty acid, oleic 
acid, on the oral absorption of DOT and showed that 
oleic acid gave even greater lymphatic absorption 
than peanut oil. These findings have been further 
supported by Gowan & Stavchansky (1986) who obtained 
the greatest bioavailability and also the highest 
lymph flow rate when radio-labelled phenytoin was 
administered in the salt of a long chain fatty acid, 
sodium o l e a t ~ . .
Charman et al. (1986b) went on to study the 
lymphatic transport of DOT in rats after oral 
(intra-duodenal) administration in oleic acid, 
showed a good linear relationship with chylomicron 
transport rather than lymph flow and demonstrated 
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the importance of chylomicron flow (determined from 
lymph turbidity measurements) in the lymphatic 
absorption of DDT. 
A review of the literature has therefore suggested 
that long chain fatty acids and their salts promote 
greater lymphatic absorption than mixed long chain 
fatty tri-acyl glycerol oils, and these in turn 
promote greater lymphatic absorption than mixed 
medium chain fatty tri-acyl glycerol oils. 
However, Hollander (1980) has reported some 
conflicting data. When a vitamin-A : bile salt 
emulsion system was perfused into the duodenum of a 
rat, the addition of a medium chain fatty acid, 
caprylic acid, to the emulsion, increased the 
lymphatic absorption of vitamin-A. In contrast, the 
addition of one of the unsaturated long chain fatty 
acids, oleic, linoleic or arachidonic (C20:0) 
resulted in a decrease in lymphatic absorption. 
These data therefore suggest that medium chain fatty 
acids would promote lymphatic absorption whilst the 
longer chain fatty acids would decrease it. 
Six oils were. selected in order to study their 
effects on the lymphatic absorption of the retinoids 
(Section 4.2.3.1.). After studying the effect of 
these oil systems on the lymphatic absorption of 
Ro 04-3780, the results suggested a number of 
features of the oils Which may be important in 
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influencing lymphatic absorption. The mixed long 
chain fatty acyl triglyceride oils, cottonseed, 
soyabean and peanut oil, promoted the lymphatic 
absorption of Ro 04-3780 to the greatest extent. The 
free long chain fatty acids, oleic acid and linoleic 
acid, gave very poor lymphatic uptake whilst the 
mixed medium chain fatty acid triacyl glycerol oil, 
Miglyol 812, gave lymphatic uptake intermediate in 
extent between the mixed long chain fatty acyl 
triglyceride oils and the unsaturated long chain 
free fatty acids. These data are consistent with 
reported data (Palin et al., 1980)., Palin & Wilson, 
1984., Palin et al., 1984., Holmberg et al., 1990). 
Lymphatic uptake of Ro 04-3780 from any of the oil 
systems was extremely poor, with a maximum rate of 
150 ng/h from a adjusted oral dose of 1 mg/kg 
(cottonseed oil). This figure represented a 
lymphatic absorption rate of only 2.00% of the 
absorbed dose per hour and 0.015% of administered 
oral dose per hour. Data obtained on the absorption 
of Ro 04-3780 from linoleic acid, which gave the 
poorest lymphatic uptake rate for this retinoid, 
showed a mean. lymphatic uptake rate of 0.71% of the 
absorbed dose per hour and approximately 0.00010 % 
of administered oral dose per hour. 
Oral dosing studies using the more lipophilic 
retinoid, Ro 10-9359 in the mixed long chain fatty 
acid triacyl glycerol oil, cottonseed oil, continued 
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to give a higher lymphatic uptake compared with 
either Miglyol 812 or linoleic acid. The lymphatic 
uptake values for Ro 10-9359 after dosing in each of 
the three oils were much higher than data obtained 
with Ro 04-3780. Linoleic acid in particular gave a 
much improved rate of lymphatic uptake (1030 ng/h), 
compared with that obtained for Ro 04-3780 in 
linoleic acid (150 ng/h). This lymphatic uptake for 
Ro 10-9359 in linoleic acid was almost twice the 
rate obtained from Miglyol 812 (514 ng/h). 
cottonseed oil however, gave the highest lymphatic 
uptake for Ro 10-9359 (3980 ng/h). 
Ro 15-0778 in cottonseed oil gave a mean lymphatic 
uptake value (4110 ng/h) which were slightly greater 
(p > 0.05) than linoleic acid (4060 ng/h) and more 
than three times greater than Miglyol 812 (1230 
ng/h). All three oils exhibited greater lymphatic 
uptake of Ro 15-0778 compared with Ro 10-9359, 
cottonseed oil and Miglyol 812 giving approximately 
three fold greater lymphatic uptake. 
The lymphatic uptake data for Ro 04-3780 shows a 150 
fold range for the six oils used for oral dosing 
however, the corresponding estimates for plasma 
uptake show a similar trend and therefore the lymph 
: plasma uptake ratios for each oil were similar and 
between 0.5% and 2.0%. Therefore, although certain 
oils increase the lymphatic uptake rate of 
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Ro 04-3780, they also increased portal absorption to 
approximately the same extent and hence, 
preferential delivery of Ro 04-3780 to the 
1ymphatics was not achieved. 
When the data for Ro 10-93.59 were examined, certain 
orally dosed oil systems were identified which 
greatly increased lymphatic uptake rate with only a 
marginal increase in portal absorption, compared 
with data obtained after dosing with Ro 04-3780. The 
lymph : plasma uptake ratio for Ro 10-9359 is 
greater than 332 % after dosing linoleic acid to the 
fasted rat compared with only 0.72 % when Ro 04-3780 
is dosed in linoleic. These data suggest that 
certain oil/retinoid combinations selectively 
deliver retinoids into the 1ymphatics and suggests 
that the higher 1ipophi1icity of Ro 10-9359, 
compared with that of Ro 04-3780, may be an 
important factor in this process. Data obtained 
after oral dosing of the more lipophilic, Ro 15-0778 
in oils seemed to confirm the importance of high 
lipophilicity of a retinoid in promoting lymphatic 
absorption. The lymphatic uptake was 2% greater 
after dosing "Ro 15-0778 in cottonseed oil compared 
with Ro 10-9359 (4060 ng/h and 3980 ng/h) , 140% 
greater from Mig1yol 812 (1230 ng/h and 514 ng/h) 
and 300% greater from linoleic acid (4110 ng/h and 
1030 ng/h). 
The lymph : plasma ratios obtained after dosing 
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Ro 15-0778 in oil were between 15% and 84%, 
generally lower than with Ro 10-9359. These data 
suggest that although high lipophilicity is an 
important factor in increasing the overall 
absorption of the retinoids, it does not increase 
the selective targeting of retinoids to the 
lymphatics. 
4.2.5.4. A self-emulsifying oil system for the oral 
delivery of Ro 15-0778. 
A number of self-emulsifying oil systems were 
developed (Chapter 3) which would spontaneously 
emulsify when gently agitated with an aqueous 
medium. One of the most promising systems was MTS, 
(a Mig1yo1 812 oil based self-emulsifying system 
containing Tween 85 and Span 85). This system 
produced an emulsion which was stable for several 
days and possessed a mean particle size of 509 
± 20 nm. In order to study the effect of this se1f-
emulsifying oil system in the rat, a series of oral 
dosing studies was performed with the retinoid, 
Ro 15-0778. 
The lymph flow rates after orally dosing Ro 15-0778 
(6 mg/kg) in MTS (0.95 + 0.26 m1/h/kg) or in Mig1yo1 
812 (0.97 ± 0.33 m1/h/kg) were almost identical 
(Table 26) but lymph turbidity was almost 2.7 times 
greater (p < 0.001) after dosing Ro 15-0778 in MTS. 
Oral dosing data (Table 26) demonstrate that 
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administration of Ro 15-0778 in a self-emulsifying 
oil system (MTS) compared with Miglyol 812 augmented 
the overall absorption rate by approximately four 
fold and lymphatic absorption rate by three fold. 
Reports in the literature have demonstrated three to 
four fold increases in the bioavailability of 
penclomidine after administration in a long chain 
triacyl glycerol emulsion system (Myers & Stella, 
1989). Myers (Myers & Stella, 1989) concluded that 
long chain triacyl glycerol oils increased lymphatic 
transport of penclomidine by an increase in 
chylomicron formation. 
4.2.5.5. Effect of food on the oral bioavailability 
of Ro 10-9359. 
The timing of a lymphatic cannulation with respect 
to the fasted state of the animal appears to affect 
the rate and extent of lymphatic absorption. Data 
from colburn et al. (1983b) demonstrated that 
mesenteric lymphatic cannulations performed in rats, 
fed three hours before oral dosing of DOT, produced 
higher mesenteric lymphatic absorption of DOT over 8 
hours post dosing compared with cannulations 
performed after a 24 hour fast, but three hours 
before oral dosing. 
Cannulations prior to a 48 hour fast produced 
greater mesenteric lymph levels of DOT over an 8 
hour period post dosing compared to levels found 
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following surgery after a 24 hour fast (Colburn et 
al., 1983b); overall lymph flow was also found to be 
greater after food. 
These effects on absorption may have been due to the 
effects of anaesthesia or changes in lipid 
metabolism and gut absorption. Lee (1965) studied an 
isolated gut preparation with intact mesentery and 
found that levels of sodium pentobarbitone could 
abolish gut motility and reduce lymphatic pressure. 
Kalin (1984) also showed that phenobarbitone 
appeared to reduce levels of retinoids found in 
tissues after intra-gastric feeding. 
Studies in humans (Holazo et al., 1990., Gibson et 
al., 1984., Colburn et al., 1983a) have shown 
increased bioavailability of the retinoids, 
Ro 15-0778, Ro 04-3780 and Ro 10-9359 after a fatty 
meal. 
In view of these reports, all the oral dosing 
studies in the present work, have been carried out 
on animals which had been fasted for at least 16 
hours to eliminate any effects due to feeding. 
However, it may be argued that this was not a 
physiologically normal state for the animals and the 
data would have been best obtained on fed animals. 
A series of dosing studies was therefore carried out 
in order to study the effects of diet on the overall 
bioavailability of the retinoids in the rat and to 
investigate any selective targeting of retinoids due 
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to the effects of food. 
The level of anaesthesia within the animals could 
not be perfectly controlled, but was administered at 
a constant inter-peritoneal dose of 72 mg/kg sodium 
pentobarbitone (Sagatal). 
Animals were dosed with a specially prepared liquid 
animal diet prior to dosing with Ro 10-9359 in 
linoleic acid. 
Linoleic acid was the oil of choice for this study 
because the lymphatic uptake of Ro 10-9359 in the 
fasted rat, after dosing with linoleic acid (1030 
ng/h) , was sufficiently high to allow sensitive 
detection of small changes in retinoid 
concentrations. The lymphatic uptake of Ro 10-9359 
with cotton seed oil (3980 ng/h) , although higher 
than with linoleic acid, may have been limited by 
factors other than the oil type Ca possible upper 
threshold limit of lymphatic uptake rate) and may 
therefore have been a poor indicator of further 
increases in lymphatic uptake. 
Animals were pre-dosed with a 2 ml bolus of the 
liquid diet, 30 minutes prior dosing with linoleic 
acid containing Ro 10-9359. The lymph which was 
produced after food was almost identical in 
turbidity (10.4 absorbance units/ml) to the lymph 
produced when linoleic acid was dosed to fasting 
animals (10.5 absorbance units/ml) ,(Table 27). The 
lymph flow rate was marginally lower after food 
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(1.38 ml/h compared with 1.48 ml/h) , (Table 25). 
The lymphatic concentration data for Ro 10-9359 in 
fasted and fed animals after dosing in linoleic acid 
were found to be almost identical, even after 
correcting the data for the slight difference in 
lymph flow rate. Feeding, prior to oral dosing with 
retinoid in an oil, was therefore ineffective in 
increasing the lymphatic uptake rate of Ro 10-9359 
in the rat. In contrast, plasma concentrations of 
Ro 10-9359 in fed animals were approximately one 
tenth of those found in the fasted group and after 
correcting the data using the volume of distribution 
of Ro 10-9359, the estimated plasma uptake rates was 
at least twelve times greater in the fasted group. 
These data have important consequences on the 
effective therapeutic dose of Ro 10-9359 if these 
findings are extrapolated to man. Since the 
estimated plasma uptake rate has been shown to 
decrease after food, this may imply that a lower 
dose of Ro 10-9359 will need to be administered to 
give the desired therapeutic effect in a patient who 
was unable to consume a normal diet, since the dose 
will be more ",readily absorbed via the portal route. 
Conversely, in a subject on a normal diet, the 
effective therapeutic dose will need to be 
increased, because of the decreased uptake rate, 
which is occurring primarily via the lymphatic 
route. 
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The literature data show greater plasma 
concentrations of the retinoids after a fatty meal 
(Holazo et al., 1990., Gibson et al., 1984., Colburn 
et al., 1983a), but none of these authors discussed 
the route of delivery of the retinoids into the 
plasma. The data presented 1 here allow a somewhat 
4 
different interpretation of the findings, concerning 
the effect of food on the bioavailability of the 
retinoids, namely that food decreases the plasma 
uptake rate of the retinoids and increases the 
lymphatic uptake of the retinoid. 
4.2.5.6. The relationship between lymphatio uptake 
rate and oil solubility. 
Solubility is defined as the amount of dissolved 
solute in equilibrium with its pure state (Szets & 
Harosi, 1991). The solubility of a non-electrolyte 
in water may be determined from the relationship in 
equation 16, (Yalkowsky & Morozowich, 1980). 
log Sw = -log P - 0.01 M.P. + 0.5 + A 
Sw -
-
M.P. = 
A -
-
Equation .•.•• 16 
Solubility in water, of a nonelectrolyte 
compound. 
Melting point of the compound. 
A variable to allow for the presence (A = 
1.0) or absence CA = 0) of an acidic 
proton in the compound. 
Using this relationship, together with the 
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calculated log. P data for the retinoids (Table 2) 
and their melting points (Day, 1992) the solubility 
of the retinoids have been calculated. As expected, 
the most polar retinoid, Ro 04-3780 (calculated 
log. P = 6.76, M.P. = 176°C), shows the greatest 
calculated solubility (log. Sw = -6.99), dependent 
upon the degree of dissociation of the terminal 
carboxyl group (Figure 3». The more lipophilic 
retinoid, Ro 10-9359 (log. P = 7.82, M.P. = 103°C), 
shows a lower solubility (log. Sw = -8.35), and the 
most lipophilic retinoid, Ro 15-0778 (calculated 
log. P = 8.66, M.P. = 90°C), shows a very low 
solubility (log. Sw = -9.06). These calculated 
solubility data would suggest that the least 
lipophilic retinoid, Ro 04-3780, would be more 
readily absorbed from the gastro-intestinal tract 
(de Blaey & Polderman, 1980), however this was not 
confirmed by the in vivo studies. 
using the oil solubility data (Table 4), it is 
possible to accurately predict a rank order for oily 
vehicles, which will promote lymphatic absorption of 
a retinoid. Since there is an inverse relationship 
between lymphatic absorption after oral 
administration in the oil and the solubility of the 
retinoid in the oil. These results were surprising, 
since it has been reported that lipophilic drugs are 
preferentially absorbed via the lymphatic route 
(Noguchi et al., 1985., Sieber, 1976), therefore an 
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increase in solubility of compound in an oil may 
have been expected to increase the lymphatic 
absorption of that compound. 
The absorption of a retinoid from the gastro-
intestinal tract may involve the release of retinoid 
from the oily vehicle, into the fluid in the gut. 
Therefore, a higher solubility of retinoid in water, 
together with a lower solubility in the oily vehicle 
may be postulated to enhance absorption (de Blaey & 
Polderman, 1980). 
A hypothesis which would explain the inverse oil 
solubility lymphatic uptake is as follows. It is 
postulated that a retinoid will escape from the oil 
before passing across the un-stirred water layer 
barrier which may exist in the gut. This phenomenon 
will relate to the solubility (affinity) of the 
retinoid in an oil (Armstrong & James, 1980). The 
more easily the process occurs (the lower the 
solubility of the retinoid in the oil), the more 
thermo-dynamically favourable it will be for the 
retinoid partition out of the oil and subsequently 
be diffuse across the un-stirred water layer. 
After this stage of the absorption process, the oil 
must then play a secondary role in facilitating the 
incorporation of drug into lymph and its subsequent 
lymphatic transport, potentially by stimulating the 
lymph flow and chylomicron formation. 
The extent of lymphatic uptake has been demonstrated 
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here to be related to the type of oil. In the oral 
dosing studies, the retinoid concentration present 
in each oil system was kept constant (3 mg/ml), in 
order that the same volume of oil (0.5 ml), would 
deliver the same dose of retinoid (6 mg/kg) was 
given to each animal (250 g body weight). 
The percentage solubility of Ro 04-3780 in each of 
the six oils, was determined using equation 17. The 
solubility data for the retinoids were determined in 
section 1.2. and are shown in Table 4. 
Peroentaqe 
saturation 
of retinoid 
in oil. 
= oonoentration of retinoid in oil x 100 
saturation solubility of 
retinoid in oil 
Equation ••••• 17 
The percentage saturation of Ro 04-3780 (3 mg/ml) is 
58 % in cottonseed oil, 53 % in soyabean oil, 49 % 
in peanut oil, 25 % in Miglyol 812, 12 % in oleic 
acid and 10 % in linoleic acid. This decrease in 
percentage saturation parallels the downward trend 
in lymphatic uptake from 150 ng/h to 1 ng/h found in 
the oral dosing studies. It may be postulated 
therefore, that either an increase in the percentage 
,. 
retinoid saturation in the oil or a decrease in the 
solubility of the retinoid in the oil may be 
important in increasing lymphatic uptake. However, 
when Ro 04-3780 was presented in linoleic acid (0.5 
ml) at an oral dose of 75 mg/kg (percentage 
saturation, 93%), the dose adjusted lymphatic uptake 
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was 150 times smaller than when Ro 04-3780 was 
administered in cottonseed oil (0.5 ml) at an oral 
dose of 6 mg/kg (59 % saturation) (Table 24). These 
data therefore support the hypothesis that a lower 
solubility of the retinoid in an oil is a key 
determinant in increasing lymphatic absorption of 
the retinoid. 
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CHAPTER 5 
GENERAL CONCLUSIONS 
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5. General conclusions. 
The retinoids are a series of vitamin-A analogues 
which have been extensively investigated in their 
role as dermatological, chemotherapeutic and 
chemopreventive agents. 
The retinoids are extremely lipophilic in nature and 
as such are thought to be absorbed into the venous 
circulation via the lymphatic route after oral 
administration in a way analogous to vitamin-A. 
It was proposed to study the physicochemical 
properties of the retinoids and various formulation 
factors which were thought to be important in the 
lymphatic absorption of the retinoids after oral 
administration. 
Three retinoids were to be used in a series of oral 
dosing studies, one being selected from each of the 
three main groups (generations) of retinoids. 
Isotretinoin (Ro 04-3780, 13-cis retinoic acid) was 
selected from the first generation of retinoids. 
Etretinate (Ro 10-9359) was selected from the second 
generation of retinoids and Temarotene (Ro 15-0778) 
was selected from the third generation of retinoids. 
NumerouS factors have been examined which were 
believed may be important determinants in the 
lymphatic absorption of the retinoids. Many of these 
factors have been found to be interrelated in their 
effects. 
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5.1. Physicochemical properties of the retinoids. 
Some of the physicochemical properties of the 
retinoids have been examined, these include their 
ultraviolet absorption, their lipophilicity and 
their solubility in a range of oil systems. 
5.1.1. ultraviolet absorption and photosensitivity 
of the retinoids. 
The first generation retinoid, Ro 04-3780 (13-cis 
retinoic acid) and the second generation retinoids, 
Ro 10-9359 (Etretinate) and Ro 11-5036 have been 
shown to have ultraviolet absorption maxima of 349 
and 360 nanometres respectively. 
The third generation retinoids, Ro 15-1570 
(Etarotene) and Ro 15-0778 (Temarotene), have been 
shown to have absorption maxima further into the 
ultraviolet at 295 and 279 nanometres, respectively. 
All of the retinoids studied show a very broad band 
of absorption around their absorption maximum, for 
example Ro 04-3780 shows 90% peak absorption at + 16 
nanometres around its peak wavelength. 
The molar absorptivity of the retinoids is typically 
high and was. found to be 2.388 x 104 litres.mol-1.cm-1 
for Ro 15-0778, 4.358 x 104 litres.mol-1.cm-1 for 
Ro 04-3780 and 5.192 x 104 litres.mol-1.cm-1 for 
Ro 10-9359. These data confirm the strong 
ultraviolet absorption of the retinoids and favoured 
the use of this attribute as a method of choice in 
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the detection and quantitation of the retinoids. 
Although this strong ultraviolet absorption of the 
retinoids is of benefit in their detection and 
quantitation, it is a disadvantage in terms of the 
handling of these compounds. Extensive degradation 
of the retinoids has been demonstrated after brief 
exposure to light. This degradation was thought to 
be due to either photo-decomposition or to photo-
isomerism of the retinoids. 
Sunlight was found to have the most damaging effect 
on the retinoids, decreasing the quantity of parent 
compound to less than 50% after 60 seconds of 
exposure (P < 0.001). Using the hplc system 
developed for the analysis of Ro 04-3780, it was not 
possible to detect any isomerisation of 13-cis-
retinoic acid to its all-trans isomer. 
Laboratory fluorescent tubes caused a significant 
decrease (P < 0.05) in concentration after 30 
minutes exposure. In contrast, exposure of the 
retinoids to light from yellow fluorescent tubes, 
which do not emit light below 500 nanometres, 
results in little loss or isomerisation of the 
retinoids (P.> 0.05), even after periods of 180 
minutes. 
These observations require the use of great care 
when retinoids are being handled. Aluminium foil 
must be used to mask the sample tubes or the use of 
protective yellow lighting conditions is recommended 
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during handling of the retinoids to protect the 
samples from light. 
5.1.2. Lipophilicity of the retinoids. 
Experimentally determined values for the octanol-
water partition coefficient (log. P) of extremely 
lipophilic compounds, such as the retinoids, have 
been shown to be difficult to measure using the 
traditional shake flask method or by the slow stir 
technique. This arises from the difficulties in 
accurately determining the very small quantities of 
compound which partitions into the aqueous (water) 
phase when the compound is allowed to distribute 
between octanol and water. 
It is proposed that the relatively high solubility 
of octanol in water (1.36 x 104 mol/I, 17.7 parts 
per million), may lead to underestimated values of 
log. P for solutes with log. P values greater than 
5. For example, in a slow stir flask containing a 
solute with a calculated log. P of 6 there will be 
17.7 times more solute present in the octan-1-ol 
which is dissolved in the water phase than the 
amount of solute dissolved in the water itself. This 
predicted negative deviation from the theoretical 
log. P might explain some of the discrepancies 
between experimentally determined and computer 
predicted log. P values. 
It was decided, to use a computer database of 
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fragmental constant data to calculate the log. P 
values for the retinoids. Two commonly used methods 
have been studied, the Rekker method, which is 
thought to be more appropriate for calculations 
based on the complete chemical structure of the 
molecule and the Hansch method which is more 
convenient when the log. P value of a parent 
compound is known and changes in various functional 
groups are been made. 
In these studies, calculated log. P data obtained 
after using the Hansch n method were in close 
agreement with data provided for log. P values 
calculated using the Rekker fragmental (Van der 
Waterbeemd, 1990). 
All the retinoids show log. P values in excess of 6 
and could be therefore classed as highly lipophilic. 
The most lipophilic compound was Temarotene (mean 
log. P = 8.48) followed by Etretinate (mean log. P = 
7.82) and Isotretinoin (mean log. P = 6.77). 
other physicochemical data have been used to assess 
the validity of these predicted log. P values. Hplc 
retention times and structural data have been 
examined and although the gross trends in log. Pare 
consistent with the theoretically expected results, 
there are some inconsistencies. On a reversed phase 
chromatographic system, polar solutes (less 
lipophilic) would be expected to be elute from the 
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chromatographic system more rapidly than less polar 
solutes (more lipophilic). However, the order of 
elution for Ro 01-4955, Ro 01-5488 and Ro 04-3780 on 
the reversed phase hplc system does not follow this 
expected pattern. Ro 01-4955 elutes with a retention 
time almost twice that of Ro 01-5488 or Ro 04-3780 
despite having a predicted log. P slightly less than 
either of these compounds. In addition, Ro 01-5488 
and Ro 04-3780 have the same empirical chemical 
formula, differing only in the geometry of the 
terminal group but were predicted to show identical 
log. P values using the two methods. However, these 
two compounds were resolved using the hplc system, 
suggesting Ro 04-3780 to be slightly less polar. 
possible explanations which might explain this 
anomaly include; 
i) The Rekker or Hansch methods do not take into 
consideration any effect of ionisation of polar 
groups in the molecules and indeed assume the 
molecule to be completely unionised and 
undissociated. Compounds such as Ro 04-3780 or Ro 
01-5488, both contain a ionisable acid group and 
would partially ionise in an aqueous environment, 
such as in the fluids within the gastrointestinal 
tract (approximately 2-8 pH units) or in the mobile 
phase (pH 6.0) of the hplc system. The degree of 
ionisation will obviously be dependent upon the pH 
of the solvent and the pR of the dissociable group. 
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In the mobile phase at pH 6.0 and with an expected 
pKa for the acidic retinoids of approximately 4 - 5 
the acidic group in both Ro 01-5488 and Ro 04-3780 
is likely to be 90% - 99% ionised. This would 
increase the polarity of these compounds and 
decrease their expected log. P values and help to 
explain their more rapid elution from the reversed 
phase hplc system compared with Ro 01-4955. 
ii) When the structures of the two retinoids, Ro 01-
5488 and Ro 04-3780 are examined, it may be 
postulated that hydrogen bonding between the 
carbonyl oxygen and the hydrogen atom on carbon-11 
may occur in the 13-cis isomer (Ro 04-3780). This 
would decrease the charge density around the 
terminal group and result in a marginally higher 
lipophilicity and greater log. P value for this 
isomer. 
5.1.3. solubility of the retinoids in various oil 
systems. 
It is well established that the retinoids are highly 
lipophilic in nature. However, lipophilicity is not 
easy to define. The ratio between the solubility of 
a compound in each of two immiscible solvents can be 
misleading. It was considered necessary to examine 
the relationship between solubility and 
lipophilicity for the retinoids using oil systems 
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which were to be used as oral delivery vehicles in 
these studies. 
For each retinoid, a rank order of increasing 
solubility in a range of oil systems was 
constructed. This revealed many interesting 
features. 
i) The more lipophilic the retinoid, as defined by 
the magnitude of its calculated log. P value, the 
greater is its solubility in a particular oil. In 
the oil systems studied, Ro 04-3780 shows 
solUbilities between 2.2 and 73.3 mg/ml (median 
= 19.9 mg/ml), Ro 10-9359 from 6.6 to 68.7 mg/ml 
(median = 25.7 mg/ml) and Ro 15-0778 between 47.8 
and 201.8 mg/ml (median = 149.5 mg/ml). These are 
consistent with predictions made after considering 
the physical interactions of lipophilic solutes in 
non-polar solvents. 
ii) The mono-acyl glycerol oils, monocaprylin and 
monoolein, give low solubility for all three 
retinoids. This may be explained by the presence of 
free hydroxyl groups on the glycerol molecule which 
make these oils slightly more polar in nature and 
decreasing their affinity for the highly lipophilic 
retinoids. 
iii) The monoglyceride oil, Neobee M5, contains a 
mixture of both monocaprylate and monocaprate esters 
of glycerol but, with the exception of Ro 04-3780, 
the solubility of the retinoids in this oil is far 
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greater than in the monoglyceride oil, monocaprylin 
(Neobee : Monocaprylin solubility ratio, for Ro 10-
9359 is 2.63 and for Ro 15-0778 is 4.22). These 
findings may be explained by hydrophobic 
interactions between the slighter longer chain 
length capric ( C w ~ ) ) ester and the tetraene side chain 
of the retinoid molecule. 
iv) The solubility of retinoids in the mixed long 
chain triglyceride oils was lower in all cases than 
in the mixed medium chain triglyceride oil, Miglyol 
812. This may be due to the effect of the more 
electrophilic nature of the LCFA triglyceride oils, 
which contain varying quantities of esters of the 
unsaturated fatty acids, linoleic and linolenic 
acids. This theory may also explain the poor 
retinoid solubility in trilinolein (glyceryl tri-
linoleate) compared with Miglyol 812 and lower 
solubility of retinoids in the unsaturated long 
chain free fatty acids, oleic and linoleic acid, 
compared with the saturated medium chain fatty acid 
caprylic ( C ~ ) . .
The relationship between solubility in pairs of oils 
varied with retinoid lipophilicity. 
v) The solubility of retinoids in linoleic acid 
compared with that in cottonseed oil decreased as 
the lipophilicity of the retinoid increased. Ro 04-
3780 shows a linoleic/ cottonseed solubility ratio 
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of 5.98, the ratio for Ro 10-9359 is 1.18 and for Ro 
15-0778 is 0.66. 
In a similar way the ratio of the solubility of 
retinoids in monocaprylin to that in monoolein 
decreased from 12.5 for Ro 04-3780 to 2.4 for Ro 10-
9359 to 0.82 for Ro 15-0778. 
These differences in relative solubility of the 
retinoids in pairs of oils may reflect differences 
in the polarity of oils and the effect these changes 
have on the solubility of a retinoid as it becomes 
more lipophilic. The differences may also be 
explained by differences in the physical 
associations of the retinoid with an oil, such as 
hydrophobic interactions (Van der Waals forces) and 
hydrogen bonding. 
Many of the variations in solubility have been 
explained by interactions between the retinoid and 
the solvent, however, some trends cannot be 
explained in this way. For example; 
vi) The solubility of Ro 04-3780 in a equivolume 
mixture of Miglyol 812 and oleic acid (36.7 mg/ml) 
is considerably higher than in either component 
alone (Miglyol 812 = 12.0 mg/ml, oleic acid = 24.4 
mg/ml), whereas for the other retinoids it lies, as 
expected, between the two values. 
vii) A discordant observation is seen between the 
solubility of Ro 10-9359 in an equivolume mixture of 
Miglyol 812 and caprylic acid (36.0 mg/ml) which is 
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less than that found in Miglyol 812 (44.5 mg/ml) or 
caprylic acid alone (68.7 mg/ml). These 
inconsistencies may be explained by a 
solvent:solvent interaction in which each oil 
component has associated with its partner and made 
it less polar in nature, however why this 
interaction is so inconsistent is uncertain. 
viii) The solubility of retinoids in a self 
emulsifying oil system (SES) which contained 80% 
peanut oil, may have been expected to be 
approximately 20% lower than in peanut oil alone to 
reflect the lower oil content. However, Ro 15-0778 
has a much lower solubility in this SES than 
predicted, whereas the more polar Ro 04-3780 shows a 
greater solubility than in peanut oil. These 
findings suggest that the ionic nature of the 
surfactant system has either a desolubilising effect 
on the non-polar compound or an ion pairing effect 
on the more polar retinoid. 
Ro 10-9359 shows almost identical solubility in the 
SES and peanut oil. 
5.2. Analytioal and in-vivo studies on the 
retinoids. 
Having established some of the physicochemical 
properties of the retinoids it was necessary to 
establish and validate a viable assay for the 
quantitation of low concentrations of retinoids in 
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small volumes of biological fluids and achieve a 
reliable animal model as an in-vivo screen for 
retinoid formulations. 
5.2.1. Analytical methods. 
sensitive and specific hplc methods have been 
developed for the analysis of the retinoids in 
biological fluids. The hplc analytical methods had 
limits of detection of 10 ng/ml for Ro 04-3780, 10 
ng/ml for Ro 10-9359 and 15 ng/ml of Ro 15-0778, all 
based on the extraction of 100 ~ l l of plasma or 
lymph. 
A reversed phase hplc system was used for both Ro 
04-3780 and Ro 15-0778 using a mobile phase 
containing acetonitrile and ammonium acetate buffer 
(70:30 and 90:10 respectively). The minimum analysis 
times for these two compounds on their respective 
systems were approximately 8 and 12 minutes, using 
Ro 11-5036 and Ro 15-1570 as the internal standards 
in the respective analytical methods. These 
compounds show similar retention behaviour and 
ultraviolet absorption properties to the retinoid 
being analysed. 
The reversed phase hplc system, used for the 
analysis of Ro 04-3780 and Ro 15-0778 was 
investigated for use in the analysis of Ro 10-9359. 
However, after testing several retinoids as a 
potential internal standard in this analytical 
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system, none was found which was sufficiently 
lipophilic to allow elution with a sufficiently long 
retention time which would allow it to be resolved 
from the solvent front when Ro 10-9359 was eluted 
with an acceptable retention time. A normal phase 
hplc system were therefore applied to the analysis 
of this retinoid. The system which was found to give 
good resolution of Ro 10-9359 from the internal 
standard, Ro 04-3780, used a mobile phase containing 
hexane, propionic acid and methyl benzoate and a 
cyano-bonded silica column (Spherisorb S3CN). 
The system allowed a minimum analysis time of 
approximately 12 minutes. 
5.2.2. Extraction systems. 
Extraction of the three retinoids from biological 
matrices including plasma and lymph, was achieved by 
direct protein precipitation using acetonitrile 
containing the appropriate internal standard. Direct 
injection of this acetonitrile showed excellent 
recovery of retinoid when the acetonitrile to plasma 
ratio was at least three parts to one (Ro 04-3780: 
99.6% ± 3.42%. from 25 - 1000 ng/ml, Ro 10-9359: 
93.8% ± 4.93% from 25 - 1000 ng/ml, Ro 15-0778: 
92.6% ± 6.93% from 2.5 - 1000 ng/ml). 
In the analysis of Ro 10-9359, an additional step 
was introduced prior to sample injection to remove 
traces of aqueous solvents which may have 
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contaminated the normal phase column. The 
acetonitrile extract was removed completely under 
reduced pressure and the samples were reconstituted 
in mobile phase prior to analysis. 
Recovery of retinoids was greater than 90% at 
concentrations > 25 ng/ml for Ro 04-3780 and Ro 10-
9359 and greater than 5 ng/ml for Ro 15-0778. All 
recovery figures are based on the extraction of a 
100 ~ l l sample of plasma. 
5.3. In-vivo studies on the retinoids. 
5.3.1. Pharmaookinetio studies. 
From the pharmacokinetic data for Ro 04-3780, a non-
proportional increase in AUC was observed with 
increasing dose, resulting from a decrease in both 
the total body clearance and the volume of 
distribution. The elimination half-life also 
increased with dose. 
The mean residence time (MRT) , was 76 minutes and 
consistent with the observed elimination half-life 
( t ~ ) ) of 55 minutes. 
At the lower dose of 0.264 mg/kg, a volume of 
distribution ,(Vd) of 220 ml, a volume of distribution 
at steady state (Vu) of 200 ml and total body 
clearance of 2.5 ml/min were obtained. These data 
are consistent with reports in the literature. 
From the pharmacokinetic data for the more 
lipophilic retinoid, Ro 15-0778, a non-proportional 
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increase in AUC was observed with increasing dose, 
resulting from a decrease in total body clearance. 
The elimination half-life also varied with dose. 
The MRT at the lower dose (MRT = 111 ± 68 min) was 
consistent with the elimination half-life observed 
at the lower dose ( t ~ ~ = 111 ± 38 min) however, the 
MRT at the higher dose was much lower (MRT = 62 
+ 14 min) than either the MRT at the lower dose or 
the elimination half-life at either dose. These 
differences, however, were not significant 
(p > 0.05) due to considerable inter-subject 
variation in the data. 
There was considerable inter-subject variation in 
the mean data for Vd (1100 ± 690 ml) and Vu (380 + 
340 ml). The volume of distribution (Vd) at the low 
dose (980 ml) and at the high dose (1220 ml) and the 
volume of distribution at steady state (Vu) 
calculated at the low dose (430 ml) and at the high 
dose (325 ml), were not significantly different 
(p > 0.05). 
There appear to be no reported pharmacokinetic data 
on this compound in the literature, however, the 
data were consistent with those expected for a 
highly lipophilic retinoid. 
After intravenous dosing of Ro 10-9359 at the higher 
dose (1.964 mg/kg), plasma concentrations fell 
exponentially to below the limit of detection at 180 
minutes. At the low dose (0.655 mg/kg), a similar 
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rapid fall in plasma concentrations was observed. 
The pharmacokinetic data showed a mean elimination 
half-life of 3.5 minutes and a mean MRT of 24 min. 
The volume of distribution was estimated to be 32 ml 
at the lower dose and 26 ml at the higher dose. At 
steady state, the volume of distribution was 
slightly higher, being 57 ml at the low dose and 
134 ml at the higher dose. 
These data were not consistent with those expected 
after studying values reported in humans nor with 
the lipophilic nature of the compound nor with the 
pharmacokinetic data obtained for other retinoids in 
this study. These data suggest that a distribution 
phase was being observed and distribution 
equilibrium had not been reached. 
This prolonged distribution phase presented problems 
in accurately measuring the low retinoid 
concentrations in plasma samples after 180 minutes 
post dose. 
In order to determine the plasma concentrations of 
this retinoid over a prolonged time period in the 
rat, it would have been necessary to increase 
greatly the plasma concentrations. This could have 
been achieved by administering a much larger dose of 
retinoid to the animal (a dose of 20 mg/kg may have 
been required). However, it was thought to be 
inappropriate to exceed the volume of intravenous 
soyabean emulsion beyond the 0.6 ml dose size 
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{approximately 5.5 % of the total blood volume in a 
250 g rat (Griffith & Campbell, 1934). It was found 
impossible to administer a higher dose of retinoid 
in other physiologically acceptable vehicles because 
of the limited solubility of Ro 10-9359 in these 
solvents. The proposed high dose would have also 
greatly increased the potential toxicity of the drug 
to the animal and would have far exceeded the upper 
therapeutic limit for a human (2 mgjkg). Alternative 
procedures would have been to use much greater blood 
sample volumes at each data point, extracting the 
whole animal blood volume (10 - 12 ml) for each data 
point, however, this procedure was considered an 
unacceptable use of animals. Alternatively, the dose 
could have been administered over an extended time 
period by intravenous infusion or a more sensitive 
analytical procedure could have been investigated. 
5.3.2. Oral dosing studies in the rat. 
The data presented here on the oral dosing of 
retinoids in the rat, suggest that the processes 
involved in the lymphatic absorption of a retinoid 
are very complex. There appear to be many 
interacting effects of oral dosing vehicle, 
retinoid solubility in the vehicle, retinoid 
lipophilicity, lipid content of the lymph and lymph 
flow rate. In summary; 
i) The more lipophilic the retinoid as defined by 
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the logarithm of the octano1 water partition 
coefficient (log. P), the higher the proportion of 
the dose which is absorbed via the lymphatic route, 
(Ro 15-0778 > Ro 10-9359 > Ro 04-3780). 
ii) The solubility of a retinoid in an oil shows an 
inverse relationship with the lymphatic uptake from 
the oil. This advantage of poorly solvating vehicles 
for the absorption of drugs is limited, however, by 
the total amount of drug which the vehicle can 
incorporate since this will control drug 
availability at the site of absorption. 
iii) certain oils appear to enhance the lymphatic 
uptake of a retinoid. However, it is difficult to 
predict which oils which will promote the greatest 
lymphatic uptake of a retinoid, since this depends 
upon both the 1ipophi1icity of the retinoid and its 
solubility in the oil. 
iv) oils may have a positive or a negative effect on 
the fasting lymph flow rate in the rat. For example 
the mean lymph flow rate after an oral dose of 
saline (0.5 ml) was 1.61 m1/h compared with a flow 
rate of 3.31 ml/h after dosing Ro 04-3780 in 
soyabean oi1,.(0.5 ml) and only 0.80 ml/h after 
dosing Ro 04-3780 in linoleic acid. 
The lymph flow rate correlate strongly with the 
lymphatic uptake of a retinoid (p < 0.001). oils 
which gave the highest lymph flow rate also gave the 
highest lymphatic uptake, whereas those which give 
- 215 -
the lowest flow rates gave the lowest lymphatic 
uptake. 
v) Lymph turbidity (lymph chylomicron concentration) 
was increased after rats were orally dosed with oils 
compared with rats dosed with saline. The long chain 
tri-acyl glycerol oils, were most effective in this 
role, increasing turbidity by up to 48 fold, whereas 
oils such as linoleic acid and Miglyol 812 increased 
turbidity by less than 10 fold. This increase in 
turbidity was strongly correlated (p < 0.001) with 
an increase in lymphatic uptake after the dosing of 
retinoid in these oils. 
vi) Food was not found to affect the lymph flow rate 
(p > 0.05), the lymph turbidity (p > 0.05) or the 
lymphatic uptake of Ro 10-9359. However, the 
estimated plasma uptake rate after food was 
decreased, resulting in an increase in the lymph 
plasma uptake ratio. These effects result in 
selective targeting of the retinoid via the 
lymphatics after food. 
vii) Administration of a retinoid (Ro 15-0778) in a 
self-emulsifying oil system (MTS), increased the 
lymph t u r b i d ~ t y y (p < 0.01) compared with dosing the 
retinoid in Miglyol 812 alone, however, the lymph 
flow rates, (0.95 ml/h after MTS, 0.97 ml/h after 
Miglyol) were not significantly affected (p > 0.05). 
The lymphatic uptake and estimated plasma uptake of 
Ro 15-0778 from the self-emulsifying oil system, 
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were almost three times greater than after dosing in 
Miglyol 812. 
This increase in overall bioavailability of the 
retinoids after oral dosing in a self emulsifying 
oil system indicates a potential advantage of such 
systems in the absorption of lipophilic drugs. 
viii) The fasted state of the animal plays a role in 
enhancing the relative amounts of retinoid which 
enters the body via both the lymphatic and portal 
venous routes of absorption. 
The results show that feeding a rat, 30 minutes 
prior to dosing with the retinoid (Ro 10-9359), has 
little or no effect on the lymphatic concentrations 
of Ro 10-9359. However, there is a marked decrease 
in the plasma concentrations of retinoid observed 
compared with the fasted animal. These changes in 
plasma retinoid concentrations after feeding give 
rise to a ten fold increase in the lymph : plasma 
uptake ratio, compared with the fasted animal. 
The data given here, although presenting a very 
complex picture, suggest many possible ways in which 
to promote or enhance the lymphatic absorption of 
the poorly absorbed retinoids. The most valuable 
results, which enable a prediction of the vehicles 
which will give the highest lymphatic uptake of a 
given compound, are the solubilities of the 
retinoids in the oily vehicles. There exists a 
definite inverse relationship between solubility of 
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a retinoid (Table 4) and its lymphatic uptake (Table 
24, Table 25 and Table 26). The retinoids were 
orally dosed in a fixed volume of oil (0.5 ml) and 
it may be postulated therefore, that either an 
increase in the percentage retinoid saturation in 
the oil or a decrease in the solubility of the 
retinoid in the oil may be important in increasing 
lymphatic uptake. However, it has been demonstrated 
in these studies that when Ro 04-3780 was presented 
in linoleic acid (0.5 ml) at an oral dose of 
75 mg/kg (percentage saturation, 93%), the dose 
adjusted lymphatic uptake was 150 times smaller than 
when Ro 04-3780 was administered in cottonseed oil 
(0.5 ml) at an oral dose of 6 mg/kg (59 % 
saturation) • 
Interpretation of these data from the rat in 
relation to its significance in man must be made 
with caution however, since the volume of the oral 
dose for the oily vehicle used in these studies in 
the rat (2 ml/kg) would extrapolate to approximately 
150 ml of oil in man. 
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ERRATA 
Page 21. Delete the sentence, "The lymphatic absorption of 
retinoid and lymph flow rate were slightly increased 
(p> 0.05) after food." 
Page 38. The line which reads, "divided over 60 and 7 days 
respectively." should be replaced by "divided over 5 
and 7 days respectively." 
Page 85. Insert the word, "is" after "the polarity of the 
mobile phase" 
Page 86. Delete the word "be" from the line which reads, 
"analysis of the retinoids had to be fulfil the 
following criteria;" 
Page 113. Insert the word "been" after the line which reads, 
"retinoids since these groups have". 
Page 145. The line which reads, "At the lower dose of 0.264 
mg/kg," should be replaced by, "At the higher dose of 
0.792 mg/kg," 
Page 173. The figure "1.38 mg/min" should be replaced by the 
figure "0.95 mg/min". 
Page 175. Replace "the lymph: plasma uptake ratio was greater 
than 10%." with "the lymph: plasma uptake ratio was 
approximately 10%." 
Page 185. The figure "(150 ng/h)" should be replaced by the 
figure "(1.1 ng/h)". 
Table 24. The estimated plasma uptake for linoleic acid of "154 
ng/h" should be replaced by "152 ng/h". 
